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Abstract 
Novel anti-arthritic drugs are often assessed in murine collagen-induced arthritis 
(CIA), which is a widely used pre-clinical model of rheumatoid arthritis. Howe\'er, 
CIA studies are lengthy, development of arthritis is not synchronised and not all 
animals develop disease. Work conducted in this thesis addressed some of these 
issues by developing short-term mechanistic models of collagen II (ClI) immunity. 
Drug effects on ClI-induced hypersensitivity, anti-CII antibodies and ex vivo CII 
stimulated CD4+ T cell proliferation in mice 14 days post-CII sensitisation were 
assessed and compared to their anti-arthritic effect in CIA. 
As this thesis progressed, it was reported that IL-l 7 secreting CD4 + T helper (Th 1 7) 
cells represent a population of cells distinct from interferon gamma (IFNy) secreting 
Th I and IL-4 secreting Th2 cells and may be involved in autoimmune disease. 
However, the role of IL-l 7 and Th 17 cells in CIA and CII immunity was not defined. 
The role of IL-l 7 and its relationship with Th 1 and Th2 cells was investigated in the 
CII stimulated CD4+ T cell assay. Results showed that CII specific Thl and Th17, but 
not Th2 cells, are present in cultures of cells from CII sensitised mice. Addition of 
anti-IL-17 to these cultures increased the number of CII specific IFNy secreting CD4+ 
T cells. Literature evidence suggests that IFNy is protective in CIA. This increase in 
IFNy may therefore represent a novel mechanism of action by which anti-IL-17 exerts 
some of its anti-arthritic activity. 
This thesis has shown that short-term models of ClI immunity can predict anti-
arthritic drug effects in CIA. A novel screening cascade has been proposed which 
could be used in drug discovery and may reduce the number of animals required for 
II 
CIA studies. Moreover, the differential effect of anti-arthritic drugs in these models 
suggests they can discriminate between drugs and identify novel mechanisms of 
action. 
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Chapter one 
Introduction 
Chapter 1 
1.1 Inflammation 
The inflammatory response has evolved as a protective response to tissue InJury. 
Tissue injury may occur as a result of trauma or chemicals, which generally gives rise 
to non-immune (innate) inflammation, or as a result of infection, which gives rise to a 
combination of non-immune and immune (adaptive) inflammation. Injury of the 
tissue results in the release of various chemical mediators from cells, for example 
histamine, eicosanoids, nitric oxide, neuropeptides and cytokines. The role of these 
mediators can change depending on the cellular environment and the pressure of other 
mediators to enhance or damp down the response as appropriate. Inflammation is 
therefore extremely complex. 
Many inflammatory mediators have vasoactive properties and act together to dilate 
local blood vessels and to contract vascular endothelial cells to increase vascular 
permeability. The consequence of this is increased blood flow and leakage of plasma 
into the injured tissue. This process gives rise to heat, redness and swelling. The 
accumulation of plasma and cells at the site of inflammation also gives rise to pain 
through stimulation of sensory nerves. Heat, redness, swelling and pain are therefore 
the characteristic hallmarks of inflammation. Inflammatory mediators also stimulate 
the expression of cell adhesion molecules such as the selectins and intracellular 
adhesion molecule-l (ICAM-l) on blood vessel endothelial cells. These adhesion 
molecules bind carbohydrate ligands and integrins respectively on circulating 
leukocytes allowing their extravasation into the injured tissue. The first cells to be 
recruited in an acute inflammatory response are polymorphonuclear granulocytes 
(neutrophils). These are followed by monocytes, which then differentiate locally into 
macrophages. Once in the tissue, these immune cells migrate along a chemotactic 
gradient to reach the site of inflammation, where they can attempt to remOH~ the 
2 
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injurious stimulus and repair the tissue. Persistence of the injurious stimulus gives 
rise to a state of chronic inflammation. Chronically inflamed tissue is characterised by 
the infiltration of mononuclear immune cells such as monocytes, macrophages. 
lymphocytes and plasma cells and is almost always accompanied by tissue 
destruction. The initial tissue damage or the reaction to it, which may be either 
temporary or pennanent, can result in loss of tissue function. For a more detailed 
review of the inflammatory process refer to Rankin (2004). 
1.2 Immune responses 
The immune system is often divided into innate and adaptive immunity. However, the 
two systems overlap and should not be viewed in isolation. The innate immune 
response is initiated immediately after tissue injury. If the injurious stimulus is an 
invading organism (pathogen) then the innate and adaptive immune responses work 
together to eliminate the infection. The innate immune response occurs to the same 
extent each time the pathogen is encountered, whereas the adaptive immune response 
improves on repeated exposure to the same pathogen. 
1.2.1 Innate immunity 
Pathogen recognition by the innate Immune system activates phagocytic cells 
(neutrophils and macrophages), other inflammatory cells (mast cells, basophils, 
eosinophils and natural killer cells) and activates the alternative pathway of 
complement. The innate response is not specific to the pathogen and is initiated hy 
the recognition of conserved molecular patterns common to entire classes of pathogen 
by Toll like receptors (TLRs) on professional antigen presenting cells (APCs) such as 
dendritic cells or macrophages. Activation of TLRs results in the production of 
3 
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chemokines and pro-inflammatory cytokines such as tumour necrosis factor alpha 
(TNFa) and interleukin (lL)-l. All these innate immune responses enhance the 
inflammatory process. In particular, the release of TNFa and interleukin IL-I from 
activated macrophages increases the expression of cell adhesion molecules. These 
bind integrins on the surface of leukocytes aiding adhesion. Chemokines such as IL-8 
are released from cells, such as macrophages, and direct large numbers of neutrophils 
to the site of infection. Activation of the complement system results in the production 
of a series of plasma proteins that coat pathogens. This process is known as 
"opsonisation" and marks the pathogen as a target for neutrophils and macrophages 
which then phagocytose and usually kill them. In addition, proteins from the 
complement system can act as chemoattractants and recruit cells to the site of 
inflammation and can form immune complexes that have direct lytic activity. 
Cytokines released as a consequence of infection also act systemically and stimulate 
what is known as the "acute-phase response", which is another component of innate 
immunity. In this response acute-phase proteins (APPs) are produced and have a 
variety of actions in host defence. Many of these APPs are synthesised in the liver by 
hepatocytes (Selinger et al., 1980) and are induced by the pro-inflammatory cytokines 
IL-I~, TNFa and IL-6 (Ramadori et al., 1988). These proteins recognise conserved 
microbial structures and bind the invading organism. Some of these APPs such as C-
reactive protein (CRP) act as opsonins and activate the complement cascade, which 
further augments opsonisation and pathogen elimination. In addition, some APPs act 
as chelators which slow microbial growth, while others are protease inhibitors which 
limit tissue destruction. 
Innate immune responses either successfully clear infection or contain it while an 
adaptive immune response develops. 
Chapter 1 
1.2.2 Adaptive immunity 
The adaptive immune response conveys specificity towards the invading pathogen 
through recognition of non-self molecules or antigens. This response requires 
proliferation and activation of antigen specific Band T lymphocytes. NaIve Band T 
cells circulate through the lymphatic system where they encounter antigen and 
recognise it through cell surface receptors. 
T cell receptors (TCR) recognise antigen presented on the surface of cells in 
association with major histocompatibility complexes (MHC). There are two classes of 
MHC molecule, class I and class II. MHC class I molecules are expressed on all 
nucleated cells, whereas MHC class II molecules are expressed on antigen-presenting 
cells (APCs) such as dendritic cells (DCs), B cells and activated macrophages. Tissue 
resident DCs are professional APCs and become activated when they recognise and 
phagocytose pathogens in infected tissue. Cytokines such as TNFa stimulate the 
migration of DCs to local lymph nodes where pathogen-derived antigens are 
processed and presented on the cell surface. However, the recognition of antigen-
MHC class II complexes alone is not sufficient to activate T cells. In addition, 
activated APCs up-regulate expression of costimulatory molecules which provide 
essential signals for successful T cell activation. Activated DCs express large 
amounts of costimulatory molecules and as a consequence are potent stimulators of 
naIve T cells. Activation of naIve T cells is often referred to as "priming" and is an 
essential step in adaptive immunity. 
T lymphocytes can be divided into two subsets according to the cluster of 
+ .' 
differentiation (CD) proteins on their cell surface. CD4 T cells recogmse antlgen-
MHC class II complexes, whereas CDS+ T cells recognise antigen-MHC class I 
complexes. Nai've T cells that encounter antigen in the correct fonnat proliferate 
5 
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(clonal expansion) into effector T cells (CD8+ cytotoxic T cells and CD4+ T helper 
(Th) cells) and memory T cells. 
Unlike T cells, B cells can recognise antigen in its native state. The B cell receptor 
(BCR) is a cell membrane anchored immunoglobulin (Ig) of the same antigen 
specificity that will ultimately be secreted as antibody (Ab). There are five subclasses 
of Ab (IgA, IgD, IgE, IgG and IgM), which are each specialised in activating 
different effector mechanisms upon binding antigen. However, B cells cannot 
proliferate or become activated by antigen recognition alone and require help from 
antigen specific effector CD4+ Th cells. This is achieved when B cells ingest antigen 
and present it in association with MHC class II molecules on their surface. CD4+ Th 
cells, that express TCRs for the same antigen, bind the antigen-MHC class II 
molecules and deliver signals (co-stimulatory molecules and cytokines) that stimulate 
B cell clonal expansion. This results in the formation of Ab secreting plasma cells and 
memory cells. 
Memory cells generated in this primary immune response enable a rapid secondary 
response to subsequent antigen exposure. This is because antigen specific cells are 
increased in comparison to when the antigen was first encountered. This secondary 
response produces a larger number of antigen specific effector T and B cells and in 
the case of B cells, induces greater levels of Ab secretion. 
The generation of effector T cells constitutes cell-mediated immunity. Circulating 
effector T cells bind cell adhesion molecules via cell surface integrins and migrate to 
the site of infection. Once activated these T cells secrete cytokines and chemokines 
that increase the recruitment of immune cells and enhance inflammation. 
Antigen specific cytotoxic CD8+ T cells are responsible for eliminating \·irally 
infected cells. Antigen derived from intracellular viruses is presented on the surface 
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of infected cells in association with MHC class I molecules. This marks the cell as a 
target for cytotoxic CD8+ T cells, which bind antigen-MHC class I complexes and kill 
the infected cell by inducing apoptosis. 
Activation of antigen specific effector CD4+ Th cells, via antigen-MHC class II 
recognition, stimulates the release of cytokines such as IL-2 and IL-4. These 
cytokines have autocrine effects that induce proliferation and differentiation. Until 
recently, CD4+ Th cells were divided into two distinct subsets depending on the 
cytokine profile they secrete. Type 1 Th (Th 1) cells secrete IL-2 and interferon 
gamma (lFNy) , whereas type 2 Th (Th2) cells secrete IL-4, transforming growth 
factor beta (TOFP) and IL-IO. These cytokines drive different immune responses. 
Thl cells convey cell-mediated immunity (macrophage activation and T-cell-
mediated cytotoxicity) and are associated particularly with obligate intracellular 
pathogens, whereas Th2 cells are associated with Ab responses and are important in 
host defence against parasitic infections. However, it is also recognised that Th 1 cells 
stimulate production of specific antibody isotypes as well. 
The production of large amounts of Ab from plasma cells facilitates the hosts defence 
by acting as an opsonin or by forming antigen-antibody complexes, which activate 
the classical pathway of complement. Immune cells such as neutrophils and 
macrophages then eliminate the invading pathogen by phagocytosis or cytotoxic 
mechanisms. Differentiation down either the Thl or Th2 cell pathway is under the 
control of cytokines produced in response to the invading pathogen. For example, 
production of IL-12 in response to pathogen stimulates Th 1 cell formation, whereas 
production of IL-4 stimulates Th2 cell formation. Whilst working on this thesis a 
further Th subset, termed "Th 17", has been described. This Th subset \\'i 11 he 
discussed in more detail later on in the thesis. 
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Normally, innate and adaptive immune responses remove pathogens and 
inflammation subsides with normal function being restored. For a detailed re\'ie\\' of 
immunity refer to Delves and Roitt et al. (2000). 
1.3 Hypersensitivity 
When immunological reactions cause more harm than good they are described as 
"hypersensitivity responses". These may occur when the body sees self-proteins as 
foreign (autoimmune responses) or where responses to otherwise innocuous antigens 
are inappropriate such as in allergy. Such responses may cause tissue injury and 
disease. 
As in adaptive immunity, hypersensitivity responses are mediated by the generation 
of antigen specific Abs and antigen specific T cells. There are four types of 
hypersensitivity response. Types I-III are immediate type hypersensitivity responses 
that occur within minutes to hours, whereas type IV is a delayed type hypersensitivity 
(DTH) response that occurs 24-48 hours later. Type I is mediated by the production 
of IgE Abs which bind receptors on mast cells that recognise the fragment 
crystallisable (Fc) component of the Ab. Antigen binding to IgE causes activation of 
the mast cell which releases inflammatory mediators. This type of hypersensitivity is 
associated with allergy. Type II is mediated by IgG Abs that bind cell surface 
antigens. This type of hypersensitivity is associated with some drugs that bind to the 
surface of cells and act as a target for anti-drug IgG antibodies that cause destruction 
of the cell. Type III is again mediated by IgG antibodies, which bind soluble antigen 
and form antigen- IgG immune complexes that are deposited in tissue. These immune 
complexes induce con1plement activation and neutrophil recruitment resulting in a 
local inflammatory response. Type IV is mediated by antigen specific effector T 
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lymphocytes such as Th 1 cells, which enter the site of exposure and recognise 
antigen-MHC class II molecules on APCs. These stimulated Thl cells secrete 
chemokines and pro-inflammatory cytokines such as IFNy which stimulate 
inflammation. Newly recruited macrophages present antigen which amplifies the 
response. The release of IFNy and TNFa in this inflammatory response also activates 
macrophages which perpetuates the reaction. Each step in this type IV DTH response 
takes several hours, thus inflammation is delayed. For a review of hypersensitivity 
responses see Janeway and Travers. (1996). 
1.4 Autoimmunity 
The successful deployment of an appropriate immune response depends on the body 
being able to distinguish foreign-antigen from self-antigen (autoantigen). 
Mechanisms exist that prevent reactivity to autoantigens while allowing a response to 
foreign antigens. These mechanisms normally occur in the thymus and bone marrow 
during development and include deletion, receptor editing and anergy of potentially 
autoimmune lymphocytes. If auto-reactive clones survive these mechanisms they are 
suppressed by regulatory cells. However, these processes can fail and self-tolerance 
can be broken allowing self-reactive lymphocytes to mature. In these circumstances 
the autoantigen becomes the target of the immune response and leads to autoimmune 
disease. Systemic autoimmune diseases such as rheumatoid arthritis can affect 
multiple organs and are generally chronic because the autoantigen can never be 
cleared from the body. Autoimmune diseases can involve both the humoral and 
cellular components of immunity, with autoantibodies and self-reacti\'c T cells 
driving the immune response against a specific autoantigen. The chronic 
intlammatory nature of these diseases usually results in tissue damage, \\'hich \eads to 
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further release of autoantigen and increased recruitment of inflammatory immune 
cells that release more cytokines and chemokines. This results in a continuing and 
evolving self-destructive process that has severe consequences for affected 
individuals. 
1.5 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease of the joint and is 
estimated to affect between 0.5 and 1 % of the adult population worldwide (Kvien. 
2004). Inflammation of the synovial tissue in the joint results in the development of a 
symmetrical polyarthritis with onset occurring usually between 40 and 50 years of 
age. However, juvenile forms of the disease exist and these can be particularly 
aggressive. Affected individuals present with pain, stiffness and swelling of the joints 
and may also suffer from fatigue, fever and weight loss. This has an impact on the 
patient's ability to perform routine daily tasks leading to reduced productivity at work 
and early retirement. RA is also associated with a reduced life expectancy of 
approximately 5 to 10 years. The direct costs of managing this disease as well as the 
indirect costs through loss of work represent a large economic burden. 
1. 5.1 RA aetiology 
There is no linkage of the disease to socio-economic factors but women are over three 
times as likely to suffer from the disease as men. Genetic and environmental factors 
SeelTI to playa role in the pathogenesis of RA. Serologically it was discovered that 
over 800/0 of patients with RA have a shared epitope (amino acids 70-74 of the major 
histocompatibility complex (MHC) class I I beta chain) consc[\'ed in the Human 
Leukocyte Antigen (HLA) DR-I and HLA-DR4 haplotypes (DRB*OIOI. DRB*0404 
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and DRB* 1402) (Stastny. 1983). In addition, patients with severe disease are more 
likely to be HLA DR positive than patients with less aggressive RA. The HLA-D 
region encodes genes for MHC class II molecules, which bind to and present antigens 
to the TCR of CD4+ T cells. However, not all RA patients are HLA DR positive and 
not all HLA DR positive individuals will develop RA suggesting non-inherited 
factors may also have a role to play in the aetiology of RA. Environmental triggers 
have therefore been implicated in disease initiation and include smoking as well as 
viral and bacterial infections. 
Researchers have also assessed the usage of subfamilies of TCRs to try and identify 
the pathogenic T cells involved in RA. In some patients there appears to be a 
preferential usage of certain TCR beta chain variable regions on T cells from diseased 
joints (Mirna et al., 1999). This suggests, in patients that have a T cell driven disease, 
that there are dominant T cell subpopulations in the joint and that these cells may be 
driven by a shared antigen. These data suggest that T cells are important in the 
pathology of RA. 
Considerable research has been conducted in an attempt to identify a specific 
autoantigen in RA. The identification of autoantibodies against collagen type II, 
chondrocyte glycoprotein 39, proteoglycans and citrullintaed proteins have suggested 
that these may be potential autoantigens in RA. However, their role in disease 
pathogenesis is not clear and the actual antigen responsible for the initiation of RA 
has not yet been identified. 
Further attempts to understand the pathogenesis of RA have come from genome-wide 
single nucleotide polymorphism studies. These studies have identified genes 
associated with disease susceptibility. RA-associated polymorphisms han~ been 
described for a number of genes such as P ADI4, a gene inH)l\cd in the production Dr 
II 
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peptidylarginine deiminase, which converts arginine to citrulline in proteins. and IL-
23R, a cytokine receptor involved in IL-I7 production (Yamamoto and Yamada. 
2005 and Hollis-Moffatt et al., 2008 respectively). Studies like these identify genetic 
risk factors in RA and lead to a better understanding of the biological pathways 
involved in disease, which may lead to novel therapeutic approaches. 
In general RA is thought to occur when the immune system is inappropriately 
activated in susceptible individuals, probably through recognition of self-antigen and 
involves both the humoral and cellular components of immunity. In affected 
individuals the cells lining the joint become hyperplastic and mainly consist of 
activated macrophages (type A synoviocytes) with the underlying layer consisting of 
fibroblast-like cells (type B synoviocytes). Deeper layers within the synovium may 
have follicles of lymphoid cells around vessels as well as lymphocytes scattered 
between them. Macrophages and T lymphocytes represent the most abundant cell 
types in the synovial tissue with B cells, plasma cells, DCs and fibroblasts also being 
present. Refer to VanderBorght et al. (2001) for a review of RA aetiology and 
pathogenesis. 
1.5.2 RA pathogenesis 
Disease pathogenesis is thought to be initiated when the unknown pathogenic 
determinant is processed and presented by APCs to CD4+ T cells. This interaction is 
mediated by binding of integrins such as lymphocyte function associated antigen-l 
(LFA-I) and costimulatory molecules such as OX40, that are expressed on T cells, to 
ICAM-I and OX40 ligand (OX40L) respectively on APCs. These associations result 
in activation of CD4+ T cells. Both LFA-I and OX40 have been shown to he 
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expressed on synovial fluid T cells in RA patients (Ueki et al., 1994 and Giacomelli 
et al., 2001 respectively). 
In addition, CD4+ T cells from RA patients express high levels of the costimulatory 
molecule CD40L on their cell surface (Toubi and Shoenfeld. 2004), which binds 
CD40 on B cells. This interaction stimulates B cells to produce immunoglobulin (lg) 
such as rheumatoid factors (RFs). RFs are autoantibodies found in the majority ofRA 
patients and titres of which are often used to indicate disease activity. Patients who 
are positive for RF are referred to as "sero positive". These autoantibodies bind the Fc 
component of circulating IgG antibodies and form immune complexes. The classical 
RF is an IgM antibody which binds IgG forming IgM-IgG complexes that are 
deposited in the joint. These complexes activate complement resulting in joint 
inflammation and may be responsible for disease perpetuation and/or the localisation 
of the inflammatory response to the joint. 
RF has been detected early in RA, prior to clinical signs of disease, suggesting it may 
have a role to play in the initiation of disease. However, RA also occurs in individuals 
who are sero negative for RF suggesting T cells may drive the disease process in 
these patients. 
In response to mediators of inflammation vascular endothelial cells increase their 
expression of adhesion molecules such as E-selectin and P-selectin, which facilitates 
cellular recruitment. Recruited neutrophils release elastase and other proteases that 
degrade proteoglycan in the superficial layer of cartilage. Depletion of proteoglycan 
enables immune complexes to precipitate in the superficial layer of collagens in the 
joint allowing inflammation to persist. Neutrophils also attract macrophages that 
secrete I L-I P which stimulates the increased expression of the adhesion molecules 
ICAM-I and vascular cell adhesion molecule I (Ve AIvl-l) on endothelial cdls. 
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These bind integrins such as LFA-l and very late antigen 4 (VLA-4) respectively that 
are expressed on CD4+ T cells. These cells then traffic to the inflamed synovial tissue. 
All these adhesion molecules and integrins have been detected in RA patients (Tak 
and Thurkow et al., 1995 and Ueki et al., 1994 respectively). 
IL-l ~ is also present in the joints of RA patients (Schlaak et aI., 1996) and plasma 
levels have been shown to correlate with disease severity (Eastgate et al., 1988), 
demonstrating its importance in disease pathogenesis. 
CD4+ T cells from the joints of RA patients produce IFNy and IL-2 which are 
characteristic Thl cell cytokines (Buchan et al., 1988 and Miltenburg et al., 1992), 
whereas they only produce low levels of characteristic Th2 cell cytokines such as IL-
4 (Miossec et al., 1990). This has lead to the hypothesis that RA is a Th 1 cell driven 
disease. INFy, as well as other cytokines, is able to activate macrophages leading to 
an increase in the transcription/production of TNFu, which is again elevated in RA 
(Schlaak et al., 1996). TNFu and IFNy act synergistically to increase the expression 
of adhesion molecules causing further cellular influx. Thus, it is the CD4 + T cell that 
is thought to orchestrate this chronic inflammatory response. However, IFNy levels in 
RA are relatively low and its significance in disease pathology is not clearly defined 
as it may also have anti-inflammatory properties (Ruschen et al., 1989). 
The inflammatory environment within the joint also stimulates macrophages and 
fibroblasts to produce other pro-inflammatory cytokines such as IL-6 and granulocyte 
macrophage colony-stimulating factor (GM-CSF). These have been detected in RA 
patients (Field et al., 1991 and Haworth et al., 1991 respectively) and have a plethora 
of biological actions. IL-l ~ and TNFu as well as aiding in cellular recruitment also 
have a broad range of other biological actions in RA and along with IL-6 and G \1-
CSF regulate the inflammatory response. 
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The acute phase response in RA is also activated by many of these pro-inflammatory 
cytokines and levels of CRP in the blood have been shown to correlate to disease 
severity (Larsen. 1988). Although the contribution of acute phase proteins to disease 
pathogenesis is unclear, their presence is often used as a marker of inflammation. 
Given the degree of lymphocyte recruitment into the joint it is surprising that T cell 
derived cytokines such as IFNy, IL-2 and IL-4 are not dramatically over-expressed. 
This has brought into debate the importance of CD4 + T cells in RA. However, the 
production of IL-17, another T cell derived cytokine, has been shown to be abundant 
in RA (Chabaud et ai., 1999) suggesting these cells may have an important role in 
disease pathology. The expression of other cytokines such as IL-7 (Harada et at., 
1999), IL-12 (Schlaak et ai., 1996), IL-15 (McInnes et ai., 1996) and IL-18 (Gracie et 
ai., 1999) have been detected in RA and are capable of activating Th cells further 
supporting a role for T cells in disease. 
At the same time as the pro-inflammatory response, anti-inflammatory mediators are 
also present in RA such as IL-4, IL-I0 and transforming growth factor beta (TGF~) 
(Schlaak et ai., 1996). In addition, IL-1 receptor antagonist (IL-l Ra, Firestein et ai., 
1992) and soluble TNF receptors (sTNFR, Cope et ai., 1992) have also been detected. 
These molecules have been shown to inhibit inflammatory processes. However, there 
appears to be a loss of negative regulation in RA. 
The B cell, as well as secreting autoantibodies, may also contribute to disease 
pathogenesis by producing cytokines such as IL-6. Cytokines derived from B cells 
promote leukocyte infiltration into the joint, formation of ectopic lymphoid structures. 
angiogenesis, and synovial hyperplasia. However, the precise cytokine pattern 
secreted by B cells in the synovium has yet to be determined. In addition. 8 cells arc 
efficient antigen presenting cells and have been shown to mediate T cell acti\'ation in 
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RA (Takemura et al., 2001). Thus, it would appear that both T and B cells are 
essential in developing an autoimmune response in the joint. 
Chronic inflammation in the joint leads to cartilage destruction and bone erosion, 
which is a major cause of disability in RA patients. This occurs when the inflamed 
synovium forms an outgrowth known as the pannus that invades the cartilage and 
bone. The pannus is comprised of mesenchymal cells such as synovial fibroblasts, 
macrophages and lymphocytes. 
Fibroblasts and activated T cells express the cytokine receptor activator of nuclear 
factor-KB ligand (RANKL), which is up-regulated in rheumatoid synovial tissue 
(Shigeyama et al., 2000). RANKL binds its receptor RANK on osteoclast precursor 
cells that are recruited to the inflamed synovium. Osteoclast precursor cells then 
differentiate into mature osteoclasts that actively resorb bone. This process is 
regulated by osteoprotegerin (OPO), a soluble decoy receptor for RANKL, which is 
also expressed in synovial tissue ofRA patients (Vanderborght et al., 2004). OPO has 
been shown to inhibit osteoclast formation and activation (Simonet et al., 1997). 
However, in RA there is an imbalance in the ratio of RANKL to OPO which favors 
RANKL induced osteoclastogenesis and bone resorption. 
Other pro-inflammatory cytokines such as TNF, IL-l p, IL-6 and IL-17, that are 
abundant in the inflamed joint, can induce the expression of RANKL and enhance 
osteoclast driven bone erosion. Many of these cytokines also induce the release of 
matrix metalloproteinases (MMPs) such as stromelysin and collagenase from 
Inesenchymal cells and osteoclasts. MMPs degrade connective tissue matrix and are 
important contributors to joint damage in RA (Vincenti et al., 1994). In addition. 
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synovial cytokines are important mediators of angiogenesis in RA, which is required 
for sustained chronic inflammation and joint destruction. 
Untreated, this chronic disease soon results in joint deformity with a severe reduction 
in the quality of life for the patient. This disease may also manifest as a systemic 
inflammatory condition at extra-articular sites giving rise to rheumatoid nodules, 
ocular disease, pulmonary fibrosis, vasculitis, pericarditis and myocarditis, which 
ultimately reduce life expectancy. 
1.5.3 Diagnosis 
RA is diagnosed using the American College of Rheumatology (ACR) classification 
criteria (Arnett et al., 1988) as outlined in Table 1.1. Four or more of the criteria have 
to be met for at least four weeks before RA is diagnosed. This ACR system is useful 
in diagnosing active disease. However, in early RA where patients may present with 
single joint involvement and no radiographic damage a firm diagnosis cannot be 
made using this system (Saraux et al., 2001). Joint erosions are present in 50-70% of 
patients two years after the onset of symptoms (Plant et ai., 1998) hence there is a 
need to diagnose RA as soon as possible. Earlier markers of RA are being developed 
and include assessment of antibodies to citrullinated peptides and better imaging 
techniques. If these prove to be accurate, treatment could be initiated earlier which 
may improve prognosis. 
1.5.4 Clinical assessment of anti-arthritic drugs 
In clinical trials the anti-arthritic effects of novel drugs are assessed using the .\CR 
core data set of measures (Felson et ui., 1993), as outlined in Table 1.1 .. \ drug is 
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assessed by its ability to improve the ACR score by 20, 50 or 700/0, with these 
thresholds being referred to as ACR20, ACR50 and ACR 70 respectivel y. 
ACR diagnosis ACR core data set for 
criteria clinical trials 
Morning stiffness for at Number of swollen joints 
least one hour 
Soft tissue swelling of Tender joint count 
three or more joints 
Swelling (arthritis) of Physicians assessment of 
hand or wrist joints global status 
Symmetrical swelling of joints Patients self-report including 
physical function, pain and 
global assessment 
Rheumatoid nodules Presence of one acute phase 
reactant, either erythrocyte 
sedimentation rate (ESR) or 
C-reactive protein (CRP) 
Presence oflgM RF in Radiographic assessment of 
abnormal amounts hands and feet in clinical 
studies of 1 year duration or longer 
Radiographic changes showing 
erosions and/or peri-articular 
osteopenia in hand and/or 
wrist joints 
Table 1.1 American College of Rheumatology diagnosis and clinical trial 
assessment criteria. 
1.5.5 Current treatment 
.---
I 
! 
Despite the fact that 50°0 of patients are unable to work within fj\l' years nf 
diagnosis, RA has until recently been regarded as something of a benign disease. This 
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has been reflected in the way the disease has been clinically managed. Most patients 
would be started on non-steroidal anti-inflammatory drugs (NSAIDs) such as 
indomethacin, progressing (as their disease progressed) to steroids such as prednisone 
and then to so called "disease modifying anti-rheumatic drugs" (DMARDs) such as 
methotrexate (MTX) and ending perhaps with joint replacement. The modem 
approach is to treat more aggressively from the start with DMARDs (Fries, 2000), 
partly because of the gastric side effects of NSAIDs and because NSAIDs provide 
only symptomatic relief and have no impact on disease progression. The most widely 
used of the DMARDs is MTX taken by approximately 500/0 of patients on DMARD 
therapy. Other commonly used DMARDs include hydroxychloraquine, leflunomide, 
sulfasalazine and azathioprine. MTX and leflunomide are effective in RA and have 
been shown to inhibit disease after 52 weeks of treatment with 46%) and 52% of 
patients achieving an ACR20 respectively (Strand et ai., 1999). However, it is 
estimated that only 20-300/0 of patients remain on treatment after five years with most 
DMARDs and 400/0 of patients on MTX discontinue treatment over this time period 
(Simon, 2000). Cessation of treatment with these drugs is normally due to adverse 
events and/or loss of response when used for long periods of time. As a consequence 
patients often progress from one DMARD to another or use them in combination. 
A recent breakthrough in the treatment of RA has been the targeting of the pro-
inflammatory cytokine TNFa with biological therapies (biologics). Biologics are 
protein-based drugs derived from living organisms that target specific components of 
the immune system. The biologics currently used in the clinic that inhibit TNFu are 
etanercept (Enbrel), a fusion protein of the human TNF receptor<~ fused to a human 
IgG 1 Fe: inflixilnab (Remicade), a chimeric monoclonal Ab (mAb); and adalimumab 
(HUlnira), a hUlnan mAb. These anti-TNFa drugs have all been sho\\'!1 to impnne 
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symptoms and signs of disease in RA. In clinical practice anti-TNFa therapy is used 
to treat patients who have failed to respond to one or more DMARD. In these patients 
DMARD therapy is normally continued with anti-TNFa treatment. Studies ha\'e 
demonstrated that anti-TNFa treatment in patients receiving concomitant MTX 
inhibits disease more effectively than MTX alone (Table 1.2). In addition, anti-TNFa 
therapy has been shown to prevent progression of joint erosions in RA (Keystone et 
al., 2004). These studies clearly show the benefit that anti-TNFa biologics have to 
offer in the treatment of RA. 
Drug treatment Duration of ACR20 Reference 
treatment response 
Etanercept + MTX 24 weeks 710/0 Weinblatt et al., 1999 
MTX only 27% 
Infliximab + MTX 30 weeks 58% Maini et at., 1999 
MTX only 20% 
Adalimumab + MTX 24 weeks 630/0 Keystone et at., 2004 
MTX only 300/0 
Table 1.2 Effect of anti-TNFa biologics in RA patients receiving concomitant 
MTX. 
In addition to these approved TNF inhibitors others are also in development such as 
certolizumab pegol (Cimzia), a pegylated fragment of antigen binding (Fab) 
fragment, which will give more choice to the physician and patient. Howe\l~r. 20-
400/0 of patients are described as "non-responders" to anti-TNF therapy and these 
patients may benefit from other biological drug approaches. 
Another available biologic is anakinra (Kineret), the I L-l receptor antagonist (I L-
I fa), which has been shown to be active in reducing disease symptoms in R.\ \\ ith 
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430/0 of patients achieving an ACR20 after 24 weeks of treatment (Bresnihan er al.. 
1998) and is effective in combination with MTX (Cohen et al., 2002). These results 
along with a number of other studies have shown IL-l blockade to be effective in the 
treatment of RA. However, the effects seen with anakinra were modest compared to 
those of the TNF inhibitors. Other available biologics include rituximab (MabThera) 
and abatacept (Orencia). Rituximab is a depleting mAb directed against the C020 
antigen on B cells and abatacept is a fully human Fc fusion protein, comprising the 
extracellular portion of cytotoxic T-Iymphocyte antigen 4 and the Fc fragment of 
human IgG 1, which inhibits CD28 T cell costimulation. Both rituximab and abatacept 
have been shown to be effective in RA (Edwards et al., 2004 and Kremer et al .. 2003 
respecti vel y). 
The successful inhibition in the signs and symptoms of RA with the drugs outlined 
above have validated TNFu, IL-1, B cells and T cells as important components in RA 
pathogenesis. 
1. 5. 6 Future treatments 
Following the success of anti-TNF biologics other pro-inflammatory cytokines and 
their pathways are being targeted with biologics and small molecules. These novel 
drugs are outlined in Table 1.3. The most advanced of these emerging treatments is 
tocilizumab a humanised mAb against the IL-6 receptor. In a clinical trial 78%) of RA 
patients achieved an ACR20 after 12 weeks administration of tocilizumab (Nishimoto 
et al., 2004). which has validated a role for IL-6 in RA. 
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Target Drug Format Development: 
stage 
IL-lP Canakinumab Anti-IL-I P Ab Phase II 
IL-6 Tocilizumab (Actemra) Anti-IL-6 receptor Ab Phase III 
IL-12/IL-23 ABT-874 Anti-IL-12/IL-23 Ab Phase III 
IL-15 HuMax (AMG 714) Anti-IL-15 Ab Phase II 
IL-17 AIN-457 Anti-IL-17 Ab Phase II 
IL-18 IL-18 binding IL-18 antagonist Phase II 
protein 
BLyS Belimumab Anti-BLyS Ab Phase II 
(LymphoStat-B) 
BLyS and Atacicept Extracellular portion Phase II 
APRIL ofTACI-human 
IgG 1 F c fusion protein 
RANKL Denosumab (AMG 162) Anti-RANKL Ab Phase II 
CD20 Ocrelizumab Anti-CD20 Ab Phase III 
p38 VX-702 p38 MAPK inhibitor Phase II 
JAK2 INCB-18424 JAK2 inhibitor Phase II 
CCR5 AZD-5672 CCR5 inhibitor Phase II 
BLyS, B lymphocyte stimulator; APRIL, a proliferation-inducing ligand; MAPK. 
mitogen-activated protein kinase; JAK, janus kinase. 
Table 1.3. Drug targets and development stage of novel therapies. 
1.5. 7 IL-17 as a drug target 
I 
i 
l 
I 
i 
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From the list of novel targets (Table 3) IL-17 has attracted a lot of interest in recent 
years. IL-17 is considered a T cell derived cytokine and has been detected in activated 
CD4+ T cells (Yao et al., 1995) and has also been shown to be produced hy memory 
CD4+ T cells (Aggarwal et al., 2003). In RA, T cells resident in the sYlHnial tissue 
have been demonstrated to produce I L-I 7, which is thought to contrihute tp 
intlatntnation (Chabaud et al., 1999). In addition, pre-clinical animal models of RA 
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have shown that IL-l 7 deficiency and blockade inhibit signs of arthritis (1\ aka t I e ea., 
2003 and Lubberts et af., 2001). Thus, these data have implicated a role for IL-17 in 
RA and suggest it is a promising target for drug intervention. 
There are numerous therapies in development with the potential for treating RA 
patients. What is not clear is how to differentiate between these new therapies in 
terms of identifying the advantages one has over another for a given patient 
population without conducting lengthy and expensive clinical trials. 
1.6 Collagen-induced arthritis 
In drug development animal models are used to identify and validate novel therapies 
which may ultimately be used in the clinic to treat patients. In non-clinical 
pharmacology the most favoured model of RA is collagen-induced arthritis (CIA), 
which is an inflammatory polyarthritis model. The development of arthritis after 
sensitisation to heterologous collagen type II (ClI) in complete Freund's adjuvant 
(CFA) was first reported by Trentham et af. in 1977 in the rat. In 1980 Courtenay et 
af. reported similar findings in the mouse. CFA, which contains mycobacterium 
tuberculosis, is essential to elicit CIA demonstrating that TLR stimulation is required 
to initiate an immune response. Since these initial studies the specific CII 
arthritogenic epitopes have been identified within peptide fragments CII 181-209 and 
CIb45-27o (Myers et af., 1993) suggesting preservation of these epitopes is required. 
However, intact ClI, which is processed and presented on the surface of APCs to T 
cells, is still routinely used to elicit disease. CII presentation by APCs initiates cdl 
contact and stimulates molecular processes such as the increased cxprL'ssion of 
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costimulatory molecules on the cell surface which is essential for the initiation of an 
Immune response. 
CIA is a long term model and not all animals will develop disease. It is also sensiti\'e 
to other factors such as stress which may affect disease development. In addition, it 
has been observed that animals acclimatised for a longer period of time prior to the 
initiation of CIA develop a more robust disease (Unpublished observation). 
Environmental conditions therefore appear to playa role in disease manifestation but 
the factors involved are unclear. Despite these issues, CIA is still routinely used in 
drug discovery as it shows many similarities to RA. However, it is a model and also 
differs from RA in a number of respects. The similarities and differences between 
CIA and RA, as reviewed by Trentham (1982), are summarised in Table 1A. AIl 
commonly used anti-arthritic therapies are effective in CIA models (Bendele et at., 
1999) including biological agents directed against TNFa (Piguet et at., 1992) 
therefore demonstrating that CIA is a clinically relevant model of RA. 
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Similarities to RA Differences to RA : 
Susceptibility linked to MHC Disease is induced 
Immunologically mediated The model "resolves" 
Erosions of cartilage and bone New bone formation more marked 
Autoimmunity to collagen seen in No synovial vasculitis 
some RA patients 
Disease centered on joints No cycles of relapse and remission 
i 
NoRF ! 
No sex predilection 
-~- --< 
CIA is acute RA is chronic 
Table 1.4 Similarities and differences of CIA to RA. 
CIA is normally conducted in DBAll mIce. This strain of mouse is genetically 
susceptible to CIA as it is H2q restricted and presents CII on an MHC class II 
background to CD4+ T cells. Generation of CII specific T cells enables the 
proliferation of B cells and production of anti-CII antibodies (Hom et aI., 1986). 
Antibodies against CII are also detected in up to 70% of patients with RA (Cook et 
al., 1996). Thus, like RA, CIA involves both the humoral and cellular components of 
the immune system. This is highlighted by the fact that mice deficient in CD4+ T cdls 
(Taneja et aI., 2002) or B cells (Svensson et al., 1998) are resistant to CIA. Adopti\'e 
transfer studies have shown that T cells alone are not sufficient to transfer sc\crc 
disease into recipient mice and only mild transient symptoms are seen (Kakimoto e/ 
aI., 1988). Likewise, antibody transfer alone from immunised donors causes onl: 
mild arthritis in recipients (Stuart & Dixon, 1983), HO\\'C\Tr, Seki el al. (Il)SS) 
detnonstrated that transfer of T cells and serum to nai\'c mice rLsultcd in SC\'Lre and 
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sustained arthritis. In addition, Tada et af. (1999) showed that the transfer of T and B 
cells resulted in the development of arthritis. 
These data illustrate that both the humoral and cellular components of the immune 
system are essential in the elicitation of CIA. Further support for the role of B cells in 
CIA has recently been provided by Holmdahl et al. (2002) who showed that B cells 
are capable of processing and presenting ClI to primed T cells. This study also 
showed that primed B cells activated T cells two-three times more effectively than 
naIve B cells, suggesting B cells have the potential to play an important role as APCs 
in the immune response to CII. In RA, cellular responses to CII have also been 
demonstrated. Trentham et af. (1978) showed that cells isolated from RA patients are 
activated by ClI and Kim et af. (1999) showed that T cells proliferate in response to 
ClI stimulation, therefore suggesting ClI may have a role to play in the pathogenesis 
ofRA. 
The presence of CD4+ T cell subsets in CIA has been investigated and Mauri et at. 
(1996) demonstrated that cells isolated from lymph nodes, six days post-ClI 
sensitisation, produce IFNy. Re-stimulation of these cells with CII resulted in an 
approximate ten-fold increase in IFNy production suggesting activation of an antigen 
specific Thl cell response. At the same time point, Th2 cell cytokine production was 
suppressed. However, during progression and subsequent resolution of arthritis I L-I 0 
levels increased and low levels of IL-4 were present throughout the time course. This 
suggests that Th2 cell responses may have a role to play in CIA but probably during 
resolution and may suppress arthritis. This study also showed that during thc 
progression and resolution of disease IFNy le\'els decreased, therefore indicating that 
Th 1 cell responses are dominant early in the immune response to CI I and may caU~l' 
the suppression of Th2 cell responses with the re\'erse being true latcr on in the 
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disease course. Similar data was also obtained by Doncarli et al. (1997) who showed 
a dominant IFNy secreting Thl cell population 15 days post-sensitisation with an 
increase in IL-4 secreting Th2 cells on Day 30. These data have led to the theory that 
CIA, like RA, is a Thl cell driven disease. However, there is controversy surrounding 
the role of IFNy in disease pathogenesis. Some researchers suggest IFNy exacerbates 
disease (Cooper et ai., 1988 and Boissier et al., 1995) and others suggest it protects 
against disease (Nakajima et ai., 1990 and Vermeire et ai., 1997). These studies hayc 
brought into doubt the importance of CD4+ Thl cells in CIA. 
The immune response in pre-clinical models of arthritis, In terms of cellular 
interactions, cytokine and chemokine profiles, is similar to that in RA. OX40, CD40L 
(Saijo et ai., 2002), LFA-l, ICAM, VLA-4, VCAM, P-selectin, IFNy, IL-4 
(Hersmann et ai., 1998), IL-2, IL-lra, TGFp (Thornton et ai., 1999), IL-I0 (Mauri l'f 
ai., 1996), IL-l p, TNFa, and IL-6 (Marinova-Mutafchieva et ai., 1997) are detected 
in the joints or produced by cells from arthritic animals. In addition, evidence from 
knockout mice or blockade of cytokine function has shown the importance of I L-12 
(Murphy et ai., 2003), IL-15 (Ferrari-Lacraz et ai., 2004), IL-17 (Nakae et at.. 2003) 
and IL-18 (Banda et ai., 2003) in CIA. Chronically inflamed joints of CIA mice also 
show marked cartilage erosion and bone destruction similar to that seen in RA, 
Examination of synovial tissue from arthritic mice has identified the expression of 
RANK and RANKL which, like RA, are thought to playa key role in bone erosion 
(Lubberts et ai., 2002). This list of immunological similarities is by Ol) J11l'3n~ 
exhausti ve. 
CIA is, however, time-consuming with experiments typically la~ting )()-70 da)~, I he 
developtnent of arthritis is not always \\'ell synchronised and not all animab dcvelop 
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disease (Caccese et ai., 1992). This variability has consequences in tenns of more 
animals being required for study. It also makes prophylactic dosing studies especially 
challenging because it is not a simple matter to differentiate between an animal that 
has responded to drug treatment and an animal that is a "non responder". 
Prophylactic drug administration will take into account both the potential 
immunomodulatory and anti-inflammatory effects a drug may ha\'e in the CIA model. 
However, prophylactic dosing cannot distinguish between these effects. Studying 
drug effects therapeutically in animals with clinical signs of disease assesses a drugs 
anti-arthritic potential. Whilst many might argue that only therapeutic studies ha\'e 
relevance to human disease, the reality is that many immunomodulatory drugs, that 
have utility in the treatment of RA, are only active in CIA when dosed 
prophylactically. This suggests that the immunomodulatory activity of a drug is likely 
to contribute to its anti-arthritic effect. In addition, drugs that are effecti\'t~ 
therapeutically in CIA are usually also effective when administered prophylactically. 
It would therefore appear that studying the immunomodulatory activity of a drug 
gives an indirect assessment of its potential anti-arthritic action. For these reasons the 
prophylactic dosing regime is often favoured for assessing new drug entities. 
CIA is usually assessed in terms of clinical scores (based on number and se\'erity of 
swollen joints) and the degree of joint destruction as assessed by x-ray and or 
histopathology. In this model there is a relatively straightforward relationship 
between severity of clinical scores and underlying joint destruction (a relationship 
that is not so clear cut in RA). So drugs that are effecti\'c in CIA. whatL\"er their 
mechanism of action, appear to ha\'e \'ery similar profiles. The model is not therLilllc 
very good at differentiating between anti-arthritic drugs. 
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Ideally, the CIA model would be short, highly reproducible and have 3 \"ariety of 
readouts that allow drugs to be differentiated on mode of action. To address some of 
the issues relating to CIA, an approach may be to develop short-term models that 
concentrate on the development of CII immunity in sensitised animals rather than 
waiting for arthritis development. Careful choice of readouts may then allow drugs to 
be differentiated mechanistically. Assessing drug effects in short-term models of CII 
immunity would evaluate their immunomodulatory activity and giye an indirect 
readout of their anti-arthritic potential. Furthermore, if these models were robust and 
appeared predictive of drug effects in CIA, they would have the potential to reduce 
numbers of animals required for drug testing and the numbers of animals that needed 
to be rendered arthritic. 
1.7 Hypothesis 
The hypothesis to be tested is that short-term models of collagen II immunity will be 
predictive of drug effects in CIA and provide a series of readouts that will allow anti-
arthritic drugs to be differentiated based on mechanism of action. 
1.8 Early readouts of ell immunity 
1.8.1 Anti-collagen II antibodies 
d ·1 d l"n serum ustn.!! In CIA, anti-CII antibodies are produced an are eaSI y measure -
enzyme-linked immunosorbent assays (ELISA) gi\'ing a readout of the hUllloral 
immune status of the animal. Analysis of the ditTerent antibody isotypes produced in 
may also I·niann on the subset of CD4; Th cells that ha\"e heen response to CII 
activated. I L-4 secreting Th2 cells han~ been demonstrated to support IgG I 
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production from plasma cells, whereas IFNy secreting Thl cells support IgG2a 
production (Stevens et al., 1988). Thus, the presence of IgG2a and IgG 1 
are 
indicators of Thl and Th2 cell responses respectively. Anti-collagen II IgG 1 and 
IgG2a Abs are readily detected in the sera of CIA mice and Doncarli et al. (1997) 
showed that although these Abs are not seen eight days after sensitisation they are 
present on Day 25 and continue to increase over the course of disease. Also, a study 
by Williams et al. (1998) demonstrated that anti-heterologous and anti-homologous 
CII IgG Ab levels, detected in pre-arthritic mice 21 days post-CII sensitisation. 
showed a statistically significant correlation to subsequent disease se\erity. These 
studies demonstrate that CII specific Abs are produced in the pre-arthritic phase and 
suggest they are predictive of arthritis in CIA. 
1.8.2 Serum amyloid A (SAA) 
Levels of CRP in clinical trails are monitored in RA patients and anti-arthritic drugs 
have been shown to reduce levels (Weinblatt et al., 1999), therefore indicating it is a 
valuable marker of drug efficacy. In the mouse, the acute-phase protein SAA is more 
responsive to inflammation than CRP. SAA levels can be easily detected in serum by 
ELISA and are present in arthritic mice (Palmer et al., 2003). Thus SAA may be a 
potential marker of drug efficacy in the CIA model. However, it is not known if SA:\ 
can be detected in CII sensitised mice in the pre-arthritic phase. 
1.8.3 Collagen II Hypersensitivity 
Sensitisation to CII and subsequent re-challenge has been demonstrated to dicit 
. . . F t al (1986) showed that a DTII rL'sponsL' could hypersensItIvIty responses. anner e . 
be detected to CI I III the ear four days after sensitisation and Sck i et a/. (19RS) 
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demonstrated the same response in the footpad 14 days after sensitisation. In another 
study, Ornata et al. (1997) showed that a DTH response, in the ear, could be elicited 
in mice with CIA 49 days after sensitisation. These data illustrate that animals 
sensitised and then re-challenged with CII, prior to disease onset react in the same 
way as those with arthritis. This suggests that a CII-induced DTH response has the 
potential to be utilised as an early readout of CII immunity. Ornata et al. (1997) also 
demonstrated that the clinically used DMARD, MTX, inhibits CIA and CII-induced 
DTH therefore suggesting this readout is responsive to anti-arthritic therapies. 
However, the effect of MTX was not assessed in the pre-arthritic phase and it is not 
clear if a CII-induced DTH response in this phase would predict drug efficacy in CIA. 
DTH responses are T cell mediated and can therefore be used to assess the etTect of 
therapies on cell mediated immunity. Furthermore, it has been demonstrated that 
immediate type hypersensitivity responses often precede DTH responses (Titus and 
Chiller., 1981). If this is true of a CII-induced response then measurements taken a 
few hours post-re-challenge could give a readout of humoral immunity. Taken 
together these readouts may give useful information on drug mechanism of action. 
1.8.4 Collagen II stimulated cell proliferation 
Cellular immunity to CII is essential for the development of CIA. Cells isolated from 
the lymph nodes of CII sensitised mice have been shown to proliferate in response to 
CII ex vivo (Farmer et al., 1986). This proliferative response is easily quantified by 
the addition of radioactive tritiated thymidine eH) to the culture which then beCl))lle-. 
incorporated into dividing cells and is measured on a beta counter. \ lauri l'I al. ( 19(6) 
detnonstrated that a statistically significant increase in proliferation pf lymph node 
cells to ell could be detected in pre-arthritic mice 13 days P()st-sl'l1-;itlsatitHl. Ihl-.. 
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cellular response therefore has the potential to be used 1 
as an ear \' readout of CII 
immunity. 
Most of these readouts of CII immunity appear to be detectable in pre-arthritic 
animals. However, they have, as yet, not been utilised to predict the effects of anti-
arthritic drugs prior to disease onset. These models and assays need to be set up to 
assess the conditions needed to obtain robust and reproducible responses. 
1.9 Pharmacological tools 
To test the hypothesis set out in this thesis a variety of experimental, established and 
novel drugs were selected for assessment in CIA and short-term mechanistic models 
of CII immunity. 
1.9.1 T lymphocytes in ell immunity 
Anti-CD4+ and anti-CD8+ mAbs 
The importance of CD4+ T cells in the CIA model is well-established. It has been 
demonstrated that mice deficient in CD4+ T cells are resistant or show reduced 
susceptibility to disease (Taneja et al., 2002 and Ehinger et al., 2001). Depleting or 
blocking mAbs against CD4 have also been shown to inhibit arthritis in mice (Ranges 
et al., 1985 and Chu and Londei. 1996). In addition, anti-CD4 therapy has hcen 
shown to be active in RA patients (Tak et at., 1995 and Choy et al., 2000). :\lthough 
this effect was only moderate, it does suggest that these cells ha\c a rok to pIa: in 
established disease. Regardless of the therapeutic merit of depleting CD4' T (l'lls in 
RA these cells represent an important target when trying to understand thc ccllular 
immune response to CII. 
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The role of CD8+ T cells in CIA is more contradictory Some res h 
. earc ers report that 
these cells are regulatory in CIA (Taneja et al 2002) whereas oth h' 
., ers report t at mice 
deficient in CD8+ T cells have a normal CIA response (Ehinger et al., 2001). Thus. 
the contribution of CD8+ T cells in disease pathogenesis is not fully understood. 
Depleting mAbs against CD4+ and CD8+ T cells will be used to confirm the role of 
these cells in CIA and to determine the underlying T cell population that drin~s the 
short-term models of CII immunity. 
1.9.2 Immunomodulation oleII immunity 
Anti-LFA-l, anti-CD40L mAbs and leflunomide 
The T cell-APC and T cell-B cell interactions are fundamental in the initiation of 
adaptive immunity. These cellular associations are dependent on costimulatory 
molecules and cell adhesion molecules binding their ligands. T cell-APC contact and 
hence antigen recognition is dependent on the binding of LF A- L expressed on T 
cells, to ICAM-l expressed on APCs. The importance of this interaction on T cell 
activation has been demonstrated using Abs directed against LFA-l which inhibit T 
cell proliferation (Dongworth et al., 1985 and Berzins et al., 1988). [n addition, 
Kikimoto et al. (1992) showed that mAbs against LFA-l and ICAM-l suppress CIA. 
These studies demonstrate a role for LFA-I in T cell activation and disease. 
Antibody generation is important in the pathogenesis of RA and is mediated in part 
through the binding of CD40L on T cells to CD40 on B cells. In the CIA modd it has 
been demonstrated that a mAb against CD40L (anti-gp39) preH?nts arthritis 
development and anti-CII Ab production (Durie et al., 1993). These data indicate the 
importance ofT cell-B cell contact and the subsequent humoral response in CI.\ 
, , 
.' .' 
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Given the role of LF A-I and CD40L in the initiation of an immune responst'. m.-'\bs 
against these targets should have profound effects on early readouts of CII immunit\. 
The use of mAbs that target these molecules will help underpin the relati\t' 
contribution of T cell-APC and T cell-B cell interactions in CII immunity. 
In addition to these experimental drugs, leflunomide, a DMARD used to treat RA. 
will also be utilised. The primary mechanism of action of leflunomide is the 
inhibition of de novo pyrimidine synthesis which is required for cell division 
(Ruckemann et al., 1998 and Breedveld and Dayer. 2000). Lymphocytes have IO\\" 
cellular pools of pyrimidine and are therefore sensitive to leflunomide. Assessing the 
effect of leflunomide on pre-arthritic readouts will further highlight the role of 
lymphocytes in elI immunity. Leflunomide has been shown to be cffective in 
experimental models of arthritis (Thoss et al., 1996 and Schorlemmer and 
Schleyerbach. 1998) therefore demonstrating the relevance of pre-clinical animal 
models in anti-arthritic drug discovery. In this thesis leflunomide will be used to 
validate the murine CIA model and the pre-arthritic readouts of CII immunity. 
1. 9.3 Pro-inflammatory cytokines in ell immunity 
Anti-TNF a and anti-IL-l fJ mAbs 
The pro-inflammatory cytokines TNFa and IL-l ~ have a wide range of biological 
actions. Both of these cytokines increase ICAM-l expression and synergisc with cach 
other to induce cellular infiltration to sites of inflammation (Doukas and Pober. 199() 
and Wankowicz et ai, 1988). These cytokines also regulate each others production 
(Brennan et al., 1989 and Williams et aI., 2000) and are both capable of inducing 
. h PGE and IL-6 sccretion (Jl)rL'.Cn...;cn t'f (/1.. 
other intlatnmatory cytoktnes sue as 2 . ~ 
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1991, Choy et al., 1999 and Saijo et al., 2002). Increased production of these 
cytokines therefore perpetuates the inflammatory response. 
In the murine CIA model, mAbs directed against TN Fa and IL-l P ha\'e been shown 
to inhibit the development of arthritis (Williams et al., 1992 and Geiger et at., 1993 
respectively) therefore demonstrating the importance of these cytokines in disease. In 
addition, TNFa has been shown to stimulate bone resorption and inhibit bone 
formation in vitro (Bertolini et al., 1986) and in the clinic anti-TN Fa therapy has 
been shown to halt joint erosion in RA patients. Additional biological actions of I L-
1 P include induction of IL-2 production and augmentation of T cell proliferation 
(Hackett et al., 1988). 
It would appear that anti-TNFa therapy exerts its anti-arthritic effects by reducing 
inflammation and preventing bone erosion. In pre-arthritic animals, where the 
immunomodulatory properties of drugs are assessed, there is no eYidence of 
inflammation or bone erosion so it is possible that the anti-arthritic effect of an anti-
TNFa mAb will not be detected. However, the role of TN Fa in the early stages of an 
immune response to CII has not been investigated. IL-I p also seems to play a 
predominantly pro-inflammatory role which may not be detected in the early readouts 
of ell immunity. However, its effect on T cell proliferation may be important in ell 
immunity and assessing an anti-IL-l p mAb in the pre-arthritic phase should establish 
this. 
Anti-IL-6 mAb 
IS IL-6. which has picotropic Another pivotal cytokine in the immune response 
actions. I L-6 is involved in the production of Ig fi'om B eel b (CrOn and Swain. Il)l) I ) . 
. , . . I I I -') 'xprl'""ill(l B cell difTerentiation (Spla\\'shi et aI., 1990), T cell prolIferatIOn ,UH. . - L. . 
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(Pankewycz et al., 1990), which are all essential in immune responses Th ~ . '. 
. u~. It h not 
surprising that blockade of the IL-6 receptor (lL-6R) with a mAb inhibits C!:\ with a 
corresponding decrease in anti-CII antibody production (Takagi et al.. 1998). From 
these data the effect of a mAb directed against IL-6 should be detected in the pre-
arthritic readouts, as it is likely to play an essential role in ClI immunity. 
Taken together, the use of these mAbs will identify the role of TNFu, IL-l p and IL-6 
in CII immunity and may shed light on the mechanisms of action of drugs that target 
these cytokines in CIA. 
The drugs outlined above will be used to characterise and validate the CIA model and 
the short-term readouts of CII immunity. Assessing such a broad range of drugs will 
determine if the pre-arthritic models and assays are predictive of drug etTects in CIA. 
In addition, they should identify the key immunological processes involved in an 
immune response towards ClI and it should become evident if these models and 
assays are capable of discriminating between drugs with different modes of action. 
1.10 Evaluation of a novel drug in elI immunity 
Anti-IL-17 mAb 
Having characterised the pre-arthritic models and assays they will be utilised to aSSl'S" 
the role of a novel drug target in CII immunity. Recently, IL-17 has been idcnti tied ~IS 
another key pro-inflammatory cytokine and has been shown to induce the production 
of IL-I~, TNFa and IL-6 from macrophages (Jo\'anovic et al .. 199X). It is also ahk to 
synergise with IL-I~ to enhance IL-6 production (Chabaud t'1 £II., ItNS) and \\ith 
TNFa to enhance both I L-6 and I L-I ~ production from syno\'iocylL's (Kat! t'l £II., 
Chapter 1 
2001). In addition, IL-17 has been demonstrated to stimulate the secretion of other 
inflammatory mediators such as IL-8 and granulocyte-colony-stimulating factor (G-
CSF) which are involved in neutrophil recruitment (Fossiez et al., 1996) and is also 
capable of inducing ICAM-l expression (Yao et al., 1995). Mice deficient in IL-17 
are resistant to CIA (N akae et al., 2003) and blocking IL-l 7 has also been shown to 
reduce signs of arthritis (Lubberts et al., 2001). Thus, IL-17 has become a focus for 
therapeutic intervention in recent years. However, its role in disease pathogenesis 
both in RA and CIA has not been fully established. Thus, IL-17 represents a novel 
target and the use of a mAb directed against this cytokine will be assessed in the CIA 
model and the pre-arthritic models and assays. This analysis may help to identify the 
role of IL-l 7 in arthritis and inform on the mechanism of action of this novel drug. 
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1.11 Aims 
1. To assess drugs with varying mechanisms of action in the CIA model. 
2. To develop short-term models of CII immunity in pre-arthritic mice. 
3. To examine the effects of drugs utilised in aim 1 on short-term models of ClI 
immunity and determine if these models are predictive of drug effects in CIA and 
whether they are capable of discriminating between drug mechanisms of action. 
4. To investigate the role of the novel pro-inflammatory cytokine, IL-17, in ClI 
immunity. 
3R 
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Materials and methods 
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2.1 Materials 
2.1.1 Laboratory equipment 
HEP A class 1000 incubator, Centra GP8R centrifuge used for cell harvesting, 
Multidkan EX microtitre plate reader, Wellwash 4 MK2 automated plate washer 
(Thermo Fisher Scientific, Loughborough, U.K.). 
Eppendorf 5415D bench top microcentrifuge used for small-scale centrifugation 
(Anachem Ltd, Luton, U.K.). 
Skatron cell harvester (Skatron Instruments Inc, Lier, Norway). 
1205 betaplate liquid scintillation beta (p) counter (PerkinElmer, Beaconsfield, U.K.). 
AID ELISpot plate reader and ELISpot reader version 4 software (AID ELISpot, 
Strassberg, Germany). 
FACScalibur flow cytometer equipped with Cell Quest software (BD Biosciences, San 
Jose, CA). 
Callipers 0-25mm range (Miltutoyo Corporation, Kanagawa, Japan). 
2.1.2 Commonly used materials 
General lab consumables were freely available and purchased by UCB. 
Chicken sternal type II collagen (MD Biosciences, Zurich, Switzerland). 
Gibco sterile tissue culture grade phosphate buffered saline (PBS) (Invitrogen, Life 
Technologies, Paisley, Scotland). 
Bovine serum albumin (BSA) (Sigma, Poole, U.K.). 
Sulphuric acid (BDH Ltd, Poole, U.K.). 
Nunc™ ELISA plates supplied by Fisher Scientific (Loughborough, U.K.). 
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2.1.3 Materials specific to methods 
CII sensitisation and CIA 
Acetic acid (BDH Ltd, Poole, U.K.). 
Complete Freund's adjuvant and incomplete Freund's adjuvant (Sigma, Poole, U.K.). 
Anti-CII antibody ELISA 
Phosphate buffered saline (PBS) powder concentrate (Fisher Scientific, 
Loughborough, U.K.). 
Anti-mouse IgG 1 and IgG2a - horseradish peroxidase conjugated (HRP) (Serotec, 
Kidlington, U.K.). 
3,3' ,5,5' tetramethylbenzidine (TMB) (Sigma, Poole, U.K.). 
Serum amyloid A ELISA 
Serum Amyloid A (SAA) detection kit (Biognosis, Tridelta Development Ltd, 
Maynooth, Ireland) containing SAA antibody coated wells, suitable wash buffer 
concentrate, appropriate sample/calibrator diluent buffer concentrate, SAA standard 
calibrator (0.95Jlg/mL), anti-SAA-HRP conjugated antibody, TMB and stop reagent. 
CD4+ T cell isolation and cultures 
Gibco RPMI 1640 medium, L-glutamine and penicillin-streptomycin (Invitrogen Life 
Technologies, Paisley, Scotland). 
Heat inactivated foetal calf serum (FCS), Trypan blue solution, 2-mercaptoethanol. 
HEPES buffer, ethylenediamine tetra-acetic acid (EDT A), Red blood cell (RBC) lysis 
buffer, Mitomycin C (Sigma, Poole, U.K.) . 
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Magnetic cell sorting (MACS) LS+ columns and CD4+ MACS separation kit 
containing biotin-antibody cocktail and anti-biotin microbeads (Miltenyi Biotec, 
Bisley, U.K.). 
Methyl-[3H]-thymidine, specific activity of 50J.lCi (Amersham Biosciences, Chalfont 
St.Giles, U.K.). 
Cytokine ELISA 
Mouse IL-4, IL-17 and IFNy DuoSet® ELISA development system kits, containing 
capture antibodies (rat anti-mouse IL-4, IL-17 and IFNy), detection antibodies 
(biotinylated goat anti-mouse IL-4, IL-17 and IFNy), standards (recombinant mouse 
IL-4, IL-17 and IFNy) and streptavidin conjugated to HRP. 
Substrate solution pack containing colour reagent A (hydrogen peroxide) and colour 
reagent B (TMB). 
All supplied by R&D Systems Europe (Abingdon, U.K.). 
Tween 20® (Sigma, Poole, U.K.). 
Cytokine enzyme-linked immunospot (ELISpot) 
Mouse IL-4, IL-17 and IFNy ELISpot assay kits, containing mouse IL-4, IL-17 and 
IFNy mAb coated 96 well microplates, detection antibodies (biotinylated polyclonal 
antibodies specific for IL-4, IL-17 and IFNy), streptavidin alkaline phosphatase, 
suitable dilution buffers, suitable wash buffer, 5-Bromo-4-Chloro-3' 
Indolylphosphate p-Toluidine Salt (BCIP) and Nitro Blue Tetrazolium Chloride 
(NBT), and recombinant mouse IL-4, IL-I 7 and IFNy positive controls. 
Recombinant mouse IL--t, IL-17 and IFNy. 
All supplied by R&D Systems Europe (Abingdon, U.K.). 
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Flow cytometric analysis 
Fluorescein isothiocyanate (FIT C) conjugated rat anti-mouse IgG2b CD4 antibody 
(clone GK1.5), phycoerythrin (PE) conjugated rat anti-mouse IgG2a CD8 antibody 
(clone 53-6.7) and polypropylene Falcon tubes (BD Biosciences, Oxford, U.K.). 
Sodium azide (Sigma, Poole, U.K.). 
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2.1.4 Buffers, solutions and media 
PBS wash buffer for 
ELISA plates 
MACSbuffer 
Fluorescence activated cell 
sorter (FACS) buffer 
Cell culture media 
RBC lysis buffer 
Block buffer for ELISA 
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137mM NaCl, 2.68mM KCI, 
10.1 mM N a2HP04, 1.76mM KH2P04, 
pH 7.4 
Sterile tissue culture grade PBS (pH 7.2) 
supplemented with 0.50/0 bovine serum 
albumin (BSA) and 2mM EDT A. Sterile 
filtered and degassed. 
Sterile tissue culture grade PBS (pH 7.2) 
supplemented with 5% FCS and 0.1 % sodium 
azide 
RPMI 1640 medium containing 100/0 FCS, 
1 % penicillin-streptomycin, 0.20/0 2-
mercaptoethanol (2xl0-5M), 1 %) L-glutamine 
and 2.7% HEPES buffer. 
Sterile tissue culture grade distilled water 
supplemented with 155mM NH4CL 10mM 
KHCOJ and 0.1 mM EDT A, sterile filtered 
1°'0 BSA in PBS 
Reagent diluent for 
cytokine ELISA 
Stop solution for ELISA 
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0.1 % BSA, 0.05% Tween 20 in Tris-buffered 
saline (20mM Trizma base, 150mM NaCI) 
pH 7.2, 0.2~m filtered 
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2.1.5 Drugs 
Monoclonal antibodies were derived in-house and are outlined in Table 2.1 below. 
Antibody Construct Afrmity 
Anti-CD4+ Rat IgG2b 59nM 
(YTS 191) 
Anti-CD8+ Rat IgG2b 72nM 
(YTS 169) 
Anti-CD40L Chimeric hamster IgG 1 0.54nM 
(MRI) 
Anti-LFA-I Rat IgG2a Not known 
(Tib 217) 
Anti-TNFa Murinised pegylated Fab 1.20nM 
(cTN3) 
Anti-IL-I p Hamster IgG 1 0.42nM 
(BI22) 
Anti-IL-6 Murinised rabbit IgG 1 0.02nM 
(54E07) 
Anti-IL-I7 Chimeric rabbit IgG 1 0.03nM 
(AbI3) 
Anti-IFNy Hamster IgG 1 Not known 
(H22) 
Table 2.1 Monoclonal antibodies 
Monoclonal antibodies were formulated in either PBS (pH 7.4) or 50mM sodium 
acetate and 125mM sodium chloride (pH 5.0). All monoclonal antibodies were 
greater than 98% pure and endotoxin levels were less than 1 EU/mg. Prior to in vivo 
testing the monoclonal antibodies were characterised in appropriate in l'itro cell based 
assays. Affinities were assessed either by F ACS analysis or by a surface resonance 
technique known as "biacore". The affinity of anti-LFA-l and anti-IFNy are nut 
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known. However, in an in vitro cell based assay anti-LFA-l has been shown to block 
LF A-I at IO/-lg/ml. In addition, anti-IFNy has been demonstrated to block the antiviral 
activity of IFNy at ng/mL concentrations, therefore indicating it is a potent inhibitor 
of IFNy (Schreiber et al., 1985). Leflunomide was utilised together with cyclosporin 
A (Sigma, Poole, U.K.). 
2.2 Animals 
Eight to ten week old male DBAII mice were purchased from Harlan (Oxfordshire, 
U.K.). Mice were housed in cages in an environmentally controlled room 
(temperature 21°C to 23 °C and relative humidity 38% to 50%) on a I2-hour 
light/dark cycle according to U.K. Home Office regulations. Animals had access to 
RMI food pellets (Lillico, Betchworth, U.K.) and water ad libitum. Animals were 
acclimatised for at least four weeks before use. 
2.3 In vivo drug treatment 
Drugs were administered prophylactically from one day prior to sensitisation (Day-I). 
The only exceptions were anti-CD4+ and anti-CD8+ mAbs, which were dosed 3 days 
prior to sensitisation. All control mice received a suitable vehicle. The dose and 
frequency of administration for each drug are stated in the results chapters. All drugs 
were dosed subcutaneously with the exception of leflunomide which was dosed 
orally. 
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2.4 Methods 
2.4.1 Collagen-induced arthritis (CIA) 
Induction of arthritis in mice requires sensitisation to CII and was originally described 
by Courtenay et ai. in 1980. CII sensitised mice mount an immune response that 
manifests as an inflammatory polyarthritis in the paws. Arthritis is assessed visually 
as a clinical score. In this thesis, a protocol similar to that outlined by Courtenay et ai. 
was used to induce arthritis in DBAIl mice. 
CII sensitisation 
Chicken type II collagen (CII, isolated from chick sternal cartilage) was dissolved in 
O.IM acetic acid at 2mg/mL and constantly rolled overnight in the dark at 4°C. The 
next day (Day 0) the CII solution was mixed with an equal volume of Complete 
Freund's Adjuvant (CFA), which contains Img/mL heat killed mycobacterium 
tuberculosis, to give a 1 mg/mL solution. The solution was mixed with a syringe by 
repeatedly drawing up and down to produce an emulsion. The correct consistency 
was achieved when a drop of emulsion could be placed in water without sinking or 
dissipating. DBAII mice were injected with 0.1 mL (100/-lg CII) of emulsion into the 
base of the tail, by an intradermal route under anaesthesia, until a white blister 
appeared just under the surface of the skin. Where indicated, normal mice (not 
sensitised) and mice sensitised with 0.1 mL of emulsified CF A only were also used. 
Each mouse was checked 30 minutes after this procedure. 
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CII boost injection 
On Day 14 post-sensitisation mice were given a booster injection of CII, following 
the same method as described in the CII sensitisation section, but with Incomplete 
Freund's Adjuvant (IF A) (containing no mycobacterium), instead of CF A. 
From Day 14 onwards animals were checked daily for signs of arthritis. When signs 
were seen, animals were weighed, disease scored on a 0-3 scale per paw (as outlined 
below) and distress scored daily. Clinical score is the sum of all 4 paws (maximum 
score is 12 per mouse). Experiments were stopped once a robust disease was 
established in CII/CF A sensitised mice. Disease severity in the CIA model varies 
between studies. A robust disease response was considered to be one which reached a 
mean clinical score of 3 or greater at termination. 
Clinical disease score 
Normal paw = 0 
Wrist/ankle swollen = 1 
Wrist/ankle and pad swollen = 2 
Wrist/ankle, pad and digits swollen = 3 
2.4.2 Cll-induced hypersensitivity 
Sensitisation to CII induces an immune response involving both T and B cells and on 
re-exposure to the same antigen hypersensitivity reactions occur. Hypersensiti\'ity 
reactions can be easily quantified by measuring swelling at the site of re-exposure. 
CII hypersensitivity was assessed using a similar protocol reported by Farmer (!( al. 
(1986). Fourteen days post-sensitisation mice were anaesthetised and challenged with 
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ClI to assess hypersensitivity reactions. One day prior to challenge chick CII was 
dissolved in PBS at a concentration of 0.8mglmL and constantly rolled overnight in 
the dark at 4°C. Mice were injected with 25~L of the solution containing 20~g of CII 
(unless otherwise stated) into the right ear or PBS only into the left ear as a negative 
control. Ear thickness was measured in mm prior to challenge (0 hour) and at 6 and 
24 hours post-challenge with callipers to assess swelling. Experiments were 
terminated 24 hours post-challenge and blood was taken via cardiac puncture under 
terminal anaesthesia for serum. 
2.4.3 Anti-elllgGJ and IgG2a ELISA 
Sensitisation to CII induces an immune response. Antibodies against CII such as anti-
CII IgG 1 and anti-CII IgG2a form part of this response and can be easily detected 
using sandwich ELISA techniques as detailed below. The presence of anti-CII IgG 1 
and anti-CII IgG2a were determined in serum samples derived from mice 15 days 
post-CII sensitisation (unless otherwise stated). 
1. CII was dissolved in PBS to give a 1 mglmL solution and constantly rolled 
overnight in the dark at 4°C. This was then stored at -70°C as a stock 
solution. Stock was defrosted when needed and diluted to a working 
concentration of 5~glmL in PBS. ELISA plates (96 well) were then coated 
with 1 OO~L per well of CII solution. Plates were then covered and stored 
overnight at 4°C. 
2. The next day plates were aspirated and washed twice \\·ith PBS on an 
automated plate washer. 
J. Plates were blocked with 1 % BSA in PBS (200pL per well) and placed on a 
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plate shaker for 30 minutes at room temperature. 
4. Plates were aspirated and washed twice with PBS on an automated plate 
washer. 
5. Serum samples were diluted 1 in 10,000 in PBS and 1 OO~L aliquots of each 
sample were added to plates in duplicate. 
6. Plates were placed on a plate shaker for 1 hour at room temperature and then 
washed twice with PBS. 
7. IgO 1 and/or Ig02a - HRP conjugated antibodies were diluted from stock 1 
in 5,000 in PBS containing 1 % BSA and 1 OO~L per well was added to the 
plates. 
8. Plates were placed on a plate shaker for 1 hour at room temperature and then 
washed four times with PBS. 
9. TMB substrate, 1 OO~L per well, was added to the plates. 
10. The reaction was stopped after 10 minutes with 1 OO~L 1 N sulphuric acid 
and read on a plate reader at 450 and 630 nM wavelength. 
2.4.4 Serum Amyloid A (SAA) assay 
Serum samples prepared from the blood of sensitised mice, taken at various time 
points, were analysed using an SAA detection kit (Biognosis, Tridelta Development 
Ltd, Maynooth, Ireland) following the manufacturers protocol as detailed below. The 
amount of SAA in the serum is determined by sandwich ELISA. A monoclonal 
antibody specific for SAA was coated directly onto the surface of 96-well microtitre 
plates and samples were added to the wells with a HRP labelled anti-SAA 
monoclonal antibody. SAA present in the samples is captured between the two 
monoclonal antibodies. TMB \\'as added to the wells to produce a colorimetric 
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reaction which is easily quantified and is directly proportional to the amount of SAA 
present. 
Reagent preparation 
Diluent buffer - 1 part of diluent buffer concentrate was diluted in 9 parts distilled 
water. 
Wash buffer - 1 part of wash buffer concentrate was diluted in 19 parts distilled 
water. 
SAA standard - SAA calibrator standard was dissolved in 200J.lL of distilled water 
with vigorous mixing to ensure the standard was completely dissolved. Serial 
dilutions were prepared with 50J.lL of SAA standard diluted in 200J.lL of diluent 
buffer and mixed well, then serially diluted four times by taking 125J.lL of previous 
solution and adding to 125J.lL diluent buffer. This gave concentrations of 0.950, 
0.475, 0.237, 0.118, 0.059 and O.OOOJ.lg/mL (diluent buffer only) for the standard 
curve. 
1. 50J.lL of anti-SAA - HRP conjugate was added to each well. 
2. Serum samples were diluted to the desired concentration in diluent buffer 
and ranged from a 1 in 200 to a 1 in 15,000 dilution. 
3. 50J.lL of diluted standards and serum samples were added in duplicate to 
each well. The sides of the plates were gently tapped to mix. 
4. The plates were covered with a plate sealer and incubated for 1 hour at 
37°C. 
5. The plates were aspirated and \\'ashed four times \\'ith wash butler. 
6. I OOpL of nvlB substrate was added to each well. 
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7. Plates were incubated at room temperature for 15 minutes. 
8. 1 OO~L of stop solution was added to each well and mixed by gently tapping 
the sides of the plates. 
9. Absorbance of the plates was read at 450 and 630nm wavelength on a plate 
reader. 
SAA levels were calculated as ~g/mL using the standard curve. A typical standard 
curve is shown in Figure 2.1 . 
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2.4.5 Cll stimulated CD4+ T cell proliferation 
Cell harvest 
CD4+ T cells isolated from CII sensitised mice can be used to assess the cellular 
immune response. Re-stimulation of these cells ex vivo with CII induces proliferation. 
The CD4+ T cell proliferation assay in this thesis was adapted from a single cell 
suspension assay described by Mauri et al. (1996). Inguinal lymph nodes were 
dissected out from normal male DBAI! mice or from mice 14 days after sensitisation 
with either complete Freund's adjuvant (CFA) or collagen II (CII) in CFA and placed 
in cell culture medium. Lymph nodes were pooled from each experimental group. In 
a class II fume hood lymph nodes were pushed through a 70 micrometer (/lm) mesh 
with a 2mL syringe plunger end and cells were collected in a petri dish. The mesh 
was washed out with medium to ensure as many cells as possible had passed through. 
U sing a plastic pipette, cell suspensions were transferred from the petri dish to a 
15mL falcon tube and centrifuged for 5 minutes at 41 Oxg. Supernatants were poured 
into verkon and disposed of down the sink at the end of experiments. The tubes were 
agitated to break up the cell pellets and cells were resuspended in 1 mL of culture 
medium. The cells were stained by diluting 1 in 100 in trypan blue in a 96 well plate. 
Cells were stained for 2-3 minutes then counted. Dead cells take up blue dye and cells 
that appeared white were counted. Counts were conducted using a graticual and 
microscope, which gave counts at I x 1 04 and were adjusted for the dilution factor 
gi ving counts at 1 x 1 06 . 
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CD4+ cell separation 
CD4+ MACS separation kit (Miltenyi Biotec, Bisley, U.K.) was used following the 
manufacturers protocol as detailed below. This is a negative selection kit where CD4+ 
T cells are isolated by removal of non-CD4+ T cells. Non-CD4+ T cells are indirectly 
magnetically labelled with a cocktail of biotin conjugated mAbs, as primary labelling 
reagent, and anti-biotin mAbs conjugated to microbeads, as secondary labelling 
reagent. Magnetically labelled non-CD4+ T cells are removed by retaining them on a 
MACS column in the magnetic field of a MACS separator, while the CD4+ T cells 
pass through the column. 
When using this magnetic labelling technique it was essential to work fast and keep 
cells cold, using chilled solutions only. 
Magnetic labelling 
1. Harvested cells were centrifuged at 41 Oxg for 10 minutes. 
2. Supernatants were removed and cell pellets resuspended in 40!J.L of MACS 
buffer per 1 x 1 07 cells. 
3. 10!J.L of biotin-antibody cocktail was added per lxl07 cells. 
4. Cells were mixed well and incubated for 10 minutes at 4-8°C. 
5. 30!J.L of MACS buffer and 20!J.L of anti-biotin microbeads were added per 
1 xl 07 cells. 
6. Cells were mixed well and incubated for 15 minutes at 4-8°C. 
7. Cells were washed with MACS buffer by adding 10-20 times the labelling 
volume and centrifuged at 41 Oxg for 10 minutes. 
8. Supernatant was completely removed and placed into verkon. 
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9. The cell pellets were resuspended in 500/-lL of buffer per 1 x 1 08 cells (for 
less cells 500/-lL was used). 
Magnetic separation 
LS+ MACS columns were used for positive cell separation. 
1. LS+ columns were placed in the MACS separator with l5mL falcon tubes 
underneath. 
2. MACS columns were prepared by rinsing with 3mL of MACS buffer, which 
was collected in the l5mL falcon tubes. Buffer was then disposed of and 
new falcon tubes were placed under the MACS columns to collect cells. 
3. Cell suspensions were applied to MACS columns and the fraction of 
unlabelled CD4+ cells were collected in the l5mL falcon tubes. 
4. MACS columns were washed four times with 3mL of MACS buffer, which 
was collected in the same tubes. 
5. Cells were centrifuged and counted by staining as described above. 
6. CD4+ cells were resuspended at 5 x 106 cells/mL in cell culture medium. 
APe cell preparation 
1. Spleens were removed from naIve mice and pooled in cell culture medium. 
2. Spleens were mashed with a syringe plunger and passed through a 70/-lm 
mesh into petri dishes. 
3. Cells were centrifuged at 410xg for 5 minutes and supernatants were 
discarded into verkon. 
4. 31nL of sterile RBC lysis buffer was added to the cell pellets for 3 minutes. 
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5. The volume was made up to 10mL with cell culture medium and centrifuged 
at 41 Oxg for S minutes. 
6. Cells were resuspended m 1 mL of cell culture medium and counted by 
diluting 1 in 100 in trypan blue stain (counts at 1 xl 06). 
7. Cells were resuspended at Sxl07 cells/mL in cell culture medium. 
8. A 0.5mglmL solution of mitomycin C was made up by adding 4mL of 
sterile PBS to one vial of mitomycin C, which was agitated and filtered 
through a 20f.!m syringe filter. 
9. 1 OOf.!L mitomycin C solution was added per ImL of cells. 
10. Cells were incubated at 37°C for 35 minutes. 
11. Cells were centrifuged and washed four times in cell culture medium. 
12. Cells were resuspended at 2x 107 cells/mL in cell culture medium. 
Unless otherwise stated 50f.!L of C04+ cells (2.5xI05 per well) were plated out with 
50f.!L of APCs (I xl 06 per well) into 96 well plates. In some experiments drugs were 
diluted in sterile PBS and assessed in vitro at a concentration of 0.1, 1, 10 and 
100f.!glmL for mAbs or 0.1, 1 and IOf.!M for cyclosporin A. 
Prior to cell harvest, chick CII was dissolved overnight at 4°C in PBS at O.Smg/mL. 
CII solution was then denatured in a water bath at 60°C for 2-3 hours and allowed to 
cool. This was done in advance and the CII solution was frozen in aliquots. Aliquots 
were defrosted as required on the day of cell culture. To stimulate cell proliferation 
20pL of the CII solution was added to some wells at a concentration of SOpg/mL 
(unless otherwise stated). The volume of each well was then topped up to 200pL with 
culture medium. Cells were placed in a humidified 37°C CO2 incubator for 72 hours 
(unless otherwise stated). 
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To assess cell proliferation 20~L 3H thymidine (1 ~Ci) was added to each well for the 
last 6 hours of culture. Plates were frozen and then defrosted at a later date for 
analysis of cell proliferation. Cells were harvested from defrosted plates by an 
automated cell harvester onto filter paper and dried in the oven for 30 minutes. 
Radionuc1ide uptake was measured by liquid scintillation counting on a p counter and 
total counts per minute (cpm) were obtained. In some experiments 3H thymidine was 
not added and cell culture supernatants (l OO~L) were removed for cytokine analysis 
as described below. 
Radioactive material was disposed of in designated bins and sinks and recorded on 
Isostock (an in-house tracking system). 
2.4.6 IL-4, IL-17 and IFNyELISA 
CD4+ T cell cultures were set up as described above. Cell culture supernatants taken 
at various time points were analysed for levels of IL-4, IL-17 and IFNy using 
DuoSet® ELISA development system kits (R&D Systems, Abingdon, U.K.) following 
the manufacturer's protocol as detailed below. These kits use sandwich ELISA 
techniques with a colorimetric endpoint to measure the amount of cytokine present in 
the supernatant. 
Reagent preparation 
All reagents were brought to room temperature before use. 
Wash buffer - 0.050/0 Tween 20 in PBS, pH 7.2. 
Reagent diluent - 1 % BSA in PBS. 
Capture antibodies for IL-4, IL-17 and IFNy were reconstituted with 1 mL of PBS. 
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Detection antibodies for IL-4, IL-17 and IFNy were reconstituted with 1 mL of reagent 
diluent. 
Recombinant mouse IL-4, IL-17 and IFNy standards were reconstituted with 0.5mL 
reagent diluent and allowed to sit for 15 minutes with gentle agitation. The 
manufacture's serial dilutions were followed to give a seven-point standard curve, 
this varied for each kit. 
Streptavidin-HRP was diluted 200 fold to give the correct working concentration. 
Substrate solution was mixed in a 1: 1 ratio of colour reagent A and B. 
Sample preparation 
Supernatants from cell cultures were used neat for IL-4 and IFNy assays and diluted 1 
in lOin reagent diluent for IL-I 7 assays. 
1. The required number of 96 well ELISA plates were coated with 1 OO~L per 
well of the appropriate capture antibody diluted to the working 
concentration. Plates were then sealed with an adhesive strip and incubated 
overnight at room temperature. 
2. The next day, plates were aspirated and washed three times with wash buffer 
on an automated plate washer. 
3. Plates were blocked by adding 300~L of reagent diluent to each well and 
incubated at room temperature for a minimum of 1 hour. 
4. Plates were washed as in step 2. 
5. 1 OO~L of sample or appropriate standard was added to plates and incubated 
for 2 hours at room temperature. 
6. Plates were washed as in step 2. 
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7. 100J-lL of the appropriate detection antibody~ diluted to the working 
concentration, was added to each well and covered with a new adhesive strip 
and incubated for 2 hours at room temperature. 
8. Plates were washed as in step 2. 
9. 100J-lL of streptavidin-HRP, diluted to the working concentration~ was 
added to each well and incubated for 20 minutes at room temperature. 
10. Plates were washed as in step 2. 
11. 100J-lL of prepared substrate solution was added to each well and incubated 
for 20 minutes at room temperature. 
12. 50J-lL of stop solution was added to each well and plates were gently tapped 
to ensure thorough mixing. 
13. Absorbance of the plates was read at 450 and 630nm wavelength on a plate 
reader. 
The levels of IL-4, IL-17 and IFNy were calculated as J-lg/mL using standard curves. 
A typical standard curve is shown in Figure 2.2. 
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2.4.7 IL-4, IL-17 and IFNyELISpot 
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ELISpot assays have been designed to detect cytokine secreting cells at the single cell 
level. These assays use the sandwich ELISA technique. CD4+ T cells and APCs were 
isolated as described above and incubated in 96-well plates pre-coated with a 
monoclonal antibody specific for either IL-4 or IL-17 or IFNy. During the incubation 
period cytokines released from cells are bound by the cytokine specific monoclonal 
antibodies. A cytokine specific biotinylated polyclonal antibody was then added to 
the wells. Alkaline-phosphatase conjugated to streptavidin was then added followed 
by a substrate solution and a blue-black coloured spot forms at the sites of cytokine 
localisation. Each spot represents an individual cytokine secreting cell which allows 
the frequency of IL-4, IL-17 and IFNy secreting cells in culture to be determined. 
Reagellt preparatioll 
Wash buffer concentrate was diluted 1 in 10 with deionised water. 
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Mouse IL-4, IL-17 and IFNy positive controls were reconstituted with 0.25mL of 
culture medium. 
Detection antibodies - 1 OO~L of the detection antibody concentrate was added to 
dilution buffer 1 and mixed well. 
Streptavidin-AP - 1 OO~L of streptavidin-Ap concentrate A was added to dilution 
buffer 2 and mixed well. 
1. 200~L of sterile culture medium was added to each well of the IL-4, IL-17 
and IFNy ELISpot microplates and incubated for 20 minutes. 
2. Culture medium was aspirated from the wells and 2.5 x 105 CD4+ T cells 
together with 1 x 105 APCs were added. Anti-IL-17 and anti-IFNy mAbs 
were also added to some wells at a concentration of 1, 10 and 1 OO~g/mL. In 
some experiments recombinant mouse IL-I 7, IFNy and IL-4 were added to 
some wells at a concentration of 1, 10 and IOOng/mL. Some wells received 
50~g/mL of denatured CII. 
3. Cells were cultured in a humidified 37°C CO2 incubator for 24 or 72 hours 
(as stated). 
4. Each well was aspirated and plates were washed four times with wash buffer 
on an automated plate washer. 
5. 1 OO~L of detection antibody was added to each well and incubated 
overnight at 2-8°C. 
6. Plates were washed as in step 4. 
7. 1 OO~L of diluted strepta\'idin-AP was added to each well and incubated for 
2 hours at room temperature. 
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8. Plates were washed as in step 4. 
9. 100J.lL of BCIPINBT chromogen was added to each well and incubated for 
1 hour at room temperature protected from light. 
10. The chromogen solution was discarded and plates were rinsed with 
deionised water. Plates were inverted and tapped to remove excess water. 
The flexible plastic underdrain was removed from the bottom of the plates. 
Plates were completely dried by leaving them at room temperature for 1 
hour. 
11. Plates were analysed for the number of IL-4, IL-17 or IFNy positive spots 
using an automated ELISpot plate reader. 
The number of IL-4, IL-17 and IFNy positive spots per total cells plated out were 
calculated. 
2.4.8 Flow cytometric analysis 
Depletion of CD4+ and CD8+ T cells after in vivo anti-CD4+ and anti-CD8+ treatment 
was confirmed using flow cytometric analysis. These antibodies have previously been 
shown to successfully deplete CD4+ and CD8+ T cells respectively (Cobbold et al., 
1984). At termination of some studies inguinal lymph nodes were dissected out and 
cell suspensions were prepared as described for cell harvest above. Cells were washed 
in 3mL of ice-cold FACS buffer and centrifuged at 410xg for 5 minutes. Cells were 
then resuspended in 1 mL of F ACS buffer and 100J.lL of each sample was removed 
and placed in 5lUL polypropylene Falcon tubes. Anti-CD4 FITC conjugated and anti-
CD8 PE conjugated antibodies were added to cell suspensions at a concentration of 
1 O~lg/mL and 4J.lg/IUL respectively. Samples were incubated for 30 minutes on ice. 
The cells were then washed twice in 3mL of F ACS buffer and resuspended in O . .5mL 
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of F ACS buffer. Analysis of the cells was carried out on a F ACScalibur flow 
cytometer equipped with CellQuest software. A decrease in the detection of 
fluorescently labelled anti-C04 and anti-C08 in cells from treated mice, as compared 
to cells from vehicle treated CII/CF A control mice, indicated depletion of C04 + and 
C08+ T cells respectively. 
2.5 Data handling 
Data handling and statistical analysis was conducted on GraphPad Prism V3.03. 
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Drug effects in the collagen-induced arthritis (CIA) model 
Chapter 3 
3.1 Introduction 
CIA is a long-tenn pre-clinical model of RA and is widely used to assess anti-arthritic 
drug effects. Many of the drug targets under investigation in this thesis have been 
demonstrated to playa role in models of arthritis. However, protocols used to induce 
CIA vary from one research establishment to another and many of the in-house mAbs 
have not previously been shown to be active in the CIA model. It was therefore 
essential to evaluate these drugs in the CIA model in-house to detennine their anti-
arthritic activity. 
The majority of the mAbs used in this thesis have pM affinities for their targets as 
outlined in Chapter 2, Table 2.1. In addition, these mAbs were assessed in in vitro 
assays and phannacokinetic studies prior to the initiation of CIA experiments. Results 
from these studies identified the concentrations of mAb needed for biological activity 
and the doses and frequencies required to achieve these levels in the blood. 
Leflunomide is a known anti-arthritic agent, however, its effect in the murine CIA 
model is not well reported, therefore a dose was chosen based on activity in other 
animal models of RA (Thoss et al., 1996). To try to avoid any adverse effects of 
leflunomide, a relatively low dose which was anticipated to be effective was chosen. 
Dose and frequency of administration for each drug are stated in the results section. 
Using these drugs as phannacological tools, the underlying mechanisms involved in 
CIA were investigated. Validation of the CIA model was conducted in this part of the 
work with the clinically relevant anti-arthritic drug leflunomide. In addition, mAbs 
targeting TNFu, IL-I p and IL-6, cytokines proven to be important in RA, were 
utilised for further validation and to detennine the cytokine dependencies within the 
model. Anti-CD4+, anti-CD8+. anti-CD40L and anti-LFA-I mAbs were used to gi\'e 
an insight into the immunological processes underlying the disease. 
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To detennine the role of the novel target IL-17 in the CIA model an anti-IL-17 mAb 
was used. A comparison between the anti-arthritic effects of anti-IL-17 treatment and 
the other drugs can then be made. Such a comparison should identify the potential of 
targeting IL-17 as a therapy. 
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3.2 ~inn 
The aim of this chapter was to assess the anti-arthritic properties of a range of drugs 
in the CIA model. Drug effects in the subsequent short-term mechanistic models can 
then be compared with their anti-arthritic activity in this chapter and the predictive 
nature of these models can be determined. 
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3.3 Results 
In these experiments data is presented as mean clinical score per group on a daily 
basis and mean area under the curve (AUC) of the clinical score. AUC was calculated 
using the statistics software on GraphPad Prism V3.03. These readouts show the 
progression of disease over time and the overall disease severity respectively. The 
anti-arthritic effect of the drugs was assessed by their ability to reduce these readouts 
relative to vehicle treated controls. Statistical analysis of data was conducted using 
the Mann Whitney test and p<0.05 was considered significant. 
3.3.1 CD4+ and CDS+ T cell depletion 
The role of CD4+ and CD8+ T cells in the CIA model was assessed using mAbs 
capable of depleting these cells (Figure 3.1). Anti-CD4+ and anti-CD8+ mAb 
treatment was assessed against the same control group. In the vehicle control group, 
mice showed signs of arthritis 26 days after sensitisation. Arthritis in this group got 
progressively worse over time resulting in a mean clinical score of 6.14 ± 1.10 on 
Day 54 when the study was terminated. CIA mice treated with anti-CD4+ mAb 
showed a complete abrogation of arthritis (Figure 3.1 a) with a statistically significant 
100% inhibition in AUC of the clinical score (Figure 3.1 b). Mice treated with anti-
CD8+ mAb showed signs of arthritis 17 days post-sensitisation with the mean clinical 
score increasing to 4.93 ± 0.84 on Day 54 (Figure 3.1a). Anti-CD8+ treatment caused 
a 19% reduction in AUC of the clinical score but this was not statistically significant 
(Figure 3 .1 b). 
Depletion of CD4+ and CD8+ T cells was confirmed in the lymph nodes of treated 
mice at tennination of the experiment by F ACS analysis (Figure 3.2). These mAbs 
ha\'c previously been shown to deplete their target cells in-house (historical data) and 
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in the literature in mice (Cobbold et al., 1984). Thus staining of CD4 and CD8 only 
was considered satisfactory to assess depletion. Anti -CD4 + treatment caused a 
statistically significant 720/0 (p<O.Ol) depletion of CD4+ T cells in the lymph nodes as 
compared to vehicle treated mice. Anti-CD8+ treatment resulted in a statistically 
significant 800/0 (p<0.05) depletion of CD8+ T cells in the lymph nodes as compared 
to vehicle treated mice. Depletion of CD4+ and CD8+ T cells was also seen in the 
blood (data not shown). 
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Figure 3.1 Effect of prophylactic anti-CD4+ and anti-CDS+ antibody treatment 
on collagen-induced arthritis. 
Male DBAIl mice were sensitised by intradermal injection of 100/-lg collagen II (CII) 
in 0.1 M acetic acid and complete Freund ' s adjuvant at the base of the tail , 14 days 
post-sensitisation animals were boosted with 100/-lg CII in incomplete Freund' s 
adjuvant. Paws were scored daily for clinical signs of arthritis on a 0-3 scale taking 
into account swelling of the wrist/ankle, pad and digits. Data presented as mean 
clinical score (a) and AUC of the clinical score (b). Some animals were dosed with 
anti-mouse CD4+ or anti-mouse CD8+ antibodies 10mg/kg s.c. on three consecutive 
days prior to sensitisation and thereafter once a week. Data presented as mean ± 
s.e.m, n = 15 per group, *** p<O.OOl statistically significant from indicated control. 
The numbers indicate percent inhibition of CIA with anti-CD4+ and anti-CD8+ 
antibody 
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Figure 3.2 Confirmation of CD4+ and CDS+ T cell depletion in lymph nodes. 
Male DBA/ 1 mice were sensitised by intradennal injection of I OOllg co ll agen Il (CII) 
in O. I M acetic acid and complete Freund's adjuvant at the base of the tail, 14 da 
post-sensiti sation animals were boosted with IOOllg crr in incomplete Fr und' 
adjuva nt. Some animal were dosed with anti-mou e C04+ or anti-mou c CD .j 
antibodi es I Omg/kg s.c. on three consecutive days prior to en iti ation and thercaft er 
oncc a week. At termination of thc experiment (Day 54) mice were killed and 
inguinal I mph nodc~ were removcd. ingl cell u pen ion wcre preparcd and ccll " 
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were stained with anti-CD4 FITC conjugated and anti-CD8 PE conjugated antibodies 
for flow cytometric analysis as described in Chapter 2. The mean percentage of gated 
cells was calculated for each group of mice (a). A representative fluorescence 
activated cell sorter plot is shown for vehicle treated CF AJCIl sensitised controls (b), 
CFAJCIl sensitised anti-CD4+ treated (c) and CFAJCIl sensitised anti-CD8+ treated 
mice (d). Data presented as mean + s.e.m, n = 15 per group, ** p<O.Ol and * p<O.05 
statistically significant from indicated control. The numbers indicate percent 
depletion of CD4+ and CD8+ T cells as compared to indicated control (a) and the 
percent gated cells (b, c and d). 
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3.3.2 Leflunomide 
In order to demonstrate that a clinically relevant drug, used in the treatment of RA, is 
active in the CIA model, leflunomide was assessed (Figure 3.3). CIA mice that were 
administered vehicle started to show signs of arthritis on Day 16 post-sensitisation. 
Disease severity in this group increased to give a mean clinical score of 5.27 ± 0.95 at 
the end of the experiment on Day 36. Mice treated with leflunomide also showed 
signs of arthritis on Day 16, however disease progression was inhibited when 
compared to vehicle control animals, with a mean clinical score of 1.47 ± 0.52 on 
Day 36 (Figure 3.3a). This reduction in disease severity with leflunomide gave a 
statistically significant 680/0 inhibition in AUC of the clinical score (Figure 3.3b). 
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Figure 3.3 Effect of prophylactic leflunomide treatment on collagen-induced 
arthritis. 
Male DBAIl mice were sensitised by intradermal injection of 1 OO~g collagen II (ell) 
in 0.1 M acetic acid and complete Freund ' s adjuvant at the base of the tail , 14 days 
post-sensitisation animals were boosted with 1 OO~g ClI in incomplete Freund 's 
adjuvant. Paws were scored daily for clinical signs of arthritis on a 0-3 scale taking 
into account swelling of the wrist/ankle, pad and digits . Data presented as mean 
clinical score (a) and AUC of the clinical score (b) . Some animals were dosed orall y 
with leflunon1ide 3mg/kg daily from one day prior to sensitisation. Data presented as 
mean ± s.e.m, n = 15 per group, * p<0.05 statistically significant from indicated 
control. The number indicates percent inhibition of CIA with leflunomide treatment. 
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3.3.3 Anti-CD40L 
The binding of CD40L on T cells to CD40 on B cells is essential in adaptive 
immunity. The effect of blocking this interaction in the CIA model was assessed 
using a mAb against CD40L (Figure 3A). Vehicle control mice showed signs of 
arthritis on Day 21 with the severity of disease increasing over time giving a mean 
clinical score of 3.20 ± 0.87 on Day 48. In mice treated with anti-CD40L attenuation 
of disease was seen, with signs of arthritis being delayed until Day 30 and the mean 
clinical score only increasing to 0.57 ± OAO on Day 48 (Figure 3Aa). Treatment with 
anti-CD40L resulted in a statistically significant 81 % inhibition in AUC of the 
clinical score (Figure 3 Ab). 
3.3.4 Anti-LFA-l 
Another fundamentally important cellular interaction in the initiation of an immune 
response is that of the T cell and the APC. This interaction occurs partly through 
LFA-l, expressed on T cells, binding its ligand ICAM, expressed on APCs. In order 
to block this interaction and identify its role in the CIA model, a mAb against LFA-l 
was assessed (Figure 3.5). CIA mice that received vehicle started to show signs of 
arthritis on Day 27 which got progressively worse over the course of the experiment 
resulting in a mean clinical score of 3.67 ± 0.84 at termination on Day 56. Mice 
treated with anti-LFA-I showed signs of arthritis on Day 30 and followed a similar 
disease pattern to vehicle control animals, with a mean clinical score of 2.73 ± 0.88 at 
the end of the study (Figure 3.5a). The AUC of the clinical score was analysed for 
each group and anti-LFA-I showed a 38% inhibition in disease, but this was not 
statistically significant (Figure 3.Sb). 
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Figure 3.4 Effect of prophylactic dosing with anti-CD40L Fab PEG antibody on 
collagen-induced arthritis. 
Male DBAII mice were sensitised by intradermal injection of 100).lg collagen II (ell) 
in 0.1 M acetic acid and complete Freund's adjuvant at the base of the tail , 14 days 
post-sensitisation animals were boosted with 100l-lg CII in incomplete Freund 's 
adjuvant. Paws were scored daily for clinical signs of arthritis on a 0-3 scale taking 
into account swelling of the wrist/ankle, pad and digits. Data presented as mean 
clinical score (a) and AUC of the clinical score (b). Some animals were dosed with 
anti-mouse CD40L Fab PEG antibody 100mg/kg s.c. once a week from one day prior 
to sensitisation. Data presented as mean ± s.e.m, n = 15 per group, ** p<O.O 1 
statistically significant from indicated control. The number indicates percent 
inhibition of CIA with anti-CD40L Fab PEG antibody treatment. 
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Figure 3.5 Effect of prophylactic dosing with anti-LF A-I antibody on collagen-
induced arthritis. 
Male DBAIl mice were sensitised by intradermal injection of 1 OO~g collagen II (elI) 
in 0_1 M acetic acid and complete Freund ' s adjuvant at the base of the tail , 14 days 
post-sensitisation animals were boosted with 1 OO~g CII in incomplete Freund 's 
adjuvant. Paws were scored daily for clinical signs of arthritis on a 0-3 scale taking 
into account swelling of the wrist/ankle, pad and digits. Data presented as mean 
clinical score (a) and AUC of the clinical score (b) . Some animals were dosed with 
anti-mouse LFA-l antibody 30mg/kg s.c. once a week from one day prior to 
sensitisation. Data presented as Inean ± s.e.m, n = 15 per group. The number indicates 
percent inhibition of CIA with anti-LFA-l antibody treatment. 
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3.3.5 Anti-TNFa 
In order to assess the role of TNF in the CIA model a mAb against TNFa was 
assessed (Figure 3.6). Vehicle control mice showed signs of arthritis on Day 19. with 
the mean clinical score rising over the course of the experiment to 4.20 ± 0.79 on Day 
45. Anti-TNFa treatment delayed disease onset until Day 30 and attenuated signs of 
arthritis throughout the study, resulting in a mean clinical score of 1.33 ± 0.46 on Day 
45 (Figure 3.6a). Anti-TNFa treatment caused a corresponding statistically 
significant 820/0 inhibition in the AUC of the clinical score (Figure 3.6b). 
3.3.6 Anti-IL-1P 
A mAb directed against IL-l p was utilised to assess the role that this cytokine plays 
in CIA (Figure 3.7). Signs of arthritis in the vehicle control group were seen on Day 
19 post-sensitisation and disease severity increased throughout the study resulting in a 
mean clinical score of 6.07 ± 0.99 on Day 40. Anti-IL-l p treatment abrogated signs 
of CIA, with a delay in disease onset to Day 39 and a mean clinical score of 0.33 ± 
0.27 on Day 40 (Figure 3.7a). This translated into a statistically significant 99.60/0 
inhibition in AUC of the clinical score when mice were treated with anti-IL-IP 
(Figure 3. 7b). 
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Figure 3.6 Effect of prophylactic dosing with anti-TNFa antibody on collagen-
induced arthritis. 
Male DBAII mice were sensitised by intradermal injection of 1 OO~lg collagen II (ell) 
in 0.1 M acetic acid and complete Freund's adjuvant at the base of the tail , 14 days 
post-sensitisation animals were boosted with 1 OO~g ClI in incomplete Freund 's 
adjuvant. Paws were scored daily for clinical signs of arthritis on a 0-3 scale taking 
into account swelling of the wrist/ankle, pad and digits . Data presented as mean 
clinical score (a) and AUC of the clinical score (b). Some animals were dosed with 
anti-mouse TNFa antibody 100mgikg s.c. twice a week from one day prior to 
sensitisation. Data presented as Inean ± s.e.m, n 15 per group, ** p<O.O I 
statistically significant from indicated control. The number indicates percent 
inhibition of CIA with anti-TNFa antibody treatment. 
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Figure 3.7 Effect of prophylactic dosing with anti-IL-IP antibody on collagen-
induced arthritis. 
Male DBAIl mice were sensitised by intradermal injection of 1 OOllg collagen II (CIl) 
in O.IM acetic acid and complete Freund's adjuvant at the base of the tai l, 14 days 
post-sensitisation animals were boosted with lOOllg ell in incomplete Freund' 
adjuvant. Paws were scored daily for clinical signs of arthriti s on a 0-3 scale taking 
into account swelling of the wrist/ankle, pad and digits. Data presented as mean 
clinical score (a) and AUC of the clinical score (b). Some animals were dosed with 
anti-mouse IL-l P antibody 10mglkg s.c. once a week from one day prior to 
sensitisation. Data presented as mean ± s.e.m, n = 15 per group, *** p<O.OO I 
statistically significant from indicated control. The number indicates percent 
inhibition of CIA with anti-IL-l P antibody treatment. 
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3.3.7 Anti-IL-6 
The role of IL-6 in the CIA model was investigated using a mAb directed against this 
cytokine (Figure 3.8). In this experiment CIA mice dosed with vehicle showed signs 
of arthritis on Day 19 post-sensitisation. The arthritis in this group increased with 
time, giving a mean clinical score of 4.67 ± 0.75 on Day 52. Anti-IL-6 treatment 
delayed the onset of disease until Day 42 and thereafter attenuated disease 
progression, as compared to vehicle controls, resulting in a mean clinical score of 
1.13 ± 0.51 on Day 52 (Figure 3.8a). Anti-IL-6 treatment caused a statistically 
significant 870/0 inhibition in AUC of the clinical score in the CIA model (Figure 
3.8b). 
3.3.8 Anti-IL-17 
To assess the effect of inhibi ting a novel target in the CIA model a mAb against I L-l 7 
was used (Figure 3.9). In this experiment vehicle control mice showed signs of 
arthritis on Day 20 post-sensitisation and disease severity increased over time giving 
a mean clinical score of 6.00 ± 0.92 on Day 53. Anti-IL-17 treatment attenuated signs 
of CIA, as compared to vehicle control mice, resulting in a mean clinical score of 
2.27 ± 0.71 on Day 53 (Figure 3.9a). Anti-IL-17 treatment showed a statistically 
significant 750/0 inhibition in disease when the data was expressed as AUC of the 
clinical score (Figure 3.9b). 
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Figure 3.8 Effect of prophylactic dosing with anti-IL-6 antibody on collagen-
induced arthritis. 
Male DBAI1 mice were sensitised by intradermal injection of 1 OO~g collagen II (ell) 
in 0.1 M acetic acid and complete Freund's adjuvant at the base of the tail , 14 days 
post-sensitisation animals were boosted with 1 OO~g ell in incomplete Freund's 
adjuvant. Paws were scored daily for clinical signs of arthritis on a 0-3 scale taking 
into account swelling of the wrist/ankle, pad and digits. Data presented as mean 
clinical score (a) and AUC of the clinical score (b). Some animals were dosed with 
anti-mouse IL-6 antibody 10mglkg s.c. once a week from one day prior to 
sensitisation. Data presented as mean ± s.e.m, n = 15 per group, *** p<O.OO I 
statistically significant from indicated control. The number indicates percent 
inhibition of CIA with anti- IL-6 antibody treatment. 
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Figure 3.9 Effect of prophylactic dosing with anti-IL-17 antibody on collagen-
induced arthritis. 
Male DBAIl mice were sensitised by intradermal injection of 1 OO~g co ll agen II (e lI) 
in 0.1 M acetic acid and cOlnplete Freund's adjuvant at the base of the tail , 14 days 
post-sensitisation animals were boosted with 100flg ell in incompl ete Freund ' 
adjuvant. Paws were scored daily for clinical signs of arthriti s on a 0-3 ca le taking 
into account swelling of the wrist/ankle, pad and digits. Data presented a mean 
clinical score (a) and AUe of the clinical score (b) . Some animals were do ed with 
anti-mouse IL-17 antibody lOmg/kg s.c. once a week from one day pri or to 
sensitisation. Data presented as mean ± s.e.m , n = 15 per group, ** p<O.O 1 
statistically significant from indicated control. The number indi cate p rcent 
inhibition of CIA with anti- IL-17 antibody treatment. 
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3.4 Discussion 
In this chapter a panel of drugs with different mechanisms of action were assessed in 
the CIA model and the results are summarised in Table 3.1 below. 
Drug CIA 
Anti-CD4+ +++ 
(100) 
Anti-CD8+ -
(19) 
Letlunomide ++ 
(68) 
Anti-CD40L +++ 
(81) 
Anti-LFA-l -
(38) 
Anti-TNFa +++ 
(82) 
Anti-IL-l p +++ 
(100) 
Anti-IL-6 +++ 
(87) 
Anti-IL-17 +++ 
(75) 
Table 3.1 Summary of drug effects on CIA. 
Note: The data is semi quantitative where + represents a low, + + represents a 
medium and +++ represents a high degree of suppression, all of which are 
statistically significant as compared to controls. 
- represents no statistically significant change from control. 
The numbers in brackets represent the percent reduction in the A UC of the clinical 
score as compared to controls. 
Although the CIA model is widely used to assess the effects of anti-arthritic drugs it 
is poorly characterised in the literature. Results presented in this chapter demonstrate 
that a depleting mAb directed against CD4+ T cells causes a complete abrogation in 
CIA. This confinns previous reports by Chu and Londei (1996) shp\\ing that 
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depleting and non-depleting Abs directed against CD4 inhibit CIA. However. in these 
studies, some mice showed signs of disease after treatment. This may be explained as 
they only treated mice for 11 days with Ab, thus the effects of treatment may ha\'e 
worn off allowing the re-population of CD4+ T cells. The current study demonstrates 
that continual treatment is required to completely prevent signs of arthritis. From the 
data reported here and in the literature it is evident that CD4+ T cells playa crucial 
role in the development of arthritis in this model. 
In contrast, it is clear that CD8+ T cells do not contribute to disease pathogenesis in 
the CIA model, as depletion of this cell population failed to inhibit arthritis. The 
majority of research conducted on CD8+ T cells in CIA has been done in CD8 
deficient mice. These mice have been reported to have a 5% reduction in the total 
number of T cells as compared to wild type mice and 80% of these cells are CD4+ 
(Taneja et al., 2002). The use of CD8 deficient mice has given rise to conflicting data. 
Taneja et al. (2002) demonstrated that CIA develops with increased disease severity 
in CD8+ deficient mice, suggesting CD8+ T cells have a regulatory role to play in 
disease. Whereas Tada et al. (1996) showed that CD8+ T cells are involved in the 
initiation of disease, while Ehinger et al. (200 I) reported CD8 deficiency had no 
effect on CIA. The variability between these studies may be due to different strains of 
mice being used to obtain CD8+ deficiency. In support of a regulatory role for CD8+ 
T cells in CIA Kadowaki et al. (1994) showed, in a transfer model of CIA. that 
depleting spleen cell cultures of CD8+ T cells prior to transfer into SCID recipient 
mice enhanced the onset of arthritis. Data in this chapter confirms work conducted by 
Ehinger et al. (2001) and showed that in DBAll mice, the most commonly used strain 
to study CIA in, CD8+ T cells are not important in the development of arthritis. 
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The results in this chapter clearly demonstrate that the T cell subset that dri\es 
disease in the CIA model is CD4+. 
To further investigate the underlying immunological processes in the CIA model 
mice were treated with anti-CD40L and anti-LF A-I mAbs. Administration of anti-
CD40L caused a statistically significant inhibition in the clinical signs of CIA. This 
demonstrates that the association between CD40L on T cells and its ligand CD40 on 
B cells is important in the immune response against ClI. These data confirm the 
reported role of CD40L in CIA (Durie et al., 1993). Durie et al. also showed that the 
production of anti-ClI Abs was attenuated after CD40L blockade. The data reported 
here, as well as the literature, indicate the importance of T cell-B cell interactions in 
disease development and anti-ClI Ab production in the CIA model. 
Anti-LFA-l treatment failed to inhibit signs of arthritis in the CIA model, which was 
surprising considering the fundamental importance of T cell-APC contact in antigen 
recognition. These data suggest that LFA-l is not essential in the development of 
arthritis in this model. This finding is in contrast to work conducted by Kakimoto et 
al. (1992) who demonstrated that mAbs against LFA-l and its ligand ICAM are 
capable of inhibiting CIA. However, the suppression of disease reported by Kakimoto 
et al. was not profound and statistical significance was only detected towards the end 
of the experiment. If these data were expressed as AUC of the clinical score, which 
would take into account the overall disease severity, this statistically significant effect 
tTIay be lost giving a similar result as reported in the current study. 
To show the CIA lTIodel responds to drugs used in the treatment of RA. letlunomide. 
a DMARD that inhibits lymphocyte proliferation. was assessed. Let1unomide cau'\ed 
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a statistically significant inhibition in clinical signs of CIA, something that has not 
been well documented in the past. These data validate CIA and demonstrate it is a 
clinically relevant model to assess anti-arthritic drugs in. These data also confirm 
previous reports of the anti-arthritic effect of leflunomide and its associated 
metabolites in other animal models of arthritis (Thoss et a!., 1996; Schorlemmer and 
Schleyerbach, 1998). Lymphocyte proliferation is therefore an important process in 
the immune response to CII and development of arthritis. 
Anti-TNFa therapy has quickly become the gold standard in the treatment of RA, 
with biologics directed against IL-l and IL-6 also being effective. In this chapter 
mAbs that target TNFa, IL-1 p and IL-6 were shown to cause a statistically 
significant reduction in clinical signs of arthritis which further validates CIA as a 
relevant pre-clinical model of RA. In addition, these findings confirm previous 
reports showing that anti-TNFa treatment inhibits CIA (Williams et a!., 1992). 
Furthermore, in the current study anti-TNFa treatment caused a delay in disease 
onset, something that was not identified in the Williams et al. paper. Other workers 
have shown that anti-IL-1 P treatment, initiated three days post-sensitisation, prevents 
the development of CIA (Geiger et a!., 1993). The data presented here confirms these 
findings and demonstrates that there is no additional benefit from dosing prior to 
sensitisation. 
The work conducted with anti-IL-6 in this chapter has shown for the first time that a 
mAb against IL-6 effectively inhibits clinical signs of arthritis in the murine CIA 
model. Blockade of the IL-6 axis has previously been reported to attenuate CL\. 
However, this was conducted using a mAb against the IL-6 receptor (Takagi et (//., 
1998) rather than IL-6 itself The present data therefore confirms a role for I L-h in 
disease pathogenesis and demonstrates that an altemati\·c IL-6 blocking strategy is 
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effective in the CIA model. Overall these data demonstrate that the anti-c:1okine 
mAbs have comparable anti-arthritic activity in CIA and demonstrate that the model 
is TNFu, IL-I p and IL-6 dependent. 
The use of a mAb directed against the novel cytokine, IL-17, caused a statistically 
significant reduction in the signs of arthritis clearly demonstrating a role for IL-I7 in 
CIA. This finding confirms reports showing that inhibition of IL-17 with an IL-I7 
receptor Fc (lL-17R:Fc) fusion protein, polyclonal anti-IL-17 Ab positive serum and 
an anti-IL-17 mAb reduce clinical signs of CIA (Lubberts et at., 200 I, Lubberts et at., 
2004 and Chu et at., 2007 respectively). However, these were all administered either 
at the time of boost or after the onset of disease. The present study therefore appears 
to be the first to demonstrate an attenuation of CIA using a mAb dosed prior to 
sensitisation in the murine CIA model. The degree of inhibition seen with anti-IL-I7 
was comparable to that of the other anti-arthritic drugs suggesting IL-17 has potential 
as a therapeutic target. 
This chapter has demonstrated that the immune response underlying CIA is CD4 + T 
cell driven. Furthermore, it has been shown that T cell-B cell interactions and 
proliferation are essential in the development of arthritis. The lack of effect seen with 
anti-CD8+ has confirmed that CD8+ T cells do not playa role in this disease. In 
addition, it has become evident that the association between LFA-l and ICA\1-1 is 
not vital for T cell antigen recognition and hence the initiation of immunity. :\nti-
CD8+ and anti-LFA-l will therefore be used as negati\"e controls throughout this 
thesis and it will be interesting to see if the pre-arthritic models and assa\s 
capable of predicting their lack of efficacy in CIA. 
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Assessment of leflunomide and mAbs against clinically relevant pro-inflammatory 
cytokines has validated the CIA model in anti-arthritic drug discovery. Moreover, 
these drugs have demonstrated a role for TNF-a, IL-I ~ and IL-6 in disease 
pathogenesis. Additionally, a role for IL-I7 in disease has been demonstrated and the 
clinical relevance of the CIA model suggests an anti-IL-I7 therapeutic may ha\'e 
utility in the clinic. 
The anti-arthritic drugs assessed in this chapter have varying mechanisms of action. 
However, they all caused a similar degree of disease suppression (Table 3.1) which 
highlights the point that the CIA model is not capable of discriminating between anti-
arthritic drugs. In the following chapters, early readouts of CII immunity were 
established. The drugs used above were then assessed in these pre-arthritic models 
and assays to determine if they are predictive of anti-arthritic drug effects. 
Furthermore, the results from these studies may help discriminate between drugs 
based on mechanism of action. 
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Short-term models of CII immunity 
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4.1 Introduction 
The pathogenesis of eIA is considered to be dependent on both humoral and cellular 
components of the immune system (Seki et al., 1988) and data presented in Chapter 3 
supports this. Evidence in the literature has demonstrated that humoral and cellular 
readouts of ell immunity, such as anti-ell Ab titres (Williams et al., 1998), ClI-
induced hypersensitivity (Farmer et al., 1986) and elI stimulated cell proliferation 
(Mauri et al., 1996) can be detected in pre-arthritic mice. These readouts hm'e the 
potential to be used to assess drug effects on elI immunity prior to disease onset and 
may be predictive of anti-arthritic drug activity in the CIA model. 
To be able to investigate this, models and assays of CII immunity were set up and 
studied. In addition to these readouts the acute phase protein, serum amyloid A 
(SAA), which is released from the liver during inflammation, was assessed in the CIA 
model. It has been demonstrated that SAA is present in arthritic mice (Palmer et al., 
2003) and therefore has the potential to act as a marker of inflammation. 
In this chapter anti-ell IgG 1 and anti-ell IgG2a production was assessed in ell 
sensitised mice over the course of a eIA study. The relationship between pre-arthritic 
anti-ell Ab production and subsequent disease severity was then investigated. SAA 
levels were also assessed over the time course of CIA to see if this acute phase 
protein can be detected in elI sensitised mice prior to disease onset. These studies 
were used to identify a time point in the pre-arthritic phase when elI immunity could 
be detected. A ell-induced hypersensitivity model and a ell stimulated C04+ T cell 
thymidine incorporation assay were then set up in this phase and the conditions 
required to produce robust and reproducible readouts were investigated. 
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4.2 Aim 
The aim of this chapter was to develop robust short-term models of ell immunity in 
pre-arthritic mice that are suitable for studying the immunomodulatory properties of 
drugs. 
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4.3 Results 
In these experiments data is presented as the mean per group. CIA is presented as the 
clinical score on a daily basis and AUC of the clinical score. The assessment of anti-
CII IgG l/IgG2a was conducted by ELISA with a colorimetric end point which \\'as 
measured as absorbance (optical density, OD) at 450nm wavelength. SAA levels 
were calculated as /-lglmL in serum by ELISA. Hypersensitivity to CII was assessed 
by measuring the change in ear thickness, in millimetres (mm), between nonnal and 
sensitised mice. In CII stimulated CD4+ T cell assays thymidine incorporation was 
quantified as counts per minute (cpm). Statistical analysis of data was conducted 
either by Mann Whitney test or one-way ANOV A with Bonferroni as the post-test 
and p<0.05 was considered statistically significant. 
4.3.1 Anti-elllgG1 and IgG2a production in CIA 
To identify when anti-CII IgG 1 and anti-CII IgG2a production can be detected, a time 
course of CIA was set up (Figure 4.1). Normal mice or mice sensitised to CF A 
produced no anti-CII Ab of either isotype throughout the study. Mice sensitised to 
CII/CF A showed no signs of anti-CII IgG 1 or anti-CII IgG2a production 7 days post-
sensitisation. However, on Day 14 post-sensitisation, anti-CII IgG 1 was detected \\'ith 
a mean absorbance at 450nm of 0.45 ± 0.13 OD, this steadily increased o\cr timc 
reaching a peak on Day 42 of 2.03 ± 0.35 OD (Figure 4.1 a), before decreasing on Day 
49. Following a similar pattern, anti-CII IgG2a was detected on Day 14 post-
sensitisation with a mean absorbance of 0.43 ± 0.14 00, this increased to 1.90 ± 0.41 
OD on Day 42 with a decrease on Day 49 (Figure 4.1 b). In this study signs pf arthritis 
were seen from Day 28 onwards where the mean clinical score increased from I, S() :+-
1.11 to 5.20 ± 1.66 on Day --l2 and then decreased to 3.60 ± OAO on Day 49 (data not 
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shown). The increase and then decrease in disease appears to mirror the production of 
anti-ell Ab isotypes at the time points assessed. 
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Figure 4.1 Anti-collagen II antibodies in collagen-induced arthritis. 
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Anti-collagen II IgG 1 and IgG2a production was assessed in nonnal male DB 
mice and in mice sensitised at the base of the tail with either complete Freund' 
adjuvant (CF A) or lOO/-lg collagen II (CII) in CF A. Blood was taken via cardiac 
puncture from 4-5 mice on Day 1, 3, 7 and 14 post-sensitisation and erum v a 
separated. On Day 14, mice sensitised to CF A received a boost inj ection of 
incomplete Freund's adjuvant (IF A) and mice sensitised to CF NCll were boo ted 
with 100/-lg CII in IFA. Further serum samples were taken on Day 15 , 17, 2 1,2 ,35, 
42 and 49 from 4-5 mice per time point. Serum samples were collected and tored at 
-70°C for later analysis. Anti-ClI IgG 1 (a) and IgG2a (b) production wa detected in 
serum samples by ELISA as described in Chapter 2. Data is presented a mean ± 
s.e.m. 
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4.3.2 Pre-arthritic anti-elllgG1 and IgG2a as markers of CIA 
To investigate the relationship between pre-arthritic anti-CII IgG lIIgG2a production 
and disease, blood samples were taken via the tail in a CIA study 1-l days post-CII 
sensitisation and serum was separated. Signs of arthritis were seen from Day 20 
onwards and increased over time, resulting in a mean clinical score of 5.44 ± 1.91 on 
Day 44 (Figure 4.2a). Serum from CII sensitised pre-arthritic mice showed a 
statistically significant increase in both anti-ClI IgG 1 and IgG2a production as 
compared to normal mice (Figure 4.2b). Plotting individual absorbance \e\'els of anti-
ClI IgG 1 (Figure 4.2c) and anti-ClI IgG2a (Figure 4.2d) against the corresponding 
area under the curve (AUC) of the clinical score, obtained over a -l-l day period, 
resulted in a statistically significant correlation. 
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Figure 4.2 Pre-arthritic anti-chick collagen II antibodies and collagen-induced 
arthritis. 
200 
Male DBA/ l mice were immunised at the base of the tail with 100)1g co llagen 11 ( II ) 
in complete Freund 's adjuvant (CFA). On Day 14 post-sensitisation blood ample 
were taken via the tail and serum was separated and stored at -70°C. Mice then 
received a boost injection of 1 OO~lg CII in incomplete Freund's adju ant. erum 
smnples were also taken from 5 nonllal mice at thi s time point. Paw c red 
dai ly for clinical signs of artlu-iti s on a 0-3 scale taking into account \ Iling of the 
wrist/ankle, pad and digits. Data is presented as mean clini ca l core (a) . nti - II 
IgG 1 and anti-CII IgG2a (b) production was detected in Day 14 erum 'amrl ': by 
ELISA as described in Chapter 2. The area under the curve ( C) c r the clini '(}I 
score was ca lcul ated and correlated with Day 14 anti-CII 19 I (c) and anti- II Ill. ' _a 
(d) production . Data pr ented a mean ± .e. m, n = 9 CF II 'en:iti:' I mi ' C anJ n 
= 5 normal mice, * * P<O.O I and * ** P 0.00 I tati ticall y i l!,ni ficant. 
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4.3.3 Serum amyloid A (SAA) levels in CIA 
To identify when the acute phase protein SAA is produced in CIA se I ~ 
, rum samp e~ 
from the time course described above were analysed. Figure 4.3 shows the leyel of 
SAA detected from serum of normal mice, mice sensitised to CFA only and mice 
sensitised to CII/CFA. 
Normal mice showed a low level of circulating SAA, 70.28 ± 30.61 ~g!mL on Day 
49. Sensitisation with either CFA or CII/CFA caused a similar increase in SAA le\\~1s 
to 4240.00 ± 1799.00 and 5719.00 ± 457.00 ~g/mL respectively 1 day post-
sensitisation. From Day 1 to Day 14 SAA levels in CF A and CH/CF A sensitised mice 
decreased back to levels seen in normal mice (77.07 ± 37.29 and 30.71 ± 8.20 ~tg'mL 
respectively). 
On Day 14, CFA sensitised mice were given an injection of IF A and CII/CF A mice 
received an injection of CII/IF A. SAA levels in serum samples taken 1 day after this 
(Day 15) increased in response to IFA, 943.30 ± 504. 70 ~g/mL and CIVIF A, 3424.00 
± 1670.00 ~g/mL, with no difference being seen between the two groups. From Day 
15 to Day 35 SAA levels in CF A sensitised mice decreased back to levels consistent 
with normal mice, 23.93 ± 6.14 ~g/mL and stayed low until termination of the 
experiment on Day 49. CII/CFA sensitised mice also showed a decrease in SAA 
levels up to Day 21, 110.50 ± 15.44 ~g/mL. Then, in contrast to CF A sensitised mice. 
there was a steady increase in SAA levels from Day 28 onwards. reaching a 
statistically significant increase of 2982.00 ± 1124.00 ~g!mL on Day 4C) as compared 
to 21.25 ± 9.31 ~g/mL in CFA sensitised mice. This increase in S:\:\ coincided WIth 
the development of arthritis in the CIIieF A group (data not shown). Wilerl\\S nu 
arthritis was detected in the CF A group. 
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Figure 4.3 Serum amyloid A levels in collagen-induced arthritis. 
Male DBAIl Inice were sensitised at the base of the tail with either complete 
Freund's adjuvant (CFA) or 100/-lg collagen II (CIl) in CFA. Blood san1ples were 
taken via cardiac puncture from 4-5 mice on Day 1, 3, 7 and 14 post-sensitisation and 
serum was separated. On Day 14, mice sensitised to CF A received a boost injection 
of incomplete Freund's adjuvant (IF A) and mice sensitised to CFA/CIl were boosted 
with lOO/-lg CII in IFA. Further serum samples were taken on Day 15 , 17, 21 , 28 , 35, 
42 and 49 from 4-5 mice per time point. Serum was also separated from the blood of 
5 nonnal mice on Day 49. Serum samples were stored at -70°C for later analysis. 
Serum amyloid A levels were detected in serum samples using an ELISA kit. Data 
presented as mean ± s.e.m. * p<O.05 statistically significant from CFA control. 
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4.3.4 ell-induced hypersensitivity in the ear 
To determine the amount of ClI needed to produce a robust hypersensitivity reaction 
in the ear, a dose response was conducted (Figure 4.4). The ear thickness of mice was 
measured in mm prior to the initiation of a hypersensitivity response (0 hours). Mice 
sensitised to ClI 14 days earlier were injected with either 2, 6 or 20/-lg of CII in the 
ear. Normal mice were used as a control and received an injection of 20/-lg CII in the 
ear. Ear thickness was then measured at 6 and 24 hours post-CII challenge. The 
change in ear thickness at 6 and 24 hours as compared to 0 hours was calculated. At 6 
hours post-challenge normal mice showed an increase in ear thickness of 0.07 ± 0.01 
mm in response to 20/-lg ClI. ClI sensitised mice challenged in the ear with 2, 6 or 
20/-lg ClI produced a statistically significant increase in ear thickness of 0.21 ± 0.01, 
0.22 ± 0.02 and 0.25 ± 0.01 mm respectively as compared to normal mice. At 24 
hours post-ClI challenge normal mice showed an increase in ear thickness of 0.05 ± 
0.01 mm. The ear thickness in CII sensitised mice challenged with 6 or 20/-lg ClI at 
this time point increased to 0.17 ± 0.02 and 0.23 + 0.02 mm respectively and was 
statistically significant as compared to normal mice. However, 2/-lg ClI failed to 
produce a significant increase in ear thickness as compared to normal mice (0.12 ± 
0.01 mm). The statistically significant increase in ear swelling seen in ClI sensitised 
mice as compared to normal mice therefore reflects CII hypersensitivity. 
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Figure 4.4 Collagen II hypersensitivity in the mouse ear. 
Collagen II (CIl) hypersensitivity was assessed in normal male DBAl l mice or in 
mice 14 days after sensitisation with CII in complete Freund ' s adjuvant. Animals 
were challenged with either 2, 6 or 20/-lg CII in 25/-lL phosphate buffered saline 
(PBS) injected into the right ear. The left ear was injected with PBS as a control. Ear 
thickness was measured in mm using callipers at 6 and 24 hours post-challenge. Data 
presented as mean ± s.e.m, n = 10 per group, *** p<O.OO 1 stati sticall y signifi cant 
from indicated control. 
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4.3.5 CII stimulated CD4+ T cell thymidine incorporation assay 
The importance of CD4 + T cells in the CIA model has been shown in Chapter 3. 
where a mAb capable of depleting CD4+ T cells caused total abrogation of disease. 
An early readout of cellular immunity to CII would therefore be of great value, not 
only in predicting the effects of anti-arthritic drugs, but also when investigating their 
mechanisms of action. To address this, a CII specific ex vivo CD4+ T cell thymidine 
incorporation assay was set up. This assay used CD4+ T cells isolated from pre-
arthritic mice taken 14 days post-CII sensitisation and antigen presenting cells 
(APCs) from normal mice. This time point was chosen as it coincides with the 
detection of anti-CII Ab production and CII-induced hypersensitivity. CII at a 
concentration of 50/-!g/mL was added in vitro to some cells as it has previously been 
shown to cause an increase in thymidine incorporation into cells from CII sensitised 
mice (Mauri et al., 1996). To establish robust and reproducible conditions for CII 
stimulated thymidine incorporation, differing concentrations of CD4+ T cells and 
APCs were investigated (Figure 4.5). Thymidine incorporation was detected as counts 
per minute (cpm). CD4+ T cells were plated out at either 2.5 x 104 or 2.5 x 105 cells 
per well, with 2.5 x 104,2.5 X 105 or 1 x 106 APCs in the presence or absence ofCH. 
CII stimulation of CD4+ T cells at a concentration of 2.5 x 104 in combination with 
2.5 x 104 or 2.5 x 105 APCs increased thymidine incorporation above that of non-
stimulated cells by 5474 and 17272 cpm respectively. Increasing the concentration of 
APCs to 1 x 106 in culture with these CD4+ T cells did not increase thymidine 
incorporation further (1433 cpm) which suggests it is the concentration of CD4 + T 
cells that are the limiting factor. This was confirmed by increasing the number of 
CD4+ T cells to 2.5 x 105 in combination with 2.5 x 104 , 2.5 x 105 or 1 x 106 APCs 
which resulted in a much greater increase in CII stimulated thymidine incorporation 
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(97270, 90738 and 164922 cpm respectively). From these data it was decided to use 
2.5 x 105 CD4+ T cells and 1 x 106 APCs in all subsequent experiments as this 
combination produced the greatest increase in CII stimulated thymidine 
incorporation. 
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Figure 4.5 CD4+ T cell and APC concentrations in the ex vivo thymidine 
incorporation assay. 
CD4+ T cells were prepared from inguinal lymph nodes of DBAIl mice 14 days after 
sensitisation with collagen II (CII) in complete Freund's adjuvant (CFA). Cells were 
plated out at 2.5 x 104 or 2.5 x 105 CD4+ T cells together with 2.5 x 104, 2.5 x 105 or 1 
x 106 mitomycin C treated antigen presenting cells obtained from normal mice 
spl eens. In some wells, cells were stimulated with 50l-lglmL denatured CII. Cell s were 
cultured for 72 hours. Tritiated thymidine was added to the wells for the last 6 hours 
of culture and thymidine incorporation was assessed as counts per minute (cpm) . The 
graph shows the .change in cpm after in vitro CII stilTIulation of cells from CH/CF A 
sensitised mice as compared to non-stimulated cell s. Lymph nodes were pooled from 
n = 10 mice and cells were plated out in replicates of 5. 
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4.3.6 CII concentration in the CD4+ T cell thymidine incorporation assay 
To determine the amount of CII required to stimulate a robust response in the 14 day 
CD4+ T cell thymidine incorporation assay, various concentrations of CII were 
investigated. 
CD4+ T cells isolated from normal mice, CF A sensitised mice and CII/CF A sensitised 
mice were cultured with APCs from normal mice in the presence or absence of 0.5,5 
or 50J.!g/mL CII. CD4 + T cells isolated from normal mice did not respond to 50J.!g/mL 
CII, as indicated by a lack of increase in cpm between non-stimulated (4054 ± 264 
cpm) and CII stimulated (4092 + 229 cpm) cells (Figure 4.6). CD4+ T cells isolated 
from mice that had received CF A sensitisation gave a mean 10920 ± 777 cpm. When 
the same cells were stimulated with 50J.!g/mL CII there was no increase in cpm 
(11048 ± 463), indicating a lack of additional thymidine incorporation in response to 
CII. CD4+ T cells from CII sensitised mice cultured without CII showed a 
background of 15315 ± 953 cpm and in a concentration dependent manner in vitro 
CII stimulation of these cells caused a statistically significant increase to 24411 ± 
378, 34933 ± 2157 and 46620 ± 2227 cpm at 0.5, 5 and 50J.!g/mL CII respectively. 
These data indicate that 50J.!g/mL CII stimulates the greatest increase in thymidine 
incorporation therefore all subsequent CD4+ T cell thymidine incorporation assays 
used this concentration of CII. Results reported in this study along with those in 
Figure 4.5 indicate that CD4+ T cells at a concentration of 2.5 x 105 and APCs at a 
concentration of 1 x 106 in the presence of 50J.!g/mL CII give a robust and 
reproducible response. In addition, there appears to be a trend towards increased 
incorporation of thymidine between non-stimulated cells isolated from nonnal mice 
and non-stimulated cells isolated from both CF A and CIIICF A sensitised mice. 
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Figure 4.6 Collagen II stimulation in the thymidine incorporation assay. 
CD4+ T cells were prepared from inguinal lymph nodes of normal male DBAl l mice 
or from mice 14 days after sensitisation with either cOlnplete Freund's adjuvant 
(CFA) or collagen II (CII) in CFA. Cells were plated out at 2.5 x 105 CD4+ T cells 
together with 1 x 106 mitomycin C treated antigen presenting cells obtained from 
normal spleens. In some wells, cells were stimulated with either 0.5, 5 or 50)lg/mL 
denatured ClIo Cells were cultured for 72 hours. Tritiated thymidine was added to the 
well s for the last 6 hours of culture and thymidine incorporation was assessed as 
counts per minute (cpm) . Lymph nodes were pooled from n = 5-10 mice per group 
and cells were plated out in replicates of 5. Data presented as mean ± s.e.m, *** 
p<O.OO I statistically significant from indicated control. 
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4.3.7 Time course of CII stimulated CD4+ T cell thymidille illcorporatioll 
Using the conditions outlined above, a time course of ClI stimulated CD4+ T cell 
thymidine incorporation was conducted (Figure 4.7). CD4+ T cells from normal mice, 
CF A sensitised mice and CII/CF A sensitised mice were cultured for 24, 48, 72 and 96 
hours with or without CII stimulation. Cells from normal and CF A sensitised mice 
showed no signs of increased thymidine incorporation in response to ClI stimulation 
at any time point. Over the time course studied there was, however, a trend towards 
increased thymidine incorporation in these cells. When CD4+ T cells from CII/CFA 
sensitised mice were cultured without CII, no increased thymidine incorporation 
above that of control cells was seen at any time point. However, when these cells 
were cultured with CII, increased thymidine incorporation was evident at 24, 48, 72 
and 96 hours. This gave a statistically significant increase in cpm, as compared to 
non-stimulated cells, from 7060 ± 252 to 14554 ± 644, 22080 ± 317 to 56114 ± 7690, 
48032 ± 4483 to 204882 ± 3947 and 76072 ± 9137 to 248296 ± 11843 cpm 
respectively. As shown, this CII stimulated thymidine incorporation increased over 
time from 14554 ± 644 cpm at 24 hours to 248296 ± 11843 cpm at 96 hours, with the 
greatest difference between non-stimulated and CII stimulated cells being detected at 
72 and 96 hours of culture. 
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Figure 4.7 Ex vivo thymidine incorporation into CD4+ T cells over time. 
CD4+ T cells were prepared from inguinal lymph nodes of nonnal male DBAIl mi ce 
or from mice 14 days after sensitisation with either complete Freund ' s adjuvant 
(CFA) or collagen II (ell) in CF A. Cells were plated out at 2.5 x 105 CD4+ T cells 
together with 1 x 106 mitomycin C treated antigen presenting cells obtained from 
nonnal spleens. In some wells, cells were stimulated with 50/-lg!mL denatured CII. 
Tritiated thYlnidine was added to the wells for the last 6 hours of culture and 
thymidine incorporation was assessed as counts per minute (cpm) . In thi s experiment 
cells were cultured for 24, 48 , 72 and 96 hours . Lymph nodes were poo led from n = 
5-10 mice per group and cells were plated out in replicates of 5. Data presented as 
mean ± s.e.m, *** p<O.OO 1 between CIIICFA sensitised and CII/CF A sensiti sed + in 
vitro CII . 
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4.4 Discussion 
In this chapter, models and assays were developed in pre-arthritic mice to assess both 
the humoral and cellular response of the immune system to ClI. From these data it is 
clear that a ClI specific humoral response can be seen in pre-arthritic mice as early as 
14 days post-ClI sensitisation. This is indicated by a statistically significant increase 
in anti-ClI IgG 1 and anti-ClI IgG2a Ab production. The production of these anti-CII 
isotypes on Day 14 post-sensitisation showed a statistically significant correlation to 
the AUC of the clinical score. This indicates that the strength of the humoral response 
to ClI in the pre-arthritic phase is directly related to the severity of arthritis that a 
mouse will develop. Thus, this 14 day readout of ClI immunity has the potential to 
predict disease severity in the CIA model. These data confirm previous findings 
reported by Williams et ai. (1998) who showed a similar correlation between pre-
arthritic anti-ClI Ab production and disease severity. However, their study used 
serum 21 days post-sensitisation, which is around the time of disease onset and they 
only looked at whole anti-ClI IgG levels. The data presented here therefore extends 
these findings indicating that earlier detection of anti-ClI Abs is possible and gives 
the same correlation as samples taken on Day 21. 
Furthermore, it has been demonstrated that both anti-ClI IgG 1 and anti-ClI IgG2a Ab 
isotypes correlate to disease severity. The detection of anti-ClI IgG 1 and anti-CII 
IgG2a isotypes also gives an indication of Th2 and Thl cell responses respectively 
therefore suggesting that these cells are present. This is something that could not be 
assessed by measuring IgG in the Williams et ai. study. Assessing these anti-CII Ab 
isotypes has the potential to assess drug effects on CD4+ T cell subsets and may help 
discriminate between drug mechanisms of action. 
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SAA levels monitored during the time course of CIA suggest it is the adjuvants, CFA. 
or IF A, that stimulate the production of this acute phase protein early on in the 
immune response (Day 1-21) and not CII itself. However, the adjuvant induced SAA 
effect soon decreases to background levels while, in CII sensitised mice it increases , 
coinciding with signs of arthritis. This suggests that the inflammation in the paw is 
stimulating SAA release. Thus, SAA detected later in CIA appears to be a biomarker 
of joint inflammation. If SAA were to be utilised as a marker of disease it would have 
to be assessed in the arthritic phase and is therefore not suitable as an early readout. 
However, the early adjuvant induced SAA response could be utilised to assess the 
effect of a drug on general immunity. This could be done by taking serum from pre-
arthritic mice between Day 1-7 post-sensitisation and identifying any inhibitory drug 
effect on SAA levels. Alternatively a CII challenge in the ear, as conducted in the 
hypersensitivity model, should elicit an SAA response. If this is the case then drug 
effects on SAA can be assessed at the same time as CII-induced hypersensitivity. This 
was investigated in Chapter 5. Monitoring SAA levels in this way may provide a 
general marker of drug activity on the immune system and could be predictive of anti-
arthritic drug effects in the CIA model. 
This chapter has demonstrated that a CII ear challenge in mice, 14 days post-CII 
sensitisation, causes an increase in ear thickness as compared to non-sensitised mice 
indicating that this response is immune driven. Measurements taken 6 hours post-CII 
ear challenge should give a readout of an immediate type hypersensitivity reaction. 
This is likely to be a type III IgG mediated hypersensitivity response as anti-ell IgG 
Abs are present in the circulation 14 days post-sensitisation. Measurements taken 24 
hours post-challenge should reflect a T cell dri\'en type IV DTH response and it is 
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evident from the CD4+ T cell thymidine incorporation assay that CII specific cells are 
present. This ClI-induced hypersensitivity model appears to be both Ab and T cell 
dependent. 
CII caused an increase in ear thickness at 6 and 24 hours post-challenge in a dose 
dependent manner. It was decided from these data that an ear challenge of 20~g CII 
gave a robust hypersensitivity response and was used in all subsequent studies. 
The data presented here confirms work conducted by Seki et ai. (1988) who showed 
that a hypersensitivity response can be elicited in mice 14 days post-CII sensitisation. 
However, Seki et ai. (1988) assessed hypersensitivity in the footpad. Thus, the current 
work has demonstrated that ClI hypersensitivity can also be detected in the ear of CII 
sensitised mice at this time point. This readout has the potential to be incorporated 
into the CIA model as an early marker of drug activity. If this were the case, mice 
may continue on to develop CIA. In this instance measuring hypersensitivity in the 
footpad may not be appropriate as it may interfere with the clinical readout of the 
disease model. An ear measurement, as demonstrated here, would therefore be 
advantageous. 
Hypersensitivity in these studies was conducted using chick ClI as ClI derived from 
mice gave rise to variable ear swelling responses between animals (historical data). 
These data indicate that the immune response to chick ClI is stronger than that to 
mouse CII, which is not surprising as mice were sensitised to chick ClI in both 
instances. However, this does suggest that a weaker immune response may occur in 
the joints of diseased mice in response to endogenous CII. This may lead to 
variability of drug effects between the hypersensitivity model and the CIA model. 
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The role of CD4+ T cells in the pathogenesis of CIA was demonstrated in Chapter 3. 
where depletion of this cell population resulted in total inhibition of arthritis. These 
data confirmed similar findings in the literature (Chu and Londei, 1996) and 
demonstrate the importance of these cells in ClI immunity, therefore making them a 
relevant cell population to study. In order to focus on this cellular component of CII 
immunity, a CD4+ T cell thymidine incorporation assay was set up. The incorporation 
of thymidine into cells is a measure of the s-phase of the cell cycle where 
deoxyribonucleic acid is duplicated prior to cell division. This was therefore used as a 
surrogate marker of proliferation. 
From the data presented here, it is evident that CD4+ T cells isolated from lymph 
nodes of mice 14 days post-ClI sensitisation proliferate in response to in vitro CII 
stimulation. This supports previous findings by Mauri et ai. (1996) who showed 
lymph node cells from ClI sensitised mice, in the pre-arthritic phase, proliferate in 
response to ClI. However, in the Mauri et ai. (1996) paper, it could not be 
determined if CD4+ T cells were proliferating as they used a single cell suspension. 
By isolating CD4+ T cells in the current study it is possible to have a readout of CII 
specific CD4+ T cell proliferation. Considering the vital role that these cells play in 
CIA it would suggest drugs that inhibit this response are likely to have anti-arthritic 
activity. This relationship was investigated in the following chapters. 
The data presented here suggest the number of CD4+ T cells is crucial in this 
response, rather than the number of APCs, as CD4+ T cells at 2.5 x 105 resulted in 
statistically significant increases in proliferation at all the APC concentrations 
investigated. Whereas a lower CD4+ T cell concentration failed to produce such 
pronounced responses. The greatest increase in ClI stimulated proliferation was seen 
using 2.5 x 105 CD4+ T cells in combination with 1 x 106 APCs. Using these cell 
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concentrations, subsequent experiments identified that 50Ilg/mL CII added in vitro to 
cells from CII sensitised mice over a 72 hour culture period ga\"e robust and 
reproducible proliferative responses. Culturing for a longer period of time (96 hours) 
was considered of no additional benefit. The culture conditions set out above were 
used in all CD4+ T cell proliferation assays. 
The data presented in this chapter also suggests that CFA and ClI/CFA may cause an 
increase in background proliferation as compared to cells from normal mice and as 
this occurs in the absence of CII stimulation it appears to be a non-specific response. 
Taken together these data show that CII specific humoral and cellular responses can 
be detected in pre-arthritic mice, 14 days post-CII sensitisation and represent 
promising markers of subsequent disease activity in CIA. However, SAA was not 
elevated above that of normal mice at this time point and appears to be induced by 
adjuvant rather than CII. Despite this, it may still be a potentially useful marker of 
non-specific inflammation. 
This chapter has identified the conditions required to produce robust readouts of CII 
immunity in pre-arthritic mice. In the following chapters the analysis of anti-CII 
IgG l/IgG2a, SAA and CII hypersensitivity were incorporated into the same 
experiments. Whereas CII specific CD4+ T cell proliferation was conducted 
separately as it was not known what effect a CII ear challenge would have on this 
readout. From the literature it does not appear that these early readouts have been 
used together to assess the anti-arthritic effects of drugs. In the following chapters the 
ability of these 14 day readouts to predict and differentiate anti-arthritic drug acti\ity, 
as determined in Chapter 3, was investigated. The drugs under investigation in this 
thesis were used to characterise these models and assays. Furthermore. these readouts 
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were tested to see if they could be of value when assessing a novel drug target such as 
IL-17 
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Drug effects on Cll-induced hypersensitivity and anti-CII 
antibody production 
Chapter 5 
5.1 Introduction 
Murine CIA is a long-term model which represents a considerable investment in time 
and resource. The ability to assess drug activity in short-term models that may be 
predictive of drug effects in CIA is therefore desirable. In this chapter drug effects on 
ell-induced hypersensitivity and anti-CII Ab production were assessed. Drugs were 
used at the same dose and frequency as in the CIA model, unless otherwise stated. 
Anti-CD4+, anti-CD8+, anti-CD40L and anti-LFA-l mAbs were used to investigate 
the underlying immune processes involved in CII immunity. Leflunomide and mAbs 
that target the clinically relevant cytokines, TNFa, IL-l p and IL-6 were used to 
validate these readouts. These mAbs were also used to identify the cytokine 
dependency of the early immune response to CII. 
Drug effects on these readouts of CII immunity were then compared to their anti-
arthritic activity (Chapter 3) and the predictive nature of CII-induced hypersensitivity 
and anti-CII Ab production were assessed. The effect of anti -IL-l 7 was then 
investigated in these readouts to determine if they are capable of predicting its anti-
arthritic activity and moreover to establish the role of IL-17 in CII immunity in pre-
arthritic mice. 
In addition to these readouts, SAA levels were assessed in the serum of mice at 
termination of the hypersensitivity model. If SAA levels were found to be elevated in 
ell sensitised mice, post-CII ear challenge, then this readout could also be assessed 
for its ability to predict anti-arthritic drug effects in CIA. This would give a general 
marker of drug activity on inflammation and may add to the potential value of this 
short-term model. 
By assessing drug effects on CII-induced hypersensitivity at 6 and 24 hours post-
challenge. anti-CII IgG I and anti-CII IgG2a production and potentially the acute 
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phase response, it may even be possible to discriminate between drugs based on their 
mechanisms of action. The use of these readouts to predict and discriminate anti-
arthritic drug activity in pre-arthritic mice has not been reported. Thus, the work in 
this chapter has the potential to identify a new early screening strategy for the 
assessment of novel anti -arthri tic drugs. 
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5.2 Aim 
The aim of this chapter was to characterise and validate the ClI-induced 
hypersensitivity model and the anti-elI Ab response with the drugs utilised in 
Chapter 3 and to determine if these readouts can predict and discriminate anti-arthritic 
drug effects. 
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5.3 Results 
In the following set of experiments data is presented as the mean per group. The 
assessment of CII-induced hypersensitivity was conducted by calculating the change 
in ear thickness, measured in millimetres (mm), between the left ear injected with 
PBS and the right ear injected with CII. A statistically significant increase in the 
change in ear thickness in mice sensitised to ClI as compared to nonnal (non-
sensitised) mice reflects a hypersensitivity reaction. The assessment of anti-CII 
IgG lIIgG2a was conducted by ELISA with a colorimetric end point which was 
measured as absorbance (optical density, OD) at 450nm wavelength. Drugs were 
assessed for their ability to reduce these readouts of CII immunity relative to vehicle 
treated controls. Statistical analysis of data was conducted by one-way ANOY A with 
Bonferroni as the post-test and p<0.05 was considered statistically significant. 
5.3.1 CD4+ and CDS+ T cell depletion 
The role of CD4+ and CDS+ T cells in the CII hypersensitivity model was assessed in 
the same study using the depleting mAbs anti-CD4+ and anti-CDS+ (Figure 5.1 a). 
Normal mice showed no statistically significant response to CII ear challenge. 
However, mice sensitised with CII showed a statistically significant increase in ear 
thickness in response to ClI challenge, as compared to normal animals, from 0.022 ± 
0.012 to 0.302 ± 0.022 mm at 6 hours and from 0.030 ± O.OlS to 0.272 ± 0.027 mm at 
24 hours post-challenge. Anti-CD4+ treatment resulted in a statistically significant 
inhibition in CII-induced ear swelling at 6 and 24 hours post-challenge. from 0.302 ± 
0.022 to 0.053 ± 0.017 and from 0.272 ± 0.027 to 0.039 ± 0.011 mm respectively. 
Anti-CDS+ treatment had no inhibitory effect on CII hypersensiti\'ity either at 6 or 2-+ 
hours post-challenge. 
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Tenninal serum samples were analysed for the presence of anti-CII Ab isotypes by 
ELISA (Figure 5.1 b). Mice sensitised to CII showed an increase in anti-CII IgG 1 
production as compared to nonnal mice from 0.089 ± 0.018 to 0.474 ± 0.130 00 at 
450nm wavelength. In the same serum samples a statistically significant increase in 
anti-CII IgG2a production was detected as compared to normal mice, from 0.023 ± 
0.001 to 1.730 ± 0.392 OD. Anti-CD4+ mAb treatment caused a decrease in anti-CII 
IgG 1 production as compared to vehicle treated CII sensitised mice, from 0.474 ± 
0.130 to 0.068 ± 0.002 OD. Furthennore, anti-CD4+ mAb treatment caused a 
statistically significant inhibition in the production of anti-CII IgG2a as compared to 
vehicle treated CII sensitised mice, from 1.730 ± 0.392 to 0.026 ± 0.005 00. Anti-
CD8+ treatment failed to inhibit CII specific Ab production. 
The ability of these mAbs to deplete CD4+ and CD8+ T cells was shown in Chapter 3. 
In accordance with this, FACS analysis of cells from lymph nodes of treated mice in 
the current study also showed that CD4+ and CD8+ T cells had been depleted (data 
not shown). 
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Figure 5.1 Effect of anti-CD4+ and anti-CDS+ antibody treatment on collagen II 
(CII) hypersensitivity and anti-CII antibody levels. 
Collagen II (CII) stimulated ear swelling was assessed in nonnal male DBA! 1 mice 
and in mice 14 days after sensitisation with CII in complete Freund's adjU\"ant. CII 
hypersensitivity is the change in ear swelling between challenge only and 
sensitised/challenged mice. Animals were challenged with 20llg CII in 251 .. 11 
phosphate buffered saline (PBS) injected into the right ear. The left ear was injected 
with PBS only as a control. Ear swelling was measured using callipers at 6 and 24 
hours post-challenge (a). At termination of the experiment (Day 15) blood samples 
were taken via cardiac puncture and serum collected. Anti-CII IgG 1 and IgG2a (b) 
production was detected in serum samples by ELISA as described in Chapter 2. In 
this experiment some animals were dosed with anti-mouse CD4+ or anti-mouse CDS+ 
antibody at 10mg/kg s.c. on 3 consecutive days prior to sensitisation and thereafter 
once a week. Data presented as mean ± s.e.m, n = 5-10 per group, *** p<O.OO 1 
statistically significant difference from indicated control. 
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5.3.2 Leflunomide 
To investigate if a known anti-arthritic drug has an effect on CII immunity prior to 
disease onset leflunomide was assessed in the CII hypersensitiyity model. 
Leflunomide when dosed at 3mg/kg orally once a day resulted in a statisticall y 
significant inhibition in the CIA model (Chapter 3). However, when used in this 
model, a dose of 3mg/kg failed to inhibit CII-induced ear swelling (historical data). A 
further study was conducted with a dose of 10mg/kg (Figure 5.2a). In this study. 
normal mice showed no response to CII ear challenge. CII sensitised mice showed a 
statistically significant increase in ear thickness at 6 and 24 hours post-CII challenge, 
as compared to normal mice (from 0.044 ± 0.012 to 0.254 ± 0.008 and 0.024 ± 0.010 
to 0.230 ± 0.030 mm respectively). Leflunomide caused a statistically significant 
inhibition in CII-induced hypersensitivity from 0.254 ± 0.008 to 0.127 ± 0.025 and 
0.230 ± 0.030 to 0.089 ± 0.014 mm at 6 and 24 hours respectively. Terminal serum 
samples were analysed for the presence of anti-CII IgG 1 and anti-CII IgG2a. ell 
sensitised mice showed a statistically significant increase in both anti-CII IgG 1 and 
anti-CII IgG2a production as compared to normal mice (0.055 ± 0.001 to 0.839 ± 
0.134 and 0.075 ± 0.001 to 1.940 ± 0.229 00 respectively). Leflunomide treatment 
resulted in a statistically significant inhibition in anti-CII IgG 1 (0.839 ± 0.134 to 
0.152 ± 0.041 00) and anti-CII IgG2a (1.940 ± 0.229 to 0.279 ± 0.090 00) 
production (Figure 5.2b). 
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Figure 5.2 Effect of leflunomide treatment on collagen II (ell) hypersensitivity 
and anti-ell antibody levels. 
Collagen II (CII) stilTIulated ear swelling was assessed in nonnal male DBN 1 mice 
and in mice 14 days after sensitisation with CII in complete Freund's adjuvant. CII 
hypersensitivity is the change in ear swelling between challenge onl y and 
sensitised/challenged mice. Animals were challenged with 20~g CII in 2S ~Li 
phosphate buffered saline (PBS) injected into the right ear. The left ear was inj ected 
with PBS only as a control. Ear swelling was measured using callipers at 6 and 24 
hours post-challenge (a). At tennination of the experiment (Day IS) blood sampl es 
were taken via cardiac puncture and serum collected. Anti -CIl IgG I and IgG2a (b) 
production was detected in serum samples by ELISA as described in Chapter 2. In 
this experiment some animals were dosed with leflunomide at 1 Omg/kg po daily from 
one day prior to sensitisa tion. Data presented as mean ± s.e. m, n = 5-1 0 per group, ** 
p<O.Ol and *** p<O.OOl stati sticall y significant difference from indicated control. 
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5.3.3 Anti-CD40L 
To show the importance of the interaction between CD40L on T cells and CD40 on B 
cells in the immune response to ClI, anti-CD40L was assessed in the ClI 
hypersensitivity model (Figure 5.3a). ClI sensitised mice showed a statistically 
significant increase in ear thickness in response to ClI at 6 and 24 hours post-
challenge as compared to normal mice (0.076 ± 0.024 to 0.276 ± 0.007 and 0.044 ± 
0.013 to 0.214 ± 0.012 mm respectively). Sensitised mice treated with anti-CD40L 
showed a statistically significant inhibition in this ClI stimulated hypersensitivity at 6 
hours (0.276 ± 0.007 to 0.053 ± 0.005 mm) and 24 hours (0.214 ± 0.012 to 0.045 ± 
0.008 mm) post-challenge. Anti-ClI Ab isotypes were analysed from terminal serum 
samples. ClI sensitised mice showed a statistically significant increase in both anti-
CII IgG 1 and anti-ClI IgG2a production as compared to normal mice (0.013 ± 0.0003 
to 0.441 ± 0.053 and 0.020 ± 0.001 to 0.938 ± 0.151 OD respectively). Treatment 
with anti-CD40L resulted in a statistically significant abrogation of anti-ClI IgG 1 and 
anti-ClI IgG2a production from 0.441 + 0.053 to 0.014 ± 0.002 and from 0.938 ± 
0.151 to 0.022 ± 0.001 OD respectively (Figure 5.3b). 
5.3.4 Anti-LFA-I 
To identify if the interaction between LFA-l on T cells and ICAM on APCs is 
required in the immune response to ClI in pre-arthritic mice, anti-LF A-I was assessed 
in the hypersensitivity model (Figure 5.4a). Normal mice showed no response to CII 
ear challenge. However, ClI sensitised animals, challenged with ClI, showed a 
statistically significant increase in ear thickness as compared to normal mice from 
0.076 ± 0.024 to 0.276 ± 0.007 and from 0.044 ± 0.013 to 0.214 ± 0.012 mm at 6 and 
24 hours post-challenge respectively. Anti-LF A-I treatment caused a statisticall y 
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significant reduction in this ear swelling from 0.276 ± 0.007 to 0.068 ± 0.012 at 6 
hours and from 0.214 + 0.012 to 0.061 ± 0.016 mm at 24 hours. Serum samples from 
sensitised mice showed a statistically significant increase in anti-CII IgG 1 and anti-
ell IgG2a production, as compared to normal mice, from 0.013 ± 0.0003 to 0.441 ± 
0.053 and from 0.020 ± 0.001 to 0.938 ± 0.151 OD respectively. Anti-LFA-l 
treatment caused a statistically significant inhibition in anti-CII IgG 1 production from 
0.441 ± 0.053 to 0.039 ± 0.016 OD and anti-ell IgG2a production from 0.938 ± 
0.151 to 0.184 + 0.075 OD (Figure 5.4b). 
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Figure 5.3 Effect of anti-CD40L antibody treatment on collagen II (CII) 
hypersensitivity and anti-CII antibody levels. 
+ 
Collagen II (CII) stimulated ear swelling was assessed in normal male DBAIl mIce 
and in mice 14 days after sensitisation with CII in complete Freund's adjuvant CII 
hypersensitivity is the change in ear swelling between challenge only and 
sensitised/challenged mice_ Animals were challenged with 20).lg CII in 25).l1 
phosphate buffered saline (PBS) injected into the right ear. The left ear was injected 
with PBS only as a controL Ear swelling was measured using callipers at 6 and 24 
hours post-challenge (a). At termination of the experiment (Day 15) blood samples 
were taken via cardiac puncture and serum collected. Anti-CII IgG 1 and IgG2a (b) 
production was detected in serum samples by ELISA as described in Chapter 2. In 
this experiment some animals were dosed with anti-CD40L antibody at 30mglkg s. c. 
once a week from one day prior to sensiti sation. Data presented as mean ± s.e.m, n = 
5- 10 per group, *** p<O.001 stati stically significant difference from indicated 
control. 
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Figure 5.4 Effect of anti-LFA-l antibody treatment on coHagen II (ell) 
hypersensitivity and anti-ell antibody levels. 
+ 
Collagen II (ell) stimulated ear swelling was assessed in normal male DBAII mIce 
and in mice 14 days after sensitisation with ell in complete Freund's adjuvant CII 
hypersensitivity is the change in ear swelling between challenge only and 
sensitised/challenged mice. Animals were challenged with 20~g CII in 25~1 
phosphate buffered saline (PBS) injected into the right ear. The left ear was injected 
with PBS only as a control. Ear swelling was measured using callipers at 6 and 24 
hours post-challenge (a). At tennination of the experiment (Day 15) blood samples 
were taken via cardiac puncture and serum collected. Anti-ell IgG 1 and IgG2a (b) 
production was detected in serum samples by ELISA as described in Chapter 2. In 
this experiment some animals were dosed with anti-LF A-I antibody at 30mglkg s.c. 
once a week from one day prior to sensitisation. Data presented as mean ± s.e.m, n = 
5- 10 per group, *** p<O.OO 1 stati stically significant difference from indicated 
control. 
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5.3.5 Anti-TNFa 
The role of TNF in ell immunity was assessed in the hypersensitivity model using 
the anti-TNFa mAb (Figure 5.5a). Statistically significant ear swelling in response to 
ClI was seen in sensitised mice as compared to normal mice at 6 hours (0.014 ± 0.007 
to 0.236 ± 0.050 mm) and 24 hours (0.004 ± 0.010 to 0.156 ± 0.050 mm) post-
challenge. Anti-TNFa treatment failed to inhibit ear swelling at 6 or 24 hours. 
Analysis of anti-ell IgG 1 and anti-ell IgG2a in terminal serum samples showed that 
sensitised mice produced a statistically significant increase in both Ab isotypes as 
compared to normal mice (0.011 ± 0.001 to 0.315 ± 0.039 and 0.024 ± 0.003 to 0.909 
± 0.154 00 respectively). Anti-TNFa treatment caused a statistically significant 
attenuation in this Ab response from 0.315 ± 0.039 to 0.165 ± 0.022 00 for anti-CII 
IgGl and from 0.909 ± 0.154 to 0.411 ± 0.060 00 for anti-CII IgG2a (Figure 5.5b). 
5.3.6 Anti-IL-IP 
The role of IL-l P in the ClI hypersensitivity model was assessed using the anti-IL-l P 
mAb (Figure 5.6a). A statistically significant increase in ear swelling was seen in 
response to ell in sensitised mice as compared to normal mice at 6 and 24 hours post-
challenge (0.076 ± 0.024 to 0.276 ± 0.007 and 0.044 ± 0.013 to 0.214 ± 0.012 mm 
respectively). Anti-IL-l P treatment had no effect on ear swelling at 6 hours post-
challenge. However, at 24 hours there was a statistically significant reduction in CII-
induced hypersensitivity from 0.214 ± 0.012 to 0.153 ± 0.017 mm. Anti-CI I IgG 1 and 
anti-CII IgG2a production was analysed in terminal serum samples and sensitised 
mice showed a statistically significant increase in both Ab isotypes as compared to 
nonnalmice (0.011 ± 0.001 to 0.315 ± 0.039 and 0.024 ± 0.003 to 0.909 ± 0.154 00 
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respectively). Treatment with anti-IL-l ~ had no effect on anti-CII IgG 1 or anti-CII 
IgG2a production (Figure 5.6b). 
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Figure 5.5 Effect of anti-TNFa antibody treatment on collagen II (ell) 
hypersensitivity and anti-ell antibody levels. 
+ 
+ 
Collagen II (ClI) stimulated ear swelling was assessed in normal male DBAl l mice 
and in mice 14 days after sensitisation with CII in complete Freund 's adjuvant. elI 
hypersensitivity is the change in ear swelling between challenge only and 
sensitised/challenged mice. Animals were challenged with 20~g CII in 2S~1 
phosphate buffered saline (PBS) injected into the right ear. The left ear was injected 
with PBS only as a control. Ear swelling was measured using callipers at 6 and 24 
hours post-challenge (a). At termination of the experiment (Day IS) blood samples 
were taken via cardiac puncture and serum collected. Anti-CII IgG 1 and IgG2a (b) 
production was detected in serum samples by ELISA as described in Chapter 2. In 
this experiment some anilnals were dosed with anti-mouse TNFa antibody at 
100mglkg s.c. twice a week from one day prior to sensitisation. Data presented as 
mean ± s.e.m, n = S-10 per group, * p<O.OS , ** p<O.Ol and *** p<O.OOl stati ti ca ll 
ignificant difference fron1 indicated control. 
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Figure 5.6 Effect of anti-IL-l~ antibody treatment on collagen II (ell) 
hypersensitivity and anti-ell antibody levels. 
+ 
Collagen II (ell) stimulated ear swelling was assessed in nonnal male DBA! 1 mIce 
and in mice 14 days after sensitisation with CII in cOlnplete Freund 's adjuvant ell 
hypersensitivity is the change in ear swelling between challenge only and 
sensitised/challenged mice. Animals were challenged wi th 20~g CII in 25~tl 
phosphate buffered saline (PBS) injected into the right ear. The left ear was injected 
with PBS only as a control. Ear swelling was measured using callipers at 6 and 24 
hours post-challenge (a). At tennination of the experiment (Day 15) blood samples 
were taken via cardiac puncture and serum collected. Anti-CII IgG 1 and IgG2a (b) 
production was detected in serum samples by ELISA as described in Chapter 2. In 
this experiment some animals were dosed with anti-mouse IL-l ~ antibody at 
1 Omgikg s.c. once a week from one day prior to sensitisation. Data presented as mean 
± s.e.m, n = 5-10 per group, * p<O.05 , ** p<O.O I and ** * p<O.OO 1 stati ti ca ll 
significant difference from indicated control. 
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5.3. 7 Anti-IL-6 
Chapter 3 demonstrated the role of IL-6 in CIA. To establish if CII immunity in the 
pre-arthritic phase is also dependent on this cytokine the mAb anti-IL-6 was tested in 
the hypersensitivity model (Figure 5.7a). In this study there was a statistically 
significant increase in ear swelling in response to CII in sensitised mice as compared 
to normal mice, from 0.076 ± 0.024 to 0.276 ± 0.007 mm at 6 hours and from 0.044 ± 
0.013 to 0.214 + 0.012 mm at 24 hours post-challenge. Anti-IL-6 treatment had no 
effect on ear swelling at 6 hours post-challenge but did cause a statistically significant 
attenuation in ear swelling at 24 hours from 0.214 ± 0.012 to 0.152 ± 0.012 mm. 
Analysis of terminal serum samples revealed that there was a statistically significant 
increase in anti-CII IgG I and anti-CII IgG2a production in sensitised mice as 
compared to normal mice (0.060 ± 0.002 to 0.6568 ± 0.070 and 0.068 ± 0.002 to 
1.178 ± 0.183 OD respectively). Treatment with anti-IL-6 resulted in a statistically 
significant inhibition of this response from 0.6568 ± 0.070 to 0.263 ± 0.043 00 for 
anti-CII IgG 1 and from 1.178 ± 0.183 to 0.574 ± 0.085 00 for anti-CII IgG2a 
production (Figure 5. 7b). 
5.3.8 Anti-IL-17 
IL-17 represents a novel therapeutic target and it was shown in Chapter 3 that a mAb 
directed against it inhibits CIA. To establish the role of this cytokine in ell immunity 
and to identify if the anti-arthritic effects of anti- IL-17 can be detected in pre-arthritic 
readouts of CII immunity, this mAb was assessed in the hypersensiti\'ity model 
(Figure 5.8a). A statistically significant increase in ear swelling in response to ell 
challenge was seen in sensitised mice as compared to normal mice at 6 hours (0.076 ± 
0.024 to 0.276 ± 0.007 mm) and 24 hours (0.044 ± 0.013 to 0.214 ± 0.012 111111) 
Chapter :; 
post-challenge. Anti-IL-17 treatment did not inhibit ell-induced ear s\\'elling at 6 
hours post-challenge but did cause a statistically significant inhibition in ear s\\'elling 
at 24 hours post-challenge from 0.214 ± 0.012 to 0.150 ± 0.012 mm. Terminal serum 
samples were analysed for the presence of anti-ell IgG 1 and anti-CII IgG23 
production and sensitised mice showed a statistically significant increase in both Ab 
isotypes as compared to normal mice (0.060 ± 0.002 to 0.657 ± 0.070 and 0.068 ± 
0.002 to 1.178 ± 0.183 OD respectively). Anti-IL-17 treatment had no effect on anti-
ell IgG 1 or anti-ell IgG2a production (Figure 5.8b). 
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Figure 5.7 Effect of anti-IL-6 antibody treatment on collagen II (ell) 
hypersensitivity and anti-elI antibody levels. 
+ 
Collagen II (CII) stimulated ear swelling was assessed in nonnal male DBAl l mIce 
and in mice 14 days after sensitisation with CII in complete Freund ' s adjuvant. CII 
hypersensitivity is the change in ear swelling between challenge only and 
sensitised/challenged Inice. Animals were challenged wi th 20llg CII in 2S~Ll 
phosphate buffered saline (PBS) injected into the right ear. The left ear was injected 
with PBS only as a control. Ear swelling was measured using callipers at 6 and 24 
hours post-challenge (a). At termination of the experiment (Day IS) blood samples 
were taken via cardiac puncture and serum collected. Anti-CII IgG 1 and IgG2a (b) 
production was detected in serum smnples by ELISA as described in Chapter 2. In 
this experiment some animals were dosed with anti-mouse IL-6 antibody at IOmg/kg 
s.c. once a week from one day prior to sensitisation. Data presented as mean ± s. e_m , 
n = S-lO per group, * p<O.OS , ** p<O.OI and *** p<O_ OOl stati ti ca ll y signi fi cant 
difference from indicated control. 
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Figure 5.8 Effect of anti-IL-17 antibody treatment on collagen II (ell) 
hypersensitivity and anti-ell antibody levels. 
+ 
Collagen II (ClI) stimulated ear swelling was assessed in normal male DBAI I mice 
and in mi ce 14 days after sensiti sation with ClI in complete Freund ' s adjuvant. CII 
hypersensiti vity is the change in ear swell ing between challenge only and 
sensi tised/challenged mice. Animals were challenged with 20l-lg CII in 251-11 
phosphate buffered saline (PBS) inj ected into the right ear. The left ear was injected 
wi th PBS only as a control. Ear swell ing was measured using callipers at 6 and 24 
hours post-challenge (a). At termination of the experiment (Day 15) blood samples 
were taken via cardiac puncture and serum collected. Anti -CII IgG I and IgG2a (b) 
production was detected in serum samples by ELISA as described in Chapter 2. In 
th is experiment some animals were dosed with anti-mouse IL- I 7 antibody at 10mg/kg 
.c. once a week from one day pri.or to sensitisation. Data presented a mean ± . . 111 , 
n = 5-1 0 per group, ** p<O.Ol and *** p<O.OOI statisticall y significant differ nce 
from indicated control. 
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5.3.9 SAA levels in the ell-induced hypersensitivity model 
Serum from the ClI hypersensitivity studies were analysed for levels of SAA. This 
analysis demonstrated that a ClI ear challenge in sensitised mice produced an increase 
in SAA production above that of normal mice (51.45 ± 26.78 to 733.30 ± 
370.40~glmL). However, this response was highly variable between mice and did not 
result in a statistically significant difference. Thus, SAA levels on Day 15 in the CII-
induced hypersensitivity model could not be utilised as a robust readout and drug 
effects were therefore not assessed. 
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5.4 Discussion 
Table 5.1 summarises drug activity in the CIA model, CII hypersensitivity model and 
anti-CII Ab assay. 
Drug CIA Hypersensitivity Anti-ell antibodies 
6h 24h 
Anti-CD4+ + + + + 
(100) 
Anti-CD8+ 
- - - -
(19) 
Leflunomide + + + + 
(68) 
Anti-CD40L + + + + 
(81) 
Anti-LFA-l - + + + 
(38) 
Anti-TNFa + - - + 
(82) 
Anti-IL-l P + - + -
(100) 
Anti-IL-6 + - + + 
(87) 
Anti-IL-17 + - + -
(75) 
Table 5.1 Summary of drug effects on CIA, CII-induced hypersensitivity and 
anti-CII antibody production. 
I 
I 
: 
Note: + represents a statistically significant inhibition in CIA, Cll-induced 
hypersensitivity and anti-Cli IgGl or IgG2a as compared to control. 
- represents no significant change from control. 
The numbers in brackets represent the percent reduction in the A UC of the clinical 
score as compared to controls. 
Refer to Chapter 3 for CIA data. 
In Chapter 3 it was demonstrated that CIA is driven by CD4+ T cells and that C08+ T 
cells are not important in the development of arthritis. The role of these T cell subsets 
in CII immunity prior to disease onset was investigated in this chapter. Anti-CO·t 
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treatment caused a statistically significant inhibition in ClI hypersensitivity and anti-
CII Ab production, illustrating that CII immunity in the pre-arthritic phase, like CIA. 
is CD4T T cell dependent. Given the role of CD4+ T cells in adaptive immunity, it is 
not surprising that their depletion resulted in such profound effects. Administration of 
the anti-CD8+ mAb had no effect on CII hypersensitivity or anti-CII Ab production 
demonstrating that CD8+ T cells do not playa role in CII immunity. These data are 
supportive of a lack of anti-arthritic activity seen in CIA. It is evident from these 
readouts that CD4+ T cells are essential in the development of an immune response to 
CII and hence CIA. 
To further investigate the underlying immune processes involved in CII immunity, 
the role of CD40L and LF A-I were investigated. Anti-CD40L treatment in the 
hypersensitivity model caused a statistically significant inhibition in ear swelling and 
anti-CII Ab production. This demonstrates that the interaction between T and B cells 
is important in the immune response to CII in this model as well as in CIA. The data 
reported here demonstrates the role of CD40L in the production of anti-CII IgG 1 and 
anti-CII IgG2a. In support of this, Durie et al. (1993) reported a reduction in anti-CII 
IgG 1 levels after CD40L blockade in CIA. However, Durie et al did not identify this 
inhibitory effect at such an early time point. 
The interaction between T cells and APCs in these early readouts of CII immunity 
was assessed using the anti-LFA-I mAb. Anti-LFA-I treatment caused a statistically 
significant inhibition in ear swelling and anti-CII Ab production in this model. These 
results were surprising as it was anticipated that anti- LF A- L having failed to inhibit 
CIA, would also fail to suppress CII immunity in the pre-arthritic phase. It therefore 
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appears that LFA-l is an important integrin in the early immune response to CII but 
as disease progresses its function is lost. 
Anti-CD4+, anti-CD40L and anti-LFA-l treatment all caused a suppression in the 
humoral response to CII. This immunosuppressive effect was associated with 
attenuation in the immediate type hypersensitivity response at 6 hours post-challenge 
and is therefore supportive of this readout being Ab mediated. In addition, the 
depletion of CD4+ T cells and the blockade of APC - T cell contact were associated 
with an inhibition in the 24 hour hypersensitivity response, suggesting this readout is 
T cell mediated. Furthermore, anti-CD40L inhibited the 24 hour readout which 
suggests that CD40L may also be involved in T cell activation as well as Ab 
production. 
In order to validate the cn hypersensitivity model, leflunomide, a clinically used 
DMARD, was assessed. In Chapter 3 it was demonstrated that leflunomide dosed at 
3mg/kg inhibited CIA, however this dose had no effect in the CII hypersensitivity 
model. Increasing the dose of leflunomide to 10mg/kg in the current study caused a 
statistically significant inhibition in CII-induced hypersensitivity and anti-CII Ab 
production. This suggests that the hypersensitivity model is not as sensitive as the 
CIA model and that the immune response to CII in the pre-arthritic phase is harder to 
inhibit. The inhibitory effect of leflunomide in this model indicates that lymphocyte 
proliferation is important in the early immune response to ell and has demonstrated 
that a clinically relevant drug is active in this short-term model. 
Anti-TNFa, anti-IL-lP and anti-IL-6 mAbs were used in this chapter to further 
\'alidate this short-term model of ClI immunity. Anti-TNFu treatment is effccti\'e in 
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the CIA model (Chapter 3), however in the current model it failed to inhibit CIl-
induced ear swelling at 6 or 24 hours post-challenge. The lack of effect at 24 hours 
suggests that anti-TNFa did not have an effect on cellular immunity in this model. 
However, it did cause a statistically significant inhibition in anti-CII Ab production. 
something which has not been reported previously. This decrease in anti-CII Ab 
production did not, however, translate into a reduction in the 6 hour hypersensitivity 
response. This lack of effect at 6 hours may be explained as anti-TNFa did not 
completely suppress anti-CII Ab production thus there is enough circulating IgG to 
elicit an immediate type hypersensitivity response to CII. In addition, the amount of 
CII used to induce ear swelling may be too high making it more difficult to suppress. 
This supports the observation made above that the model is not as sensitive as CIA. 
TNFa is reported to be a pro-inflammatory cytokine and Williams et al. (1992) had 
previously shown that anti-TNFa treatment has no effect on anti-CII IgG production 
in CIA. Thus, the identification of an immunomodulatory effect of anti-TNFa was 
unexpected. In addition, the study by Williams et al assessed anti-CII IgG production 
in the arthritic phase which suggests this pre-arthritic model may give an insight into 
drug mechanism of action that could be lost later on. The reduction in anti-CII Ab 
production detected in the current study may, at least in part, contribute to the anti-
arthritic activity of anti-TNFa in the CIA model and represents a novel mechanism of 
action. 
Administration of anti-IL-I ~ failed to inhibit CII-induced hypersensitivity 6 hours 
post-challenge and also failed to suppress anti-CII Ab production, suggesting it does 
not affect hUlnoral immunity. However, it did result in a statistically signi ticant 
inhibition in elI-induced hypersensitivity 24 hours post-challenge. This suggests that 
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anti-IL-l ~ may be exerting some of its anti-arthritic effect in the CIA model by 
inhibiting cellular immunity to CII. 
Anti-IL-6 treatment caused a statistically significant inhibition in CII-induced 
hypersensitivity at 24 hours post-challenge and anti-CII Ab production, therefore 
demonstrating an essential role for IL-6 in CII immunity. These data strongly suggest 
that the anti-arthritic activity of anti-IL-6 in the CIA model is mediated through its 
immunomodulatory effects on both cellular and humoral immunity. These results 
were not surprising given the reported role of IL-6 on B cell differentiation, Ab 
production and T cell proliferation (Splawshi et al., 1990, Croft and Swain. 1991 and 
Pankewycz et al., 1990 respectively). However, anti-IL-6 treatment did not inhibit 
CII-induced hypersensitivity at 6 hours post-challenge and it did not completely 
suppress anti-CII Ab production. This is similar to the results seen with anti-TNFa 
and the same arguments regarding the model can be applied. In addition, anti-IL-6 
and anti-IL-l ~ treatment failed to completely attenuate hypersensitivity at 24 hours 
post-challenge. This may suggest that these drugs only have a partial effect on 
cellular immunity or that this time point, like the 6 hour one, is much harder to 
inhibit. The data from the anti-cytokine drugs has demonstrated that CII immunity in 
the pre-arthritic phase is dependent at least in part on TNFa, IL-I ~ and IL-6. 
The role of IL-17 in CII immunity was assessed using the anti-IL-17 mAb. This Ab 
had no effect on the production of anti-CII IgO 1 or anti-CII Ig02a and did not 
prevent ell-induced hypersensitivity at 6 hours post-challenge. Anti-lL-17 treatment 
did cause a statistically significant inhibition in hypersensitivity when measured at 2-l 
hours post-challenge. This early effect of blocking IL-17 on ell immunity has not 
been reported before. These data suggest that the anti-arthritic activity of anti-II-I ~ 
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in CIA may be due in part to its effect on the cellular immune response to CII. It is 
evident that IL-17, like the other cytokines investigated, has a role to play in CII 
immunity. Moreover, it has been demonstrated that these early readouts of ClI 
immunity have the potential to detect the activity of novel therapies. 
This chapter has demonstrated that CII-induced hypersensitivity and anti-CII Ab 
production in pre-arthritic mice, like CIA, are dependent on CD4+ T cells and T cell-
B cell contact and proliferation. However, unlike CIA, LF A-I seems to play an 
essential role in these short-term readouts and demonstrates the importance of T cell-
APC interactions in CII immunity in the pre-arthritic phase. These short-tenn 
readouts have also been validated using leflunomide and mAbs that target TNFa, IL-
I P and IL-6 suggesting that they are clinically relevant. 
The data presented here (Table 5.1) has shown that, in general, drugs which had anti-
arthritic activity in the CIA model also had inhibitory effects on CII-induced 
hypersensitivity and/or anti-CII Ab production. Furthermore, anti-CDS+ treatment, 
which had no effect on CIA, also had no effect on these readouts. Thus, it appears 
these early readouts of CII immunity are capable of predicting anti-arthritic drug 
effects in CIA and have the potential to be utilised as part of a screening cascade in 
drug discovery. However, there was one notable exception, anti-LFA-I, which failed 
to cause a statistically significant inhibition in CIA, but did have a profound effect in 
reducing both CII-induced hypersensitivity and anti-CII Ab production. If these 
readouts were incorporated into a screening cascade, key findings would be follow~d 
up in the CIA model. In respect of anti-LF A-I it would become clear that th~ 
hypersensitivity and anti-CII Ab data represented false positive results in terms of 
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their predictive value. From a drug discovery point of view, this is much better than 
having a false negative result, where active drugs may be overlooked. 
It has also become apparent that these readouts should be used in combination when 
assessing novel therapies as anti-TNFu only inhibited anti-CII Ab production 
whereas anti-IL-l p and anti-IL-17 only inhibited CII-induced hypersensiti\'ity at ~-+ 
hours. If used in isolation, the potential anti-arthritic properties of some drugs may 
not be detected. 
The differing effect between these drugs has, however, demonstrated that these 
readouts of CII immunity are capable of discriminating between drugs based on 
mechanism of action. In respect to anti-TNFu, it appears it may be exerting some of 
its anti-arthritic effect in the CIA model by inhibiting the humoral immune response 
to CII. Anti-IL-I p and anti-IL-17, on the other hand, may be exerting some of their 
anti-arthritic effect by inhibiting the cellular immune response to CII. Unfortunately, 
the assessment of anti-CII IgG 1 and anti-CII IgG2a did not infer any differential drug 
effects on Th2 and Thl cell responses respectively and drugs that had an effect on 
humoral immunity suppressed the production of both isotypes. This suggests that 
drugs may be either inhibiting both Thl and Th2 cell activity or having a direct effect 
on antibody production. 
Overall, the CII-induced hypersensitivity model and the anti-CII Ab assay appear to 
represent a promising early screen for novel anti-arthritic drugs. In addition. there 
appears to be less variability in these readouts and a reduced number of animals \\ ere 
used as compared to the CIA model to obtain robust and reproducible data. This. in 
conjunction with animals not being rendered arihritic, has clear welfare advantages as 
compared to CIA. 
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It has been indicated in this chapter that a number of drugs studied have an etTect on 
the cellular immune response to CII. In order to confirm these effects dru!2s were 
assessed in the following chapter in the ex vivo ClI stimulated CD4+ T cell thymidine 
incorporation assay. These drugs were also used to characterise this assay and to 
determine if it is predictive of the CIA model. 
1-+6 
Chapter six 
Drug effects on CII stimulated CD4+ T cell proliferation 
Chapter 6 
6.1 Introduction 
It has been demonstrated in pre-arthritic mice that humoral and cellular readouts of 
cn immunity, such as anti-CII Ab production and ClI-induced hypersensiti\ity 
appear, on the whole, to be predictive of anti-arthritic drug effects in CIA (Chapter 5). 
In addition, data from the CII-induced hypersensitivity model suggested that a 
number of the drugs under investigation in this thesis may have an effect on the 
cellular immune response to CII. In this chapter, drugs were assessed in the ex l'il'O 
cn stimulated CD4+ T cell thymidine incorporation assay to confirm their effects on 
cellular immunity to CII and to determine if this short-term readout is predicti\'c of 
anti-arthritic drug activity. Anti-CD40L and anti-LFA-l mAbs were used to 
investigate the underlying immune processes involved in CII stimulated CD4+ T cell 
thymidine incorporation. Leflunomide, anti-TNFu, anti-IL-I ~ and anti-IL-6 were 
used for validation. Once characterised, the role of IL-17 in this short-term cellular 
readout of CII immunity was investigated using the anti-IL-17 mAb. Moreover, the 
use ofanti-IL-17 will identify if this assay can be used to assess the activity of novel 
therapeutics. 
Drugs were administered at the same dose and frequency as outlined in Chapter 5. In 
addition to assessing in vivo drug effects on ex vivo CII stimulated CD4 + T cell 
thymidine incorporation, drugs were also added in vitro (where possible) to cultures 
of cells from CII sensitised animals. Assessment of drugs both in l'il'o and in vitro in 
this assay may help to identify whether drugs are having an effect on the gcneration 
of CD4+ T cells or whether they are capable of influencing CD4+ T cells that afC 
already activated. Furthermore, this cellular readout of CII immunity may help to 
discriminate drugs based on their mechanisms of action. 
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6.2 Aim 
The aim of this chapter was to characterise and validate the CII stimulated CD-t - T 
cell thymidine incorporation assay with the drugs utilised in Chapter 3 and to 
determine if this readout can predict and discriminate anti-arthritic drug effects. 
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6.3 Results 
In the following set of experiments the incorporation of tritiated th) l11idine into C04 ~ 
T cells measured as counts per minute (cpm) was used as a surrogate marker of 
proliferation. A statistically significant increase in cpm between non-stimulated and 
CII stimulated cells isolated from vehicle treated CII/CF A sensitised mice \\'as 
considered to represent a proliferative response. Drugs were assessed either in \'i\'o in 
CIIICF A sensitised mice or in vitro on cells from vehicle treated CIVCF A sensitised 
mice, for their ability to reduce this response. Data is presented as mean cpm per 
group. Statistical analysis of the data was conducted by one-way ANOY A with 
Bonferroni as the post-test and p<0.05 was considered statistically significant. 
6.3.1 Leflunomide 
In order to validate this assay, a known inhibitor of lymphocyte proliferation, 
leflunomide (Chong et al., 1993), was assessed on CII stimulated C04+ T cell 
thymidine incorporation. Leflunomide has already been shown to inhibit CIA when 
administered at 3mg/kg (Chapter 3). In the current study letlunomide was dosed at 3 
and 10mg/kg once a day (Figure 6.1). Cells from normal mice cultured in the absence 
of CII (non-stimulated) gave counts of 9871 ± 656 cpm and the same cells did not 
respond to in vitro CII stimulation as indicated by a lack of increased thymidine 
incorporation (9024 ± 897 cpm). Cells cultured from CF A sensitised mice showed an 
increase in thymidine incorporation to 21135 ± 918 cpm. Howe\,er, no further 
increase was seen when these cells were cultured with CII (20500 ± 1157 cpm), ~on­
stimulated cells isolated from CII/CFA sensitised mice showed similar counts to cdb 
from CF A sensitised mice (10914 ± 1078 cpm), howen?r, when these cells \\ LTe 
stimulated with CII in \'itro there was a statistically significant increase in th:l11idim: 
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incorporation to 58666 ± 2530 cpm. This CII specific response was inhibited in a 
dose dependent manner when CII/CF A sensitised mice were treated in \'i\'o \\"ith 
leflunomide at 3 and 10mg/kg, reducing counts to 34192 ± 1983 cpm and 22103 ± 
1680 cpm respectively. There was also a statistically significant inhibition in 
thymidine incorporation from 20914 ± 1078 cpm in non-stimulated cells from 
CII/CF A sensitised mice to 10746 ± 618 and 7055 ± 395 cpm in non-stimulated cells 
isolated from leflunomide treated mice at 3 and 10mglkg respectively. 
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Figure 6.1 Effect of in vivo treatment with leflunomide on ex vivo collagen II 
stimulated thymidine incorporation. 
CD4+ T cells were prepared from inguinal lymph nodes of normal mal e DBA) I mIce 
or from mice 14 days after sensitisation wi th either complete Freund ' adjuvant 
(CFA) or collagen II (CII) in CFA. Cells were plated out at 2.5 x 105 CD4+ T ce ll 
together with 1 x 106 mitOlnycin C treated antigen presenting cells obtained from 
nonna! spleens. Some cells were stimulated with 50!-lg/ml denatured Cll. T riti ated 
thymidine was added to the wells for the last 6 hours of culture and thyrnidin 
incorporation assessed as counts per minute (cpm). Some animals were do ed orall 
with leflunomide at 3 or 10mg/kg once a day from one day prior to en iti ation . 
Lymph nodes were pooled from n = 5-10 mice per group and cell s were plated out in 
replicates of 5. D ata presented as mean ± s.e.m, *** p<O.OO I tati tical! igni fi ant 
from indi cated control. 
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6.3.2 Anti-CD40L and allti-LFA-J 
The importance of T cell - B cell and T cell - APC interactions in the CD-.+ + T cell 
thymidine incorporation assay were investigated in the same study using anti-CD40L 
and anti-LFA-1 respectively (Figure 6.2). Data for each drug is presented in separate 
graphs. Control cells isolated from normal mice and CF A sensitised mice showed no 
increase in thymidine incorporation due to in vitro ClI stimulation. Howe\'er, there 
was still a slight increase between these two groups with non-stimulated cells from 
CFA sensitised mice increasing to 14391 ± 935 cpm as compared to 5904 ± 391 cpm 
in cells from normal mice. A further increase in thymidine incorporation to 258-.+2 ± 
1612 cpm was seen in non-stimulated cells from CII/CFA sensitised mice. When 
these cells were stimulated with ClI in vitro, there was a statistically significant 
increase in thymidine incorporation to 48212 ± 2468 cpm. Treatment with anti-
CD40L (Figure 6.2a) and anti-LFA-1 (Figure 6.2b) resulted in a statistically 
significant attenuation in this CII specific CD4+ T cell thymidine incorporation to 
10924 ± 521 cpm and 17167 ± 863 cpm respectively. In addition, both anti-CD40L 
and anti-LFA-l caused a statistically significant inhibition in counts from 25842 ± 
1612 cpm in non-stimulated cells from CII/CFA sensitised mice to 6758 ± 564 cpm 
and 4955 + 480 cpm respectively in non-stimulated cells from drug treated mice. 
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Figure 6.2 Effect of in vivo treatment with anti-CD40L and anti-LFA-l 
antibodies on ex vivo collagen II stimulated thymidine incorporation. 
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CD4+ T cells were prepared from inguinal lymph nodes of normal male DBAI} mice 
or from mice 14 days after sensitisation with either complete Freund's adjuvant 
(CFA) or collagen II (CII) in CF A. Cells were plated out at 2.5 x 105 CD4+ T cells 
together with 1 x 106 mitomycin C treated antigen presenting cells obtained from 
normal spleens. Some cells were stimulated with 50Jlglml denatured CII. Tritiated 
thymidine was added to the wells for the last 6 hours of culture and thymidine 
incorporation assessed as counts per minute (cpm). Some animals were dosed with 
anti-mouse CD40L (a) or anti-mouse LFA-l (b) antibodies at 30mglkg s.c. once a 
week from one day prior to sensitisation. Lymph nodes were pooled from n = 5-10 
mice per group and cells were plated out in replicates of 5. Data presented as mean ± 
s.e.m, *** p<O.OO 1 statistically significant from indicated control. 
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6.3.3 Anti-TNFa 
To identify if the pro-inflammatory cytokine TNFa has a role to play in CD-+ - T cell 
proliferation, the anti-TNFa mAb was administered to mice sensitised to CIL CF:-\ 
(Figure 6.3). In this study control cells isolated from normal mice gaye counts of 
1033 ± 69 cpm. Cells from CF A sensitised mice showed an increase in thymidine 
incorporation to 2549 ± 242 cpm. When these control cells were stimulated in \'itro 
with CII there was no statistically significant increase in thymidine incorporation. 
Cells isolated from CIVCF A sensitised mice showed no increase in counts above that 
seen in cells from CF A sensitised mice. When these cells were stimulated with CII in 
vitro they showed a statistically significant increase in thymidine incorporation from 
3283 ± 105 to 9395 ± 872 cpm. Treatment with anti-TNFa failed to inhibit this CII 
stimulated thymidine incorporation (11511 ± 1292 cpm). 
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Figure 6.3 Effect of in vivo treatment with anti-TNFa antibody on ex vivo 
collagen II stimulated thymidine incorporation. 
CD4+ T cells were prepared from inguinal lymph nodes of nonnal male DB AI I mIce 
or from mice 14 days after sensitisation with either complete Freund's adjuvant 
(CFA) or collagen II (CII) in CFA. Cells were plated out at 2.5 x 105 CD4+ T cells 
together with 1 x 106 mitomycin C treated antigen presenting cells obtai ned from 
normal spleens. Some cells were stimulated with 50~g/ml denatured CI l. Tritiated 
thymidine was added to the wells for the last 6 hours of culture and thymidine 
incorporation assessed as counts per minute (cpm). Some animals were do ed with 
anti-mouse TNFa Fab PEG antibody at 100mg/kg s.c. twice a week from one day 
prior to sensitisation. Lymph nodes were pooled from n = 5-10 mice per group and 
cells were plated out in replicates of 5. Data presented as mean ± .e. m, ** p<O.O I & 
*** p<O.OOl statistically significant from indicated control. 
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6.3.4 Anti-IL-lfi 
To investigate the role of IL-l ~ in the CII stimulated CD4- T cell th)1nidine 
incorporation assay, the anti-IL-l ~ mAb was used (Figure 6.4). Control cells from 
normal mice and mice sensitised to CF A showed no response to in vitro CII 
stimulation. In this study there was no increase in counts between cells isolated from 
normal and CF A sensitised mice. Furthermore, non-stimulated cells from CII/CF A 
sensitised mice showed no increase in thymidine incorporation compared to control 
cells. However, when cells from CIVCFA sensitised mice were stimulated in vitro 
with CII there was a statistically significant increase in thymidine incorporation from 
9446 ± 844 to 17690 ± 596 cpm. Anti-IL-l ~ treatment resulted in a statistically 
significant attenuation of CII stimulated CD4+ T cell thymidine incorporation from 
17690 ± 596 to 9986 ± 420 cpm. Furthermore, non-stimulated cells isolated from 
anti-IL-I ~ treated mice showed a statistically significant reduction in counts as 
compared to non-stimulated cells from CIVCF A sensitised mice, from 9446 ± 844 to 
5375 ± 485 cpm. 
-E 
OJ c.. r::~ 
:s r:: 
.- 0 E~ 
20000 
~ nJ 10000 
.r:: ~ 
"-8. Z~ 
M 0 
(J 
r:: 
CFA sensitised 
CII/CFA sensitised 
CII in vitro challenge 
Anti-IL-1 in vivo 
+ 
Chapter 6 
** 
+ + 
+ + + + 
+ + + 
+ + 
Figure 6.4 Effect of ill vivo treatment with anti-IL-l~ antibody on ex vivo 
collagen II stimulated thymidine incorporation. 
CD4+ T cells were prepared from inguinal lymph nodes of nonl1al male DBA/ l mice 
or from mice 14 days after sensitisation with either complete Freund 's adjuvant 
(CFA) or collagen II (CII) in CFA. Cells were plated out at 2.5 x l05 CD4+ T cells 
together with 1 x 106 mitonlycin C treated antigen presenting cells obtained from 
nonnal spleens. Some cells were stimulated with 5 o I-lg/m I denatured CIL Tritiated 
thymidine was added to the wells for the last 6 hours of culture and thymidine 
incorporation assessed as counts per minute (cpm). Some animals were dosed with 
anti-mouse IL-I ~ antibody at 10mglkg s.c. once a week from one day prior to 
sensitisation. Lymph nodes were pooled from n = 5-10 mice per group and cells were 
plated out in replicates of 5. Data presented as mean ± s.e. m, ** p<O.O l & *** 
p<O.OOl statistically significant from indicated contro l. 
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6.3.5 Anti-IL-6 and anti-IL-17 
The dependency of the CII stimulated CD4+ T cell thymidine incorporation assay on 
IL-6 and IL-17 was detennined using the anti -IL-6 and anti -I L-1 7 mAbs in the same 
study (Figure 6.5). Moreover, anti-IL-17 was used to establish if this assay can detect 
activity of a novel drug. Data for each drug is presented in separate graphs. In this 
study there was an increase in thymidine incorporation between non-stimulated 
control cells isolated from nonnal and CF A sensitised mice. These counts were 
increased further in non-stimulated cells from CII/CFA sensitised mice. Control cells 
did not respond to in vitro CII stimulation. However, the addition of CII in vitro to 
cells from CIVCF A sensitised mice resulted in a statistically significant increase in 
thymidine incorporation from 45349 ± 1333 to 105320 ± 7771 cpm. Mice treated in 
vivo with anti-IL-6 (Figure 6.5a) and anti-IL-17 (Figure 6.5b) showed a statistically 
significant inhibition in CII stimulated thymidine incorporation, resulting in counts of 
29467 ± 1824 and 29897 ± 1424 cpm respectively. In addition, anti-IL-6 and anti-IL-
17 caused a statistically significant reduction in counts from 45349 ± 1333 in non-
stimulated cells isolated from CH/CF A sensitised mice to 8360 ± 513 and 12152 ± 
728 cpm respectively. 
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Figure 6.5 Effect of in vivo treatment with anti-IL-6 and anti-IL-17 antibodies on 
ex vivo collagen II stimulated thymidine incorporation. 
CD4+ T cells were prepared from inguinal lymph nodes of normal male DBA 1 mice 
or from mice 14 days after sensitisation with either complete Freund's adjuyant 
(CFA) or collagen II (CII) in CFA. Cells were plated out at 2.5 x 105 CD4+ T cells 
together with 1 x 106 mitomycin C treated antigen presenting cells obtained from 
normal spleens. Some cells were stimulated with 50!-lglml denatured CII. Tritiated 
thymidine was added to the wells for the last 6 hours of culture and thymidine 
incorporation assessed as counts per minute (cpm). Some animals were dosed with 
anti-mouse IL-6 (a) or anti-mouse IL-17 (b) antibodies at 10mglkg s.c. once a week 
from one day prior to sensitisation. Lymph nodes were pooled from n = 5-10 mice per 
group and cells were plated out in replicates of 5. Data presented as mean ± s.e.m, 
*** p<O.OOI statistically significant from indicated control. 
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6.3.6 Effect of in vitro drug administration 011 CII stimulated CD4+ T cell 
thymidine incorporation 
When cells were isolated to study the effects of in vivo drug administration on CD4 ~ 
T cell thymidine incorporation, culture plates were also set up to assess the effect of 
drugs in vitro on CD4+ T cells isolated from ClI/CF A sensitised mice. Leflunomide 
could not be assessed in vitro as it is a pro-drug and the active constituent is a 
metabolite which is not commercially available. Instead cyclosporin, another anti-
proliferative drug that has been used in the treatment of RA, was assessed. In \'itro 
drug effects on CII stimulated thymidine incorporation are summarised in Table 6.1. 
Cyclosporin caused a statistically significant concentration dependent inhibition in 
ClI stimulated CD4+ T cell thymidine incorporation. Anti-LF A-I and anti-IL-I ~ also 
caused a concentration dependent inhibition in CII stimulated CD4+ T cell thymidine 
incorporation which became statistically significant at I and I O~g/mL. Anti-CD40L, 
anti-TNFa, anti-IL-6 and anti-IL-I7 had no effect on CII stimulated CD4+ T cell 
thymidine incorporation, when added in vitro. 
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Drug Concentration CD4+ T cell thymidine 
in vitro incorporation 
CycIosporin 0.1, 1 and 10/-lM + 
Anti-CD40L 0.1, 1 and 10/-lglmL -
Anti-LFA-l O.I/-lglmL -
1 and 10/-lglmL T 
Anti-TNFa 0.1, 1 and 10/-lglmL -
Anti-IL-l ~ O.I/-lglmL -
1 and 10/-lglmL + 
Anti-IL-6 0.1, 1 and 10/-lglmL -
Anti-IL-17 0.1, 1 and 10/-lglmL -
Table 6.1 Summary of in vitro drug effects on ex vivo collagen II stimulated 
thymidine incorporation. 
I 
CD4+ T cells isolated from in vivo studies were plated out at 2.5 x 105 CD4+ T cells 
together with 1 x 106 mitomycin C treated antigen presenting cells obtained from 
normal spleens. Some cells were stimulated with 50/-lglml denatured CII. Tritiated 
thymidine was added to the wells for the last 6 hours of culture and thymidine 
incorporation assessed as counts per minute (cpm). Some cells isolated from CII/CF A 
sensitised mice and stimulated in vitro with CII received cyclosporin at a 
concentration of 0.1, 1 or 10/-lM. Other CII stimulated cells received anti-CD40L, 
anti-LFA-l, anti-TNFa, anti-IL-6 or anti-IL-17 at 0.1,1 or 10/-lglml. Lymph nodes 
were pooled from n = 5-10 mice per group and cells were plated out in replicates of 5. 
Drugs were assessed for their ability to inhibit CII stimulated thymidine incorporation 
in cells from CII/CFA sensitised mice. + represents a statistically significant 
inhibition and - represents no effect. 
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6.4 Discussion 
Table 6.2 summarises drug activity in the CIA model and CII stimulated CD4+ T cell 
thymidine incorporation assay. The incorporation of thymidine in this assay was used 
as a marker of cell proliferation. It was assumed that the depletion of CD4+ T cells 
would make this assay impractical therefore the anti-CD4+ mAb was not assessed in 
this assay. In addition, the anti-CD8+ mAb was not assessed as it has been 
demonstrated that CD8+ T cells do not playa role in CIA or CII immunity (Chapters 
3 and 5). 
Drug CIA CD4+ T cell thymidine CD4+T cell 
incorporation thymidine 
(in vivo drug effect) incorporation 
(in vitro drug 
effect) 
Leflunomide + + N/A 
(68) 
Anti-CD40L + + -
(81) 
Anti-LFA-I - + + 
(38) 
Anti-TNFa + - -
(82) 
Anti-IL-I P + + + 
(100) 
Anti-IL-6 + + -
(87) 
Anti-IL-17 + + -
(75) 
Table 6.2 Summary of drug effects on CIA and ex vivo CII stimulated thymidine 
incorporation. 
~ 
Note: + represents a statistical~v significant inhibition in CIA or Cll stimulated thymidine 
incorporation, as compared to control. 
- represents no change/rom control. 
The numbers in brackets represent the percent reduction in the ,-1 UC of the clinical 
score (IS compared to controls. 
Refer to Chapter 3/or CIA data. 
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In this chapter, leflunomide was used to validate the CII stimulated CD4 - T cell 
thymidine incorporation assay. In vivo treatment with leflunomide caused a 
statistically significant inhibition in CII stimulated CD4+ T cell thymidine 
incorporation. These data show that leflunomide is capable of inhibiting CII 
stimulated cell proliferation and confirm its reported anti-proliferative acti\'ity 
(Chong et al., 1993). However, leflunomide could not be assessed in vitro in this 
assay. Instead the clinically relevant agent cyclosporin, which has been shown to 
inhibit CIA (Takagishi et al., 1986) and is a known inhibitor of lymphocyte 
proliferation (Kasaian and Biron, 1990), was assessed in vitro. In the current study its 
anti-proliferative activity was confirmed by its ability to inhibit CII stimulated 
thymidine incorporation into CD4+ T cells. 
The effects of these anti-proliferative drugs on thymidine incorporation support this 
readout as a marker of proliferation. Furthermore, these data confirm the importance 
of CD4+ T cells in CII immunity and demonstrated that clinically relevant drugs are 
active in this pre-arthritic readout. 
The underlying immune response to ell in this assay was investigated using anti-
CD40L and anti-LF A-I mAbs. In the current study, in vivo anti-CD40L treatment 
caused a total abrogation of CII stimulated CD4+ T cell proliferation. These data 
demonstrate the importance of T cell - B cell interactions in CII immunity and 
confirm the role of this interaction in T cell proliferation as reported by Cayabyab et 
al. (1994). Furthermore, these data support findings in the hypersensitivity model 
(Chapter 5) which suggested CD40L may have a role to play in T cell acti\'ation. 
However, when anti-CD40L was added to cell cultures in l'itro it failed to inhibit cell 
proliferation (Table 6.1). 
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The administration of anti-LFA-I, both in vivo and in vitro, caused a statistically 
significant inhibition in CII stimulated CD4 -r T cell proliferation. This demonstrates 
that T cell - APC interactions are essential in the cellular immune response to CII in 
the pre-arthritic phase and confirms a role for LFA-I, as suggested in Chapter 5, in 
these short-term readouts. It is surprising that such a profound suppression on CD4+ T 
cell proliferation with anti-LFA-I did not translate into a statistically significant 
inhibition in CIA. This further supports the theory that LF A-I is an essential integrin 
in the initiation of CII immunity but less important as disease progresses. This 
suggests that LF A-I may not be the only integrin to playa role in T cell - APC 
interactions. 
The role of TNFa, IL-I p, IL-6 and IL-17 in this assay was investigated using mAbs 
that target these cytokines. In vivo administration of anti-IL-l p, anti-IL-6 and anti-IL-
17, but not anti-TNFa, had profound effects on CII stimulated CD4+ T cell 
proliferation. However, it was only the addition of anti-IL-l P in vitro that caused a 
statistically significant inhibition in cell proliferation. 
These data confirm findings in Chapter 5 which suggested a lack of effect of anti-
TNFa on the cellular immune response to CII. In support of these findings, Campbell 
et al. (2001) showed that TNF deficient mice have normal T cell proliferation in 
response to CII. The anti-arthritic effect of anti-TNFa therefore appears not to be 
dependent on inhibition of CD4+ T cell proliferation. However. it does suggest that 
the anti-arthritic effects of anti-IL-1 p, anti-IL-6 and anti-IL-17 may be mediated in 
part through their inhibitory action on CD4+ T cell proliferation. Furthermore, the 
inhibitory effect of anti- IL-I p on cell proliferation in l'itro suggests it may be capable 
of influencing an established immune response as well as the generation of CII 
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specific cells in vivo. Whereas it appears anti-IL-6 and anti-IL-17 only inhibit the 
generation of CII specific T cells and have no effect on an established response. 
These data con finn work conducted in CIA models by Saijo et al. (2002) and Takagi 
et al. (1998) who identified a role for IL-1 and IL-6 respectively in CII stimulated cell 
proliferation. However, it would appear that this is the first time that mAbs against 
IL-1 p, IL-6 and IL-17 have been shown to inhibit CII stimulated CD4+ T cell 
proliferation in pre-arthritic mice. These data have further validated this short-term 
readout of CII immunity and shown the assay to be IL-1 p, IL-6 and IL-17 dependent. 
In addition, it appears this assay is capable of detecting the activity of novel therapies 
such as anti -IL-1 7. 
Data in Chapter 5 suggested that leflunomide, anti-CD40L, anti-LFA-I, anti-IL-l p, 
anti-IL-6 and anti-IL-17 may have effects on the cellular immune response to CII as 
indicated by their ability to suppress CII induced hypersensitivity at 24 hours. This 
chapter has demonstrated that these drugs also suppress CD4+ T cell proliferation 
thereby confinning their role in cellular immunity. These data also suggest that the 24 
hour hypersensitivity time point can be used as a readout of cellular immunity. 
In addition, this assay has shown that in response to CFA sensitisation there appears 
to be an increase in non-stimulated CD4+ T cell proliferation as compared to cells 
from nonnal mice. This response seems to be enhanced further when mice have been 
sensitised to CIIICFA. This suggests, in vivo, that CD4+ T cells are proliferating in 
response to adjuvant and CII prior to being re-stimulated. Drugs that inhibited CII 
stimulated CD4+ T cell proliferation also caused a statistically significant reduction in 
this antigen independent proliferation, suggesting they suppress the initial cellular 
response to sensitisation. 
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Most of these drugs had profound anti-proliferative effects. However, it appears that 
cells isolated from drug treated mice can still proliferate in response to CII ex \'ivo, 
albeit at a much lower magnitude than cells from CII/CF A sensitised mice. This 
proliferative response was statistically significant in cells isolated from leflunomide. 
anti-LFA-l (P<O.OO 1), anti-IL-l~, anti-IL-6 and anti-IL-17 (P<O.O 1) treated mice 
(statistical significance not indicated on graphs). This suggests, even in the presence 
of a drug, there are a small proportion of cells capable of responding to CII. Howeyer. 
it appears that these cells are not able to elicit CIA. Anti-CD40L was the only drug 
that prevented this statistically significant increase in proliferation suggesting the 
interaction between T cells and B cells in vivo is vitally important in the generation of 
CII specific CD4+ T cells. 
The data summarised in Table 6.2 showed, in general, that drugs which suppressed 
CII stimulated CD4+ T cell proliferation, after in vivo administration, also inhibit 
CIA, therefore demonstrating this assay is predictive of anti-arthritic drug activity. 
However, anti-LFA-l was an exception as it caused a statistically significant 
reduction in cell proliferation but failed to suppress CIA. The effect of anti-LFA-I in 
this short-term readout of CII immunity, like its effects on the other readouts in 
Chapter 5, represents a false positive result. However, this is better than having a 
false negative result where active anti-arthritic drugs may be overlooked. This is of 
much more concern and in this assay anti-TNFa gave a false negative result as it had 
no effect on cell proliferation but did suppress CIA. This assay should therefore not 
be used in isolation. 
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The lack of effect seen with anti-TNFa in the current study does however suggest 
that this assay may be able to discriminate between drugs based on their mechanism 
of action. 
The assessment of drugs in vitro was unable to predict the anti-arthritic activity of a 
number of drugs. However, it may be of value when trying to differentiate drugs 
mechanistically. 
In this chapter the CII stimulated CD4+ T cell thymidine incorporation assay has been 
characterised and validated as another short-term readout of CII immunity that is 
predictive of drug effects in CIA. It has also been demonstrated that anti-IL-17 may. 
at least in part, exert its anti-arthritic activity in the CIA model by inhibiting CD4+ T 
cell proliferation. These results suggest that IL-I 7 is a key cytokine in ClI stimulated 
CD4+ T cell biology. The role of IL-17 in T cell biology in this model is currently not 
well defined, the next chapter therefore sought to investigate this further. 
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The role oflL-17 in CII immunity 
Chapter 7 
7.1 Introduction 
So far this thesis has demonstrated that CIA and ClI immunity are dependent on 
CD4+ T cells, with depletion of these cells resulting in the inhibition of disease, CII-
induced hypersensitivity and anti-ClI Ab production. Furthermore, it has been 
demonstrated that CD4+ T cells isolated from ClI/CFA sensitised mice proliferate in 
response to in vitro ClI stimulation. However, the relative involvement of the 
different CD4+ T cell subsets in ClI immunity could not be determined using the 
proliferation assay. 
Research has shown that cells cultured from CIA mice produce IFNy and IL-4 in 
response to in vitro ClI stimulation indicating the presence of Thl and Th2 CD4+ T 
cell responses respectively (Mauri et al., 1996 and Doncarli et al., 1997). In these 
studies, cytokine analysis at various time points during CIA suggested the temporal 
involvement of Thl and Th2 cells in disease progression and resolution respectively. 
The recent identification of a population of CD4+ IL-17 producing T cells, termed 
"Th17 cells", that are distinct from Thl and Th2 cells (Harrington et aI., 2005) has 
brought into focus a shift in this cellular paradigm. However, the role of IL-17 
secreting Th 17 cells in relation to IFNy secreting Th 1 and IL-4 secreting Th2 cells in 
the CIA model has not been defined. 
In this chapter the relative involvement of Thl, Th2 and Th17 cells during disease 
progression was inferred by measuring IFNy, IL-4 and IL-17 respectively. The 
production of these cytokines in response to CII was assessed in supernatants from 
CD4+ T cell cultures by ELISA. In addition, cytokine specific enzyme-linked 
imlTIUnOspot (ELISpot) assays were utilised. ELISpot assays detect cy10kines 
produced by cells in culture as spots and one spot is thought to represent a single 
cytokine secreting cell. These assays were used to detennine the frequency of IFNy, 
172 
Chapter 7 
IL-4 and IL-17 positive spots produced in CII stimulated CD4+ T cell cultures, 
something that could not be determined by ELISA. 
The relationship between IFNy, IL-4 and IL-17 was then investigated in these cell 
cultures by adding anti-IFNy, anti-IL-17, recombinant mouse (rm) IFNy, rmIL-4 and 
rmIL-17 to different cytokine specific ELISpot plates. 
The cytokine network involved in CII immunity was investigated further using the 
anti-IL-6 Ab. This research arose because IL-6 was recently shown to support the 
differentiation of naIve CD4+ T cells into IL-17 producing T cells (Veldhoen et al., 
2006). However, its role in IL-17 production in CII immunity has not been 
investigated. The effect of in vivo anti-IL-6 treatment on ex vivo IL-17 production 
from CD4+ T cells was therefore assessed in this chapter. In addition, the effect of in 
vivo anti-IL-17 treatment on ex vivo IL-17 production was also investigated. 
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7.2 Aim 
The aim of this chapter was to investigate the role of IL-17 in CII immunity and 
investigate the relationship that may exist between Th 1 7, Th 1 and Th2 cells. 
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7.3 Results 
In the following set of experiments CII stimulated CD4+ T cell cultures were set up. 
In some studies IL-17, IFNy and IL-4 production was assessed in cell culture 
supernatants by ELISA and quantified as picograms per millilitre (pglmL). In other 
studies the frequency of IL-17, IFNy and IL-4 positive spots was determined by 
ELISpot. To assess CII stimulated CD4+ T cell proliferation the incorporation of 
tritiated thymidine into cells was analysed and measured as cpm. For a detailed 
description of the ELISA and ELISpot protocols refer to Chapter 2. Data is presented 
as the mean per group and statistical analysis of the data was conducted by one-way 
ANOV A with Bonferroni as the post-test, p<O.05 was considered statistically 
significant. 
7.3.1 Time course of IL-17, IFNrand IL-4 production in the CII stimulated 
CD4+ T cell assay 
In order to identify the time course of cytokine production a CII stimulated CD4+ T 
cell assay was set up. Cell culture supernatants were analysed over a 96 hour culture 
period for the presence of IL-I 7, IFNy and IL-4 (Figure 7.1), which are indicative of 
Th 17, Th 1 and Th2 cell responses respectively. 
CD4+ T cells isolated from normal mice and mice sensitised to CF A were used as 
controls. There was no statistically significant change in IL-17. IFNy or IL-..J. levels in 
supernatants from control cells over time. Furthermore, in vitru CII stimulation of 
these cells did not cause any statistically significant increase in IL-17. IFNy or I L-..J. 
levels above that of non-stimulated cells (Figure 7.1a, b and c). Cells isolated from 
CHieF A sensitised mice showed no statistically significant increase in I L-l 7, I F:'\y or 
I L-..J. levels over the culture period as compared to CF A control cells. Howeyer. when 
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cells from ClI/CFA sensitised mice w.ere stimulated with CII in l'itro they produced a 
statistically significant increase in IL-17 as compared to non-stimulated cells at 24 to 
96 hours of culture. In addition, the amount of IL-17 produced from these cells 
increased over time (100 + 21,372 ± 31,1019 + 80 and 1491 ± 184 pglml at 24,48. 
72 and 96 hours respectively, Figure 7.la). 
Assessment of IFNy levels in the same samples showed that cells isolated from 
CII/CF A sensitised mice did not increase their production in response to in \'itro CII 
stimulation at 1 or 24 hours of culture. At 48 hours of culture IFNy was detected in 
culture supernatants from these cells (90 ± 70 pglml) but this was not statistically 
significant compared to non-stimulated cells. However, the production of IFNy in 
response to in vitro ell was statistically significant at 72 hours (87 ± 19p9lml) and 96 
hours (64 ± 16 pglml) of culture as compared to non-stimulated cells (Figure 7.1 b). 
Further assessment of these samples showed that in vitro CII stimulation of cells from 
CII/CF A sensitised mice did not increase IL-4 production above that of non-
stimulated cells at any time point (Figure 7.lc). 
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Figure 7.1 Time course of IL-17, IFNy and IL-4 production in the collagen II 
stimulated CD4+ T cell assay. 
CD4+ T cells were prepared from inguinal lymph nodes of normal male DBAl1 mice 
or from mice 14 days after sensitisation with either complete Freund 's adjuvant 
(CFA) or collagen II (CII) in CF A. Cells were plated out at 2. 5 x 105 CD4+ T cell s 
together with 1 x 106 mitomycin C treated antigen presenting cells obtained from 
normal spleens. Some wells were stimulated with 50~glmL denatured Cll . Cell 
supernatants were ren10ved at 1, 24, 48 , 72 and 96 hours of culture and mouse IL-1 7 
(a), IFNy (b) and IL-4 (c) levels assessed by ELISA (R&D Systems). Lymph nodes 
were pooled from n = 5-10 mice per group and cells were pl ated out in replicates of 5. 
Data presented as mean ± s.e.m, *** p<O.OOI stati sticall y signifi cant di fference as 
compared to non-stimulated cells from CIIICF A sensiti sed mice. 
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7.3.2 Investigation into the relationship between IL-17 and IFNy ill the ell 
stimulated CD4+ T cell assay 
To investigate the relationship between IL-17 and IF Ny in CII stimulated CD4+ T cell 
cultures, ELISpot assays were utilised. As in previous experiments cell concentrations 
of 2.5 x 105 CD4+ and I x 106 APCs were cultured in the presence or absence of CII 
and the frequency of IL-17 and IFNy positive spots were assessed by ELISpot. 
The addition of CII in vitro to cells from CII/CF A sensitised mice resulted in \vells 
that were too dark to count and no discrete spot formation could be identified for 
either IL-17 or IFNy at 24 and 72 hours of culture (historical data). In order to obtain 
a quantifiable response, further studies were conducted using a range of CD4+ and 
APC concentrations (historical data). Results from theses studies indicated that a 
concentration of 2.5 x 105 CD4+ T cells cultured with a reduced APC concentration of 
I x 105 in response to CII stimulation produced quantifiable IL-17 and IFNy positive 
spots. 
In order to show that this APC concentration, which has not been previously used in 
culture, was capable of stimulating CD4+ T cells, a thymidine incorporation assay 
was set up (Figure 7.2). In this assay, control cells did not respond to in vitro CII 
stimulation and showed similar levels of thymidine incorporation consistent with 
previous work (Chapter 6). CD4+ T cells isolated from CII/CFA sensitised mice 
showed a similar level of thymidine incorporation as controls (6652 ± 1181 cpm). In 
vitro CII stimulation of these cells caused a statistically significant increase in , 
thymidine incorporation (12128 ± 1443 cpm). These data show that APCs at a 
concentration of 1 x 105 are sufficient to elicit a proliferative response to CII which is 
similar to that seen when using a concentration of 1 x 106 APCs (Chapter 6). 
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Figure 7.2 Ex vivo collagen II stimulated thymidine incorporation. 
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CD4+ T cells were prepared from inguinal lymph nodes of normal male DBAIl mice 
or from mice 14 days after sensitisation with either complete Freund 's adjuvant 
(CFA) or collagen II (CII) in CF A. Cells were plated out at 2.5 x 105 CD4+ T cells 
together with 1 x 105 mitomycin C treated antigen presenting cells obtained from 
normal spleens. Some wells were stimulated with 50I-lg/ml denatured ClIo Tritiated 
thymidine was added to the wells for the last 6h of culture and thymidine 
incorporation assessed as counts per minute (cpm) . Lymph nodes were pooled from n 
= 5-10 mice per group and cells were plated out in replicates of 5. Data presented as 
mean ± s.e.lTI, ** p<O.O I statistically significant from indicated control. 
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These culture conditions were then used in ELISpot assays to analyse the frequency 
of IL-17 and IFNy positive spots (Figure 7.3). In these assays. low leyels of IL-17 
(Figure 7.3a and b) and IFNy (Figure 7.3c and d) positive spots were detected in \\'ells 
from control cells isolated from normal mice and CF A sensitised mice at 24 and 72 
hours of culture. ClI stimulation of these control cells did not increase the number of 
positive spots. There was, however, a slight increase in the number of IL-17 and IFNy 
positive spots in these controls over time, but this was not statistically significant. 
When cells from CIIICF A sensitised mice were cultured there was no change above 
control levels in the number of IL-17 positive spots at 24 or 72 hours (9.80 ± 1.80 and 
23.40 ± 0.93 positive spots respectively). Stimulation of these cells with CII in vitro 
resulted in a statistically significant increase in the number of IL-17 positive spots at 
24 and 72 hours (27.20 ± 2.08 and 44.40 ± 2.29 respectively). These data also show 
that there is an increase in the number of IL-17 positive spots over time. The 
relationship between IFNy and IL-17 was investigated in this assay by using an anti-
IFNy mAb which was added to some wells (Figure 7.3a and b). Anti-IFNy at a 
concentration of 1 ~glml caused a slight increase in the number of CII stimulated IL-
17 positive spots at 24 and 72 hours (38.00 ± 4.66 and 52.00 ± 3.41 positive spots 
respectively) as compared to ClI stimulated cells from CIVCF A sensitised mice. 
However, this was not statistically significant. Anti-IFNy at 10 and IOOIlg/ml had no 
effect on the number of IL-17 positive spots produced in response to CII at 24 or 72 
hours of culture. 
Assessment showed that IFNy positive spots III cultures of cells from CII, CF A 
sensitised mice were consistent with those levels seen in controls at 24 and 72 hours 
(0.60 ± 0.25 and 0.20 ± 0.20 positi\'e spots respectiYely). Howc\'t?L when these cells 
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were stimulated with CII there was an increase in the number of IFNy positive spots 
at 24 hours (4.60 + 0.75 positive spots). This response became statistically significant 
at 72 hours of culture (12.00 ± l.05 positive spots). These data also indicate that the 
number of CII stimulated IFNy positive spots increase over time. In these cultures the 
effect of blocking IL-17 on the number of IFNy positive spots was assessed using 
anti- IL-17. In cultures of CII stimulated cells isolated from CIVCF A sensitised mice, 
anti-IL-17 caused an increase in the frequency of IFNy positive spots at a 
concentration of 1, 10 and 100/-lg/ml after 24 hours of culture (8.00 ± 0.32. 9.80 ± 
2.29 and 10.60 ± 1.327 positive spots respectively). This response was statistically 
significant at 10 and 100/-lg/ml as compared to CII stimulated cells from CII/CF A 
sensitised mice. 
At 72 hours of culture anti-IL-17 at 1/-lg/ml increased the number of CII stimulated 
IFNy positive spots (15.20 ± 2.52 positive spots), however this was not statistically 
significant. Unfortunately, anti-IL-17 at 10 and 100/-lg/ml resulted in wells that were 
too dark to distinguish individual IFNy positive spots (Figure 7.3e). 
These data suggest that anti-IL-17 increases the frequency of IFNy positive spots in a 
concentration dependent manner. In a previous study, where a reduced CD4+ T cell 
concentration was used that was not capable of responding to ell, anti-IL-17 at 
100/-lg/ml had no effect on the number of IFNy positive spots (data not shown). 
indicating that it is not the antibody itself affecting the ELISpot readout. 
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Figure 7.3 The effect of anti-fL-17 and anti-IFNy on IFNy and IL-l7 positive 
spots respectively in the collagen II stimulated CD4+ T cell assay. 
CD4+ T cell s were prepared from inguinal lymph nodes of normal male DBA/ I mI ce 
or from mice 14 days after sensitisation with either complete Freund ' adjuvant 
(CFA) or collagen II (CII) in CF A. Cells were cultured in 96 well IL- 17 (a & b) and 
IFNy (c, d & e) ELISpot plates at 2.5 x 105 CD4+ T cells together with I x 105 
mitomycin C treated antigen presenting cells obtained from normal spleen . Some 
well s were stimulated with 50).lglml denatured CII. Anti-IFNy and anti-IL-1 7 at 1, 10 
and IOO).lglml were added to some well s in the IL-1 7 and IFNy ELI Spot plat 
respectively. Cell s were cultured for 24 or 72 hours and as ayed for I L- 17 or IF y 
positi ve spots follo wing the ELISpot protoco l suppli ed with the kit. The number f 
lL-1 7 and IFNy pos iti ve spots were counted in individual \ ell on an aut )lll atcd 
LI pot reader. Additi on of 10 and I OO~l a ml anti -IL-1 7 to the IF y ELl P t plate 
r ulted in we ll that were too dark to count indi idual pot (e) . Lymph nc des wer ' 
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pooled from n = 5-10 mice per group and cells were plated out in replicates of 5. Data 
presented as mean ± s.e.m, * p<O.05, ** p<O.OI and *** p<O.OOI statistically 
significant from indicated control. 
IR6 
Chapter 7 
7.3.3 Effect of recombinant mouse IL-17 (rmIL-17), IFJ.Vy(rmIF1YyJ and IL-.J 
(rmIL-4) in the CII stimulated CD4+ T cell assay 
The relationship between IL-17, IFNy and IL-4 in the CII stimulated CD4+ T cell 
assay was investigated using recombinant mouse cytokines. Cell cultures were set up 
in cytokine specific ELISpot plates and cultured for 72 hours. The effect of rmIFNy 
and rmIL-4 on CII stimulated IL-17 positive spots (Figure 704a and b), rmIL-l 7 and 
rmIL-4 on CII stimulated IFNy positive spots (Figure 704c and d) and rmIL-17 and 
rmIFNy on CII stimulated IL-4 positive spots (Figure 704e and t) was assessed. 
Consistent with previous data, cells isolated from normal mice and CF A sensitised 
mice produced a low number of IL-17 and IFNy positive spots and these cells did not 
respond to in vitro CII stimulation. In line with control cell responses, cells isolated 
from CIVCFA sensitised mice produced 16040 ± 2.14 IL-17 positive spots and 1.20 ± 
0.58 IFNy positive spots. When these cells were stimulated with CII there was a 
statistically significant increase in the number of IL-17 positive spots which rose to 
69.20 ± 5.70 (Figure 704a and b). The addition of rmIFNy had no effect on the 
number of CII stimulated IL-17 positive spots detected in culture (Figure 704a). 
Adding rmIL-4 at 1 and 100ng/ml also had no effect on the frequency of CII 
stimulated IL-17 positive spots (Figure 704b). However, 10ng/ml rmIL-4 caused a 
statistically significant increase in the number of CII stimulated IL-17 positive spots 
(106.00 ± 7044). CII stimulation of cells isolated from ClI/CFA sensitised mice 
caused an increase in the number of IFNy positive spots (6.60 ± 0.93 positive spots), 
however this was not statistically significant (Figure 704c and d). In the presence of 
rmIL-17 there was no statistically significant change in the number of ell stimulated 
IFNy positive spots (Figure 704c). The addition of rmIL-4 at l. 10 and I OOng mL 
187 
Chapter ..., 
caused an increase in the number of CII stimulated IFNy positive spots (13.00 ± l. 73, 
30.20 ± 2.75 and to 30.80 + 6.99 positive spots respectively). This increase \\"as 
statistically significant at 10 and 100ng/mL of nnIL-4 (Figure 7 Ad). 
The frequency of IL-4 positive spots in the CII stimulated CD4+ T cell assay was also 
assessed in this study (Figure 7Ae and f). In these assays only a few IL-4 positi\"e 
spots were detected in control cell cultures and the addition of CII to these cells had 
no effect. Cells isolated from CII/CFA sensitised mice produced control levels of IL-
4 positive spots (4.20 ± 0.92 positive spots) and this was not increased by ell 
stimulation (4.80 ± 1.24 positive spots). Culturing these cells with nnIL-17 and 
nnIFNy had no effect on the number of IL-4 positive spots (Figure 7 Ae and f). 
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Figure 7.4 The effect of recombinant mouse IL-17, IFNy and IL-4 on the 
frequency of cytokine specific positive spots in the collagen II stimulated CD4+ T 
cell assay. 
CD4+ T cells were prepared from inguinal lymph nodes of normal male DBA 1 mice 
or from mice 14 days after sensitisation with either complete Freund's adjuvant 
(CFA) or collagen II (CII) in CFA. Cells were cultured in 96 well IL-17 (a & b), IFNy 
(c & d) and IL-4 (e & f) ELISpot plates at 2.5 x 105 CD4+ T cells together with 1 x 
105 mitomycin C treated antigen presenting cells obtained from normal spleens. Some 
wells were stimulated with 50Jlg/ml denatured CII. The effect of rmIL-l 7, rmIFNy 
and rmIL-4 at 1, 10 and 100ng/ml was assessed on the frequency of cytokine specific 
spots in some wells. Cells were cultured for 72 hours and plates assayed for the 
presence of IL-17, IFNy or IL-4 positive spots following the ELISpot protocol 
supplied with the kit. IL-17, IFNy and IL-4 positive spots were counted in individual 
wells on an automated ELISpot reader. Lymph nodes were pooled from n = 5-10 
mice per group and cells were plated out in replicates of 5. Data presented as mean ± 
s.e.m, *** p<O.OOI statistically significant from indicated control. 
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7.3.4 Effect of in vivo anti-IL-17 and anti-IL-6 treatment on IL-17 productioll 
in the CD4+ T cell assay 
Samples from a CII stimulated C04+ T cell thymidine incorporation assay (Chapter 6 
Figure 6.5) were used to address the question of whether in 1'ivo treatment of 
CII/CFA sensitised mice with anti-IL-17 or anti-IL-6 would inhibit ex 1'l1'O IL-17 
production. 
IL-17 levels in cell culture supernatants from this study were analysed and results are 
shown in Figure 7.5. Control cells produced low levels of IL-17 and there was no 
statistically significant difference seen when these cells were stimulated with CII in 
vitro. Cells isolated from CII/CF A sensitised mice produced a similar amount of IL-
17 as compared to controls (86.79 ± 36.47 pglml). Consistent with previous work 
these cells produced a statistically significant increase in IL-17 when stimulated with 
CII (2315.00 ± 564.00 pglml). Cells isolated from mice treated with anti-IL-17, 
cultured in the absence of CII, produced IL-17 at a similar level as non-stimulated 
cells from CIVCFA sensitised mice (132.80 ± 64.85 pglml). When cultured with CII 
these cells showed a reduction in IL-17 production as compared to CII stimulated 
cells from CIVCFA sensitised mice (1104.00 ± 765.40 pglml), however this was not 
statistically significant. 
Strikingly, cells isolated from anti-IL-6 treated mice showed a statistically significant 
abrogation in CII stimulated IL-17 production (90.47 ± 76.35 pglml) as compared to 
cells from CII/CFA sensitised mice. In addition, non-stimulated cells from anti-IL-6 
treated mice had no detectable levels of IL-17. 
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Figure 7.S Effect of in vivo anti-IL-17 and anti-IL-6 on IL-17 production in the 
collagen II stimulated CD4+ T cell assay. 
CD4+ T cells were prepared from inguinal lyn1ph nodes of nonnal male DBAl } tnlCe 
or from mice 14 days after sensitisation with either complete Freund 's adjuvant 
(CFA) or collagen II (CII) in CFA. Cells were plated out at 2.5 x 105 CD4+ T cells 
together with 1 x 106 mitomycin C treated antigen presenting cells obtained from 
nonnal spleens. Some wells were stimulated with 50~g/ml denatured ClI. In thi 
experiment some animals were dosed with anti-mouse IL-17 or anti-mouse IL-6 
antibodies at 10mg/kg s.c. once a week from one day prior to sensitisation. Cell 
supernatants were removed at 72 hours of culture and mouse IL-17 levels asse ed by 
ELISA (R&D Systems). Lymph nodes were pooled from n = 5-10 mice per group and 
cells were plated out in replicates of 5. Data presented as mean ± s.e. m, ** p 0.0 I 
stati sticall y significant from indicated control. 
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7.4 Discussion 
Table 7.1 and 7.2 summarise the thymidine incorporation, cytokine production and 
ELISpot data from the ex vivo CII stimulated CD4+ T cell assays. 
+ CD4 T cell Cytokine levels 
thymidine 
incorporation IL-4 IL-17 IFNy 
CII/CF A controls + # + + 
In vivo anti-IL-17 - # 
In vivo anti-IL-6 - -
Table 7.1 Summary of thymidine incorporation, cytokine levels and drug effects 
in the ex vivo CII stimulated CD4+ T cell assay. 
ELlS pot 
IL-4 IL-17 IFNy 
CII/CF A controls # + + 
In vitro anti-IL-17 + 
In vitro nn1L-17 # # 
In vitro anti-IFNy # 
In vitro nnlFNy # # 
In vitro nn1L-4 + + 
Table 7. 2 Summary of ill vitro drug and recombinant mouse cytokine effects on 
ex vivo CII stimulated IL-4, IL-17 and IFNy positive spots in the ELlS pot assay. 
i 
Note: + represents a statistical~v sign~licant increase and - represents a 
,\'tatisticalll' Si(Tl1i/ical1t decrease as compared to relenlllt control. ~ ~. 
# represents no statistical~l' signUicwlt change/j'om rele"wlt control. 
Reter to Chapter 6/i)r CD4+ T cell thymidine inco/poration data. 
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In this chapter the role of IL-17 in CII immunity and in particular its relationship with 
IFNy and IL-4 was investigated. It is clear from the data that CD4 + T cells isolated 
from CIVCF A sensitised mice release IL-17 and IFNy but not IL-4 in response to CII 
(Table 7.1). 
In addition, IL-17 production from these cells was evident 24 hours post-CII 
stimulation, whereas IFNy production was not seen until 48 hours. Furthermore, the 
amount of IL-17 detected at 72 hours in these cultures was 11.7 fold greater than 
IFNy. The relative speed and magnitude at which IL-17 was produced compared to 
IFNy suggests that IL-17 may be the dominant cytokine in these cultures and 
therefore infers an important role for Th 17 cells in CII immunity. 
To investigate the frequency of IFNy, IL-4 and IL-17 secreting CD4+ T cells in this 
assay, something that cannot be determined by measuring cytokine levels, ELISpot 
assays were set up. Consistent with the analysis of cytokine levels, cells isolated from 
CII/CF A sensitised mice showed an increase in the number of IL-17 and IFNy 
positive spots in response to CII stimulation (Table 7.2). In addition, there were more 
IL-17 positive spots than IFNy positive spots. The increase in IL-17 positive spots 
was statistically significant at 24 and 72 hours, whereas the increase in IFNy positive 
spots only reached statistical significance at 72 hours. There was no increase in IL-4 
positive spots in response to CII stimulation. 
Taken together, these data strongly suggest that Th 17 cells from sensitised mice are 
preferentially activated by CII and predominate over Thl cells, while Th2 cells do not 
appear to have a role in the cellular arm of CII immunity 14 days post-Cl I 
sensitisation. There was also an increase in the number of CII stimulated IL-17 and 
IFNy positive spots over time, which suggests Thl7 and Thl cells may be 
proliferating. 
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From the total number of CD4+ T cells plated out in the ELISpot assay it would 
appear that only 1 in 11,905 (0.008%) secrete IL-17 and only 1 in 2 L 186 (0.00500) 
secrete IFNy in response to CII stimulation at 72 hours of culture. This suggests that 
the population of Th 17 and Th 1 cells involved in CII immunity is very small. 
To assess the relationship that may exist between IL-17 and IFNy in CII immunity, 
anti-IL-17 and anti-IFNy were added to ELISpot cell cultures. The addition of anti-
IFNy in vitro had no effect on the number of IL-1 7 positive spots either at 24 or 72 
hours of culture, suggesting that IFNy secreting Th 1 cells are not capable of 
regulating the frequency of IL-1 7 secreting Th 17 cells. However, the number of IFNy 
positive spots in culture is low so the amount of IFNy present may not be sufficient to 
affect ThI7 cells, therefore blocking it has no effect. The addition of anti-IL-17 in 
vitro caused a concentration dependent increase in the number of IFNy positive spots 
at 24 hours of culture. This suggests that IL-17 secreting Th 17 cells may be involved 
in regulating the frequency of ThI cells in these cultures and are capable of 
suppressing their development, something that has not previously been reported. 
The relationship between these T cell subsets was investigated further in ELISpot 
assays using recombinant mouse (rm) IL-17 and rmIFNy. In addition, the potential 
role that Th2 cells may have in these assays was investigated using rmIL-4. The in 
\'itro addition of rmIFNy had no effect on the number of CII stimulated IL-17 positive 
spots in culture, suggesting again that Th 1 cells are not capable of regulating Th 17 
cells. In general, the presence of rmIL-4 had no effect on the number of I L-l 7 
positive spots. However, 1 Ong/mL nnIL-4 did cause an increase in the number of IL-
17 positive spots. It would therefore appear that, at certain concentrations, IL-4 may 
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be capable of regulating Th 17 cells. However, endogenous IL-4 is extremely low and 
not CII specific in these cultures and is therefore not likely to influence the CII 
stimulated Th 1 7 cell response. These data suggest that Th I and Th2 cells are not 
capable of regulating committed CII specific Thl7 cells, something that has not been 
reported before. In support of this, Harrington et al. (2005) reported similar findings 
using in vitro derived Th17 cells. 
ELISpot assays have been designed to analyse the number of positive spots being 
formed but not the quantity of cytokine being produced, thus it is possible that Thl 
and Th2 cells may still be able to alter IL-17 production. To address this possible 
effect, ELISpot assays should be run in conjunction with quantitative ELISA assays. 
The increase in IFNy positive spots seen when anti-IL-17 was added to cultures 
suggested that IL-17 may suppress Th I cells and it was therefore anti ci pated that 
rmIL-17 would inhibit the number of IFNy positive spots. However, the addition of 
rmIL-17 had no effect on the number of IFNy positive spots. These assays have been 
developed to assess IL-17 positive spots with the number of IFNy positive spots being 
minimal. It may therefore be difficult to detect a suppressive effect with exogenous 
IL-17 on such a low number of IFNy secreting Th 1 cells. Furthermore, the low 
number of IFNy secreting Th 1 cells detected in these cultures suggests that 
endogenous IL-17 may be efficiently suppressing these cells, therefore the addition of 
exogenous IL-17 has no additional effect. Hence these data cannot be used to 
discount a potential role for IL-17 in the regulation of IFNy secreting Th 1 cells. 
Further assays, optimised for IFNy positive spots, are needed to assess the possible 
inhibitory effect of nnIL-17. 
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From the data presented so far it would appear that Th2 cells do not playa role in 
regulating cellular immunity to CII. It was therefore surprising that the addition of 
rmIL-4 caused an increase in the number of IFNy positive spots. It is possible that in 
these cultures exogenous IL-4 represents an inappropriate Th2 cell response and in an 
attempt to suppress this, CII specific Thl cells respond by proliferating and secreting 
IFNy. 
The addition of rmIL-I 7 and rmIFNy to ELISpot cell cultures had no effect on the 
number of IL-4 positive spots which suggests that these cytokines do not regulate Th2 
cells. However, the low frequency and lack of CII specificity of IL-4 secreting Th2 
cells in these cultures makes it difficult to assess any inhibitory effects that IL-17 or 
IFNy may have on Th2 cells. 
In Chapter 6 it was demonstrated that in vivo treatment with anti-IL-17 and anti-IL-6 
caused a statistically significant inhibition in CII stimulated CD4+ T cell proliferation 
as compared to cells from non-treated CIVCF A sensitised mice. In this chapter IL-l 7 
levels in the supernatants from these cell cultures were assessed. It was shown that in 
vivo treatment with anti-IL-17 caused a reduction in CII stimulated IL-17 production. 
However, this effect was not statistically significant suggesting that anti- IL-17 is not 
capable of preventing the formation of ClI specific IL-17 secreting Th 17 cells 
completely. Anti-IL-6 treatment caused a complete suppression in ex \'iv(} CII 
stimulated IL-17 production from CD4+ T cells. This finding suggests that anti-IL-6 
may inhibit the formation of ClI specific Th 17 cells and therefore implies a role for 
IL-6 in their generation. In support of this, Veldhoen et al. (2006) demonstrated that 
IL-6 is important in Th17 cell differentiation from nalye CD4+ T cells. The data 
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presented in the current study is the first to show that blocking IL-6 in vivo inhibits ex 
vivo IL-17 production in a ClI immune response. The inhibition of Th 1 7 cell 
formation may therefore represent a more novel mechanism of action by which anti-
IL-6 exerts its anti-arthritic effect in CIA. 
It is clear from the work conducted in this chapter that IL-l 7 secreting Th 17 cells are 
important in ClI immunity. It would appear that these cells are first to respond to re-
stimulation with ClI and produce greater quantities of IL-17 relative to the amount of 
IFNy produced by Thl cells, suggesting they dominate the immune response. The 
data has also indicated that Thl and Th2 cells may not be capable of regulating ClI 
specific Thl7 cells and that, in fact, it is Th17 cells that may regulate Thl cells in CII 
stimulated CD4 + T cell cultures. 
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8.1 Discussion 
Table 8.1 summarises drug effects on CIA and pre-arthritic readouts of ClI immunity 
as assessed in this thesis. 
Drug CIA Hypersensitivity Anti-CII CD4+ T cell 
antibodies proliferation 
6h 24h In vivo In vitro 
Anti-CD4+ +++ +++ +++ +++ N/A N/A 
Anti-CD8+ 
- - - -
N/A N/A 
Leflunomide ++ ++ ++ +++ +++ N/A 
Anti-CD40L +++ +++ +++ +++ +++ 
-
Anti-LFA-1 
-
+++ +++ +++ +++ +++ 
Anti-TNFa +++ - - ++ - -
Anti-IL-1 p +++ - + - +++ ++ 
Anti-IL-6 +++ - + ++ +++ -
Anti-IL-17 +++ - + - +++ -
Table 8.1 Summary of drug effects on CIA, CII hypersensitivity, anti-CII 
antibody production and CII stimulated CD4+ T cell proliferation. 
Note: The data is semi quantitative where + represents a low, ++ represents a 
medium and +++ represents a high degree of suppression, all of H'hich are 
statistica/(v significant as compared to controls. 
- represents no significant change from control. 
NIA represents not applicable. 
Refer to Chapter 3 for CIA data, Chapter 5 for Cll hypersensiti\'i(I' and anti-Cll 
IgG J IJgG]a data and Chapter 6for Cll stimulated CD4+ T cell proh(eration data. 
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8.2 CD4+ T cell dependence of CIA and short-term readouts of CII 
immunity 
In this thesis, anti-CD4+ and anti-CD8+ were used to characterise CIA and the short-
tenn readouts of CII immunity. The literature has shown that CIA is CD4+ T cell 
dependent (Kadowaki et aI., 1994, Chu and Londei. 1996, Ehinger et al.. 2001 and 
Taneja et ai., 2002) and data presented in this thesis confinns these findings. It has 
been demonstrated that CD8+ T cells do not playa role in CIA, confinning work 
conducted by Ehinger et ai. (2001). In addition, CD8+ T cell depletion also had no 
effect on the short-tenn readouts, demonstrating that these cells are not involved in 
CII immunity in pre-arthritic mice. Depletion of CD4+ T cells caused an inhibition in 
CII induced hypersensitivity and anti-CII Ab production, indicating that like CIA ell 
immunity in pre-arthritic mice is dependent on CD4+ T cells. 
8.3 Predicting anti-arthritic drug effects in CIA 
The data presented in this thesis demonstrates that sensitisation of mice to CII causes 
humoral and cellular immune responses. Furthennore, these responses can be easily 
detected in pre-arthritic mice 14 days post-sensitisation to CII by assessing anti-CII 
Abs, CII induced hypersensitivity in vivo and CII stimulated CD4+ T cell proliferation 
ex vivo. Part of the hypothesis to be tested was whether pre-arthritic readouts of CII 
immunity could be used to predict the anti-arthritic effects of drugs in the CIA model. 
8.3.1 Drug effects in CIA and short-term readouts of Cll immunity 
In general, these models and assays which assess the immunomodulatory activity of a 
drug are indirectly predictive of anti-arthritic effects in CIA. Howcvcr. it is clear from 
Table 8.1 that this is not always the case. For example. anti-LFA-I failed to show a 
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statistically significant inhibition of CIA but did suppress cn induced 
hypersensitivity, anti-ClI Ab production and ClI stimulated CD4+ T cell proliferation. 
indicating an inability of these models and assays to predict drug activity in CIA in 
this case. Other drugs were active in the CIA model but did not necessarily show 
suppressive activity in all the pre-arthritic readouts. For example, anti-TNFa did not 
inhibit ClI hypersensitivity or CD4+ T cell proliferation but did suppress anti-Cn Ab 
production. In addition, anti-IL-l~ and anti-IL-17 caused a statistically significant 
inhibition in ClI induced hypersensitivity and CD4+ T cell proliferation but had no 
effect on anti-ClI Ab production. From these data it appears that the drugs 
investigated affect the Immune response to CII in different ways, potentially 
providing a basis for discriminating between anti-arthritic drugs based on mechanism 
of action. 
The drug effects observed in the ClI hypersensitivity model at 24 hours post re-
challenge generally mirror those seen in the CII stimulated CD4+ T cell proliferation 
assay. This suggests that the hypersensitivity model at this time point is CD4+ T cell 
dependent and is consistent with evidence obtained in Chapter 5 where anti-CD4+ 
treatment abolished the hypersensitivity response. However, for some drugs there 
appears to be a discrepancy in the degree of suppression seen in the ClI stimulated 
CD4+ T cell proliferation assay and the 24 hour hypersensitivity response to ClI. In 
particular it is evident that anti-IL-l~, anti-IL-6 and anti-IL-17 all had profound 
effects on ClI stimulated CD4+ T cell proliferation but only caused partial inhibition 
in the 24 hour hypersensitivity response. 
What is not known in this model is the potential contribution that the immediate Ab 
mediated response seen at 6 hours may have on the delayed hypersensiti\'ity response 
at 24 hours. It may be that some of the ear swelling at 24 hours in this model is 
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mediated through the immediate Ab response. If the Ab mediated response does 
contribute to ear swelling at 24 hours then this may explain the partial effect seen 
with anti-IL-I~, anti-IL-6 and anti-IL-17 as they had either no effect or a partial 
effect on anti-CII Ab production. In support of this, leflunomide, anti-LF A-I and 
anti-CD40L not only suppressed CD4+ T cell proliferation but also attenuated anti-
CII Ab production resulting in a much greater inhibition of the 24 hour 
hypersensitivity response as compared to the anti-cytokine drugs. 
To determine whether the Ab mediated response does contribute to 24 hour 
hypersensitivity, B cell deficient mice could be used. B cell deficient mice have 
dramatically reduced Ig levels but have normal T cell responses to CII (Svensson et 
al., 1998). If B cell deficient mice showed a reduction in the 24 hour CII induced 
hypersensitivity response as compared to wild type mice this would suggest that the 
immediate Ab mediated response does contribute to ear swelling at 24 hours. 
Furthermore, if drugs that inhibit CD4+ T cell proliferation but not anti-CII Ab 
production such as anti-IL-I ~ and anti-IL-17 were capable of greater suppression of 
the 24 hour response in B cell deficient mice as compared to wild type mice this 
would confirm a role for the Ab mediated response at 24 hours in normal mice. 
Mice treated with anti-IL-I~, anti-IL-6 and anti-IL-17 showed a profound 
suppression of arthritis. However, the degree of suppression in the hypersensitivity 
response at 24 hours with these drugs, although statistically significant, was not 
profound. The hypersensitivity model measures the immune response against chick 
CII to which the mice have been sensitised. However, in the CIA model the 
endogenous release of CII in the joint of diseased mice is thought to perpetuate the 
immune response. It is likely that a mouse that has been sensitised to chick CI I will 
205 
Chapter S 
not mount such a strong immune response against mouse CII as it would against 
chick CII. Therefore, it may be easier to suppress the immune response in the CIA 
model than in the hypersensitivity model resulting in different drug effects between 
the models. It was shown in Chapter 4 that the hypersensitivity response was 
dependent on the amount of chick CII used for ear challenge with a lower dose 
showing a reduced response at both 6 and 24 hours. By reducing the amount of chick 
CII and hence the immune response in the hypersensitivity model it may be possible 
to mirror the effects of anti-IL-l p, anti-IL-6 and anti-IL-17 in the CIA model more 
closely. 
Taken as a whole, the data suggests individual pre-arthritic readouts should not be 
used in isolation to predict anti-arthritic drug effects. However, the data does indicate 
that if these readouts are used in conjunction with one another they represent a strong 
basis for a pre-clinical screening cascade for anti-arthritic drugs, as set out in Figure 
8.1. All drugs examined that were effective in CIA were effective in one or more of 
the short-term readouts. However, for some drugs such as anti -LF A -1 these short-
term readouts may not always predict their anti-arthritic activity. 
Many researchers use CII induced hypersensitivity, CII stimulated cell proliferation 
and anti-CII Ab isotype levels to try to understand how a drug is affecting CIA. 
However. not all readouts are used in the same studies and analysis is quite often 
done at the end of experiments. The use of these pre-arthritic models and assays as a 
screemng cascade for predicting anti-arthritic drug effects is therefore a novel 
approach. 
The short-term models developed in this thesis gave robust and reproducible readouts 
ofCII immunity and used a reduced number of animals as compared to CIA. If these 
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readouts were to be used as a screening cascade they would therefore reduce the 
number of animals required for drug testing and the number that needed to be 
rendered arthritic. This has clear welfare advantages. 
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Figure 8.1 Proposed screening cascade for anti-arthritic drugs. 
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Drugs evaluated 14 days after Cll sensitisation and reductions in ear swelling to Cll 
challenge or circulating Cll antibodies provide decision points as to whether to 
proceed to CIA. If no reduction is seen in these readouts then Cll stimulated CD4+ T 
cell prol((eration is conducted to confirm lack of effect. 
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8.3.2 Prophylactic and therapeutic dosing regimes 
The use of prophylactic dosing regimes, as opposed to therapeutic dosing regimes, in 
CIA and short-term models was deliberate. Events occurring immediately post-
sensitisation with ClI such as antigen uptake, proliferation and differentiation of 
effector cells provide many potential opportunities for immunomodulatory drugs. In a 
chronic disease such as RA these events are presumably ongoing and so the 
possibility exists that restricting the models to therapeutic dosing may not capture the 
immunomodulatory activities of some drugs. 
In the clinic, administration of a depleting anti-CD4+ mAb had moderate effects in 
RA patients (Tak et al., 1995 and Choy et al., 2000). Williams and Whyte. (1996) 
showed that depleting CD4+ mAbs administered at the time of sensitisation 
suppressed CIA. However, when these Abs were given 3 weeks post-sensitisation 
they did not affect disease indicating that therapeutic dosing was not capable of 
predicting drug activity in the clinic in this instance. In addition, targeting the IL-6 
receptor (IL-6R) with a mAb has been shown to be effective in RA (Nishimoto et al., 
2004), but therapeutic dosing of anti-IL-6R (Takagi et al., 1998) and in our hands 
anti-IL-6 (historical data) had no effect on CIA whereas prophylactic dosing did. It 
would therefore appear that prophylactic dosing regimes in CIA and short-term 
models of ell immunity are more predictive of drug effects in the clinic than 
therapeutic dosing regimes. What cannot be ascertained using prophylactic dosing 
regimes in these models is how effective a drug will be clinically. It is likely that 
results from prophylactic studies will overestimate drug effects. 
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8.4 Drug mechanisms of action 
The CIA model when used alone only really gives a yes or no answer in respect to the 
disease suppressing activity of a drug and does not enable the researcher to identify 
their mechanisms of action. The second part of the hypothesis to be tested was 
whether the pre-arthritic readouts could be used to differentiate between drugs~ based 
on their mechanisms of action. 
8.4.1 Mechanisms of action of leflun om ide, anti-CD40L and allti-LFA-1 
Leflunomide was used in this thesis to validate the CIA model and the short-tenn 
readouts of ClI immunity. Leflunomide is a known anti-proliferative drug 
(Cherwinski et al., 1995 and Chong et al., 1993) and its anti -arthritic activity has been 
shown in experimental models of arthritis (Thoss et al. ~ 1996 and Schorlemmer and 
Schleyerbach. 1998). In the current study, the anti-arthritic activity of leflunomide 
was confinned at a dose of 3mg/kg. However, this dose did not completely suppress 
CIA. In addition, ClI stimulated CD4+ T cell proliferation was inhibited at 3mg/kg 
but ClI-induced hypersensitivity was not affected at this dose (historical data). 
Increasing the dose of leflunomide to 10mg/kg caused a statistically significant 
inhibition in ClI-induced hypersensitivity and anti-ClI Ab levels. These data again 
suggest that the hypersensitivity model may be more difficult to suppress than CIA. 
The effect of leflunomide on CD4+ T cell proliferation~ hypersensitivity and anti-CII 
Ab production demonstrated that these short-tenn readouts of CII immunity are 
capable of identifying drug mechanisms of action which were consistent with the 
known effects of leflunomide on lymphocytes. 
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Anti -CD40 L and anti -LF A -1 were used to detennine the importance of T cell - B cell 
and T cell - APC interactions respectively in CIA and ClI immunity. In the current 
study, in vivo administration of anti-CD40L inhibited signs of arthritis in CIA and 
abrogated anti-ClI Ab production in pre-arthritic mice. In support of this Durie et al. 
(1993) demonstrated that blocking CD40L-CD40 binding inhibited CIA with a 
corresponding reduction in anti-ClI antibody levels. The role of T cell - B cell 
interactions in CIA was further highlighted by Tellander et al. (2000) who showed 
that administration of a stimulatory mAb against CD40 resulted in early onset and 
increased severity of disease. This was associated with increased anti-Cn antibody 
production, suggesting the amount of CD40 stimulation during the immune response 
to ClI may detennine the severity of arthritis. 
Anti-CD40L inhibited ClI-induced hypersensitivity at 6 and 24 hours suggesting it 
may have an effect on T cells as well as Ab production. However, the influence of the 
immediate Ab mediated hypersensitivity response at 6 hours on 24 hour ear swelling 
is not known, therefore the inhibition of Ab production with anti-CD40L may 
contribute to the suppression of the 24 hour response. However, an inhibitory effect 
of in vivo anti-CD40L on T cells was confinned in the ex vivo ClI stimulated CD4+ T 
cell proliferation assay. This suggests that CD40L is involved in the generation of ClI 
specific CD4+ T cells. In support of this Cayabyab et al. (1994) showed the 
importance of the CD40L-CD40 interaction in T cell proliferation using a cell line 
transfected with CD40 which augmented the proliferative response. 
Further evidence suggests that CD40L itself can induce T cell proliferation in a T cell 
_ T cell dependent manner (Fanslow et aI., 1994). In the current study, anti-CD40L 
failed to inhibit CD4+ T cell proliferation when added in vitro suggesting Cll specitic 
T cell - T cell interactions are not essential in this assay. This lack of effect in vitro 
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also suggests that any B cells present in the naIve spleen preparation are not capable 
of stimulating T cell proliferation by acting as APCs. In support of this, Holmdahl et 
al. (2002) showed that naIve B cells did not activate CII specific T cell hybridomas as 
effectively as primed B cells from lymph nodes of CII sensitised mice therefore 
suggesting B cells act as APCs in disease. These data suggest that CII primed B cells 
may play a role in T cell proliferation and this may be through increased CD40 
expression. Therefore, it appears that blocking CD40L in vivo, not only inhibits B cell 
Ab production, but also stops CD40 from stimulating T cell proliferation suggesting 
there is a reciprocal stimulatory pathway between T cells and B cells. 
The profound effect of anti-LFA-I in the pre-arthritic models and assays would 
suggest it is, potentially, a potent anti-arthritic drug. Anti-LFA-I had an effect on 
humoral immunity as it attenuated the production of anti-CII isotypes and inhibited 
the 6 hour CII-induced hypersensitivity response. Blocking LF A-I also attenuated the 
24 hour CII-induced hypersensitivity response indicating it also has an effect on 
cellular immunity, a result supported by its inhibitory effect on CII stimulated CD4+ 
T cell proliferation, both in vivo and in vitro. This confirms work by Dongworth et al. 
(1985) and Berzins et al. (1988) who showed that Abs directed against LF A-I inhibit 
T cell proliferation. These data indicate that T cell - APC contact is essential in an 
immune response and suggest that LF A-I is important in initial immunity to CII. In 
support of this, Hersmann et al. (1998) reported that LF A-I is strongly expressed in 
the joint of mice in the acute phase of arthritis. However, the same study 
demonstrated that LFA-l expression in the joint decreases in the chronic phase of 
disease. This suggests that LFA-l may not be as important later on in CIA and work 
conducted in this thesis appears to confirm this as anti-LF A-I treatment only caused a 
partial inhibition of arthritis. 
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Mikecz et al. (1994) showed that blocking LFA-I and its ligand, ICAM-l. only ga\'e 
a modest reduction in signs of arthritis. Whereas Kikimoto et al. (1992) reported that 
mAbs against LFA-l and its ligand ICAM-l caused a statistically significant 
suppression in CIA. However, even in this paper, the suppression was not profound. 
In contrast to the effect of anti-LF A-Ion anti-CII Abs in the current study Kikimoto 
demonstrated that blocking the interaction between LF A-I and ICAM-l did not affect 
anti-CII Ab production and concluded that anti-LFA-l only affects cellular immunity. 
In the study by Kikimoto, anti-CII Ab production was assessed on Day 35 post-
sensitisation as compared to Day 15 in this thesis. It is therefore possible that an 
earlier inhibitory effect of blocking LF A-I activity on humoral immunity may have 
contributed to the attenuation of disease in their study. Taken together, these data 
indicate that anti-LFA-I is not an effective anti-arthritic drug in the CIA model. 
The bond between ICAMs and LF A-I is not exclusive. For example, IC AM-3 and 
LFA-2 (C02) expressed on T cells can also bind DC-SIGN, a recently identified 
lectin on DCs, and LF A-3 (CD58) on APCs respectively, suggesting Ag recognition 
can occur without LFA-I involvement. Thus, cellular adhesion between T cells and 
APCs may primarily be dependent on LF A-I, but in its absence these other 
interactions can compensate and this is why there is a delay in arthritis in the CIA 
model but not an inhibition. 
LFA-I is also important in cell recruitment to sites of inflammation, again via ICAM 
binding, which may explain the inhibitory effect seen with anti-LFA-I in the 
hypersensitivity model. However, another integrin, very late activation antigen -l 
(VLA-4), is expressed on activated T cells and binds its ligand VCAM-I which is up 
regulated on endothelium at sites of inflammation. This integrin is expressed later on 
in the intlammatory response, hence its name, and is able to recruit T cells. In a 
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chronic inflammatory environment, such as an arthritic joint. VLA-4 may be able to 
compensate for the lack of LFA-l and recruit T cells, thus helping to render anti-
LF A-I treatment less effective. It is possible that VLA-4 is not expressed in the acute 
24 hour hypersensitivity model so LFA-l is the dominant integrin in respect to 
mediating cell accumulation. 
It appears from the data that there may be a temporal difference in the underlying 
immune process between the short-term readouts and CIA. In terms of predicting 
anti-arthritic activity this may lead to either a false positive result, as in the case of 
anti-LFA-l, or perhaps a false negative result in the short-term models. 
8.4.2 Mechanisms of action of anti-TNFa, anti-IL-lfi and Qllti-IL-6 
TNFa and IL-l p are well studied cytokines with a wide range of pro-inflammatory 
actions. It was evident from the short-term readouts of CII immunity that TNFa had 
little immunomodulatory activity as blocking it with anti-TNFa had no effect on 
cellular immunity. This was indicated by a failure to inhibit the 24 hour 
hypersensitivity response and CII stimulated CD4+ T cell proliferation. This finding 
confirms work by Campbell et af. (200 1) who showed that TNF deficient mice have 
normal T cell proliferation, in response to CII and Choy et al. (1999) who showed 
that anti-TNFa therapy has no effect on T cell activation in RA patients. In the pre-
arthritic hypersensitivity model, anti-TNFa did reduce anti-CII IgG 1 and IgG2a 
production, suggesting it may affect the humoral response to CII and that this could 
contribute to its anti-arthritic activity in the CIA model. This reduction in anti-Cll 
Abs did not translate to an effect on 6 hour hypersensitivity suggesting there is still 
enough circulating anti-CII Ab present to elicit ear swelling. Williams et al. (1992) 
had previously shown anti-TNFa treatment inhibits CIA, but in contrast to the present 
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study showed no effect on anti-CII IgG production. In this paper~ anti-CII IgG was 
assessed in the arthritic phase of disease and it may be that other compensatory 
mechanisms have had a chance to elevate Ig levels at this time point. Further 
evidence to support the role of TNFa in the humoral response comes from TNF 
deficient mice that have impaired Ig class switching (Campbell et al., 2001) therefore 
suggesting the humoral response is compromised by a lack of TN Fa. Also, a study by 
Kehrl et al. (1987) showed that activated B cells have prolonged DNA synthesis~ 
increased TNFa binding sites and increased Ig secretion when stimulated with TNFa 
and IL-2. These data suggest that TNFa has a role to play in humoral immunity and 
that anti-TNFa may have some minor immunomodulatory activity. 
TNFa has been shown to regulate the production of IL-l (Brennan et al., 1989 and 
Williams et al., 2000) and IL-6 (Choy et al., 1999). This indirect effect on IL-6 may 
explain the inhibition in anti-CII Ab production in the pre-arthritic model. However, 
if anti-TNFa treatment were having a profound effect on IL-l p and IL-6 production 
an effect on CII-induced hypersensitivity and CD4+ T cell proliferation would be 
predicted, similar to that of blocking these cytokines directly. It may be that anti-
TNFa inhibits at least in part IL-6, resulting in reduced anti-CII antibody production, 
but does not suppress IL-6 and IL-l p enough to inhibit cellular immunity. 
The biological actions of TNFa are predominately pro-inflammatory therefore anti-
TNFa is likely to be exerting the majority of its anti-arthritic activity by inhibiting 
inflammation. The models and assays in this thesis are not designed to detect drug 
effects on non-immune inflammation and this is one weakness in the use of these 
readouts as a screening cascade for novel anti-arthritic agents. A readout of non-
imtTIune inflammation such as neutrophil accumulation may be a useful addition to 
such a screeni ng cascade. 
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Anti- IL-l ~ attenuated signs of arthritis in CIA indicating that IL-l ~ is a key cytokine 
in this model. In support of this IL-l has been shown to accelerate signs of disease in 
CIA (Killar and Dunn. 1989 and Hom et at., 1988). In the short-term readouts ofCII 
immunity anti-IL-l ~ reduced ear swelling at 24 hours and inhibited CII stimulated 
CD4+ T cell proliferation both in vivo and in vitro. However, anti-IL-l ~ failed to 
inhibit the humoral response, as indicated by no effect on 6 hour CII induced ear 
swelling or anti-CII Ab production. This suggests that anti- IL-l ~ may exert its anti-
arthritic effect at least in part by modulating cellular immunity to CII. These data 
confirm results obtained in a CIA study using IL-l deficient mice, which showed 
normal Ab but decreased T cell responses (Saijo et at., 2002). 
The in vitro effect of anti-IL-l ~ in the CII stimulated CD4+ T cell proliferation assay 
suggests that IL-l ~ may have a direct effect on the cells in culture. This was not 
evident with any other anti-cytokine treatment. It has been shown that IL-l ~ 
stimulates the production of IL-2 and induces the expression of its receptor, IL-2R, 
(Hackett et at., 1988) and can synergise with IL-6 to increase IL-2 production (Holsti 
and Raulet. 1989), with IL-2 being vital in T cell proliferation. Cyclosporin 
effectively inhibited CII stimulated CD4+ T cell proliferation in vitro demonstrating 
that the assay is dependent on IL-2, as cyclosporin acts by disrupting signalling 
through the T cell receptor and inhibits IL-2 production. Blocking IL-l ~ in "..,itro may 
therefore inhibit the production of IL-2 from T cells and IL-2R expression on T cells .. 
thus attenuating CII stimulated CD4+ T cell proliferation. 
Another explanation as to how anti-IL-l ~ may be inhibiting proliferation in "itro 
again comes from the study in IL-l deficient mice (Saijo et at. .. 2002). These authors 
showed that the absence of IL-l causes a decrease in CD40L and OX40 (CD13'+) 
expression on T cells. The data in Chapter 6 indicates that CD40L docs not playa 
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role in T cell proliferation in vitro, therefore ruling it out as a mechanism by which 
anti-IL-l ~ had its effect in this assay. However, the costimulatory molecule OX40 is 
a potential candidate for regulation by IL-l ~ in vitro. This theory is supported hy 
Nakae et al. (2001) who showed that IL-l enhances T cell priming through induction 
of OX40 on T cells. The relevance of OX40 - OX40L binding in CIA has been 
demonstrated by Yoshioka et al. (2000) using a mAb against OX40L which 
successfully inhibited arthritis. OX40 is also expressed on CD4+ T cells in synovial 
fluid from RA patients (Giacomelli et al., 2001), suggesting it is of clinical relevance. 
A way to ascertain if OX40 is involved in vitro in CD4+ T cell proliferation would be 
to use an anti-OX40 mAb something that has not been undertaken in this thesis. 
These data suggest the in vitro effect of anti -IL-l ~ on T cell proliferation may be due 
to blocking the action of IL-l ~ on OX40 and IL-2/IL-2R expression. These effects 
may also explain the potent in vivo activity of anti-IL-l ~ treatment on CD4+ T cell 
proliferation. 
The precise mechanisms by which anti-IL-l ~ is causing its anti-arthritic effect cannot 
be fully identified in these pre-arthritic readouts. Literature evidence suggests that, 
like anti-TNFa, anti-IL-l ~ is probably exerting many of its anti-arthritic effects by 
inhibiting inflammation. 
Another pivotal cytokine in the immune response is IL-6, which again has pleotropic 
actions. Anti-IL-6 treatment caused an inhibition in anti-CII antibody production, CII-
induced ear swelling at 24 hours and CII stimulated CD4+ T cell proliferation. These 
data suggest that anti-IL-6 is an immunomodulatory agent capable of affecting both 
the humoral and cellular components of the immune system. \Vith these effects on CII 
immunity it was not surprising that anti-IL-6 treatment caused a statistically 
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significant inhibition in CIA. These results demonstrate that IL-6 is another essential 
cytokine in the immune response to CII. In support of this Alonzi et al. (1998) 
showed that IL-6 deficient mice are protected against CIA with a corresponding 
decrease in anti-CII Ab levels. In these IL-6 deficient mice the anti-CII Ab response 
was not totally inhibited, a result similar to that described here. This suggests anti-CII 
Ab production is not totally dependent on IL-6. This may explain why anti-IL-6 failed 
to inhibit the 6 hour hypersensitivity time point as there is still enough circulating 
anti-CII Ab to cause a response. This reduction in anti-CII IgG 1 and IgG2a Ab 
production may be due to blocking the direct effect of IL-6 on B cells, which has 
been reported to augment the generation of Ig secreting cells and secretion of Ig. IL-6 
has also been demonstrated to enhance T cell dependent induction of B cell 
differentiation and this is thought to be due in part to IL-2 (Splawshi et aI., 1990). 
Antibodies against IL-6 and IL-2 have been shown to inhibit Ig production in CD4+ T 
cell driven assays, supporting a role for IL-6 and IL-2 in B cell activation (Croft and 
Swain. 1991). Another study by Takagi et al. (1998) showed that blocking the IL-6R 
with a mAb also inhibited CIA when dosed at or just after sensitisation with Cll and 
caused a decrease in the humoral response. In this study, a decrease in anti-CII IgG2a 
and IgG2b was detected, but not IgG 1, suggesting there could be a shift towards a 
Th2 cell response that may be protective in CIA. However, anti-IL-6 treatment in the 
present study did inhibit IgG 1 levels suggesting this is not the case 14 days post-
sensitisation. Takagi et al. assessed levels of anti-CII Abs on Day 34 post-
sensitisation suggesting that if a shift towards a Th2 response does occur, it takes 
longer than two weeks of treatment. 
ClI stilllulated cell proliferation in the study by Takagi et al. was completely inhibited 
by anti- I L-6R mAb and supports findings reported here. It has also been shown that 
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IL-6 is capable of inducing proliferation of thymocytes and can synergise with IL-I in 
this respect (Helle et al., 1988), therefore playing a role in the development of thymic 
T cells. Blocking IL-6 could reduce the number of T cells in the circulation that are 
capable of seeing CII thereby preventing T cell priming and the initiation of the 
immune response. This would explain the profound effect seen with anti-IL-6 in the 
CII stimulated CD4+ T cell proliferation assay. A lack of CII specific T cells would 
also reduce the amount of help available for stimulating the humoral response and 
could explain in part the reduction in anti-CII Abs. 
IL-6 has been shown to promote T cell proliferation and increases the accumulation 
of stable IL-2 transcription in stimulated T cells, with IL-2 amplifying the 
proliferative response (Pankewycz et aI., 1990). IL-6 has also been reported to have 
synergistic effects with IL-I in respect to these responses (Holsti and Raulet. 1989). 
Anti-IL-6 may therefore inhibit IL-2 production and attenuate CII stimulated CD4+ T 
cell proliferation. 
Anti-IL-6 had no effect when added in vitro in the CII stimulated proliferation assay. 
Pankewycz et al. (1990) used anti-CD3 stimulation of resting T cells whereas the 
cells in the in vitro CII assay here were stimulated in vivo with CII so are already CII 
specific. This could explain differences in findings between Pankewycz and the 
results presented here. It may be that prophylactic in vivo anti-IL-6 treatment inhibits 
the generation ofCII specific T cells from naIve cells but cannot suppress CII specific 
CD4+ T cells themselves. In support of this, Vink et al. (1990) showed that IL-6 was 
critical for initiating rather than maintaining T cell proliferation, as anti-IL-6 lost its 
inhibitory effect when added late in a T cell assay. This may explain why blockade of 
IL-6 signalling with an Ab against the IL-6R dosed on Day 7 post-sensitisation or 
later had no effect on CIA (Takagi et al., 1998). 
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In Chapter 7, it was shown that in VIVO treatment with anti-IL-6 inhibited IL-17 
production in the ex vivo CII stimulated CD4+ T cell assay. This suggests IL-6 is 
capable of regulating the production of IL-17 in vivo. IL-17 is another important 
cytokine involved in the immune response and has a number of actions such as the 
induction of TNFa, IL-I ~ and IL-6 which have important roles to play in 
inflammation and immunity and it has been shown in this thesis that blocking IL-l 7 
inhibits CII immunity and CIA. It is possible that anti-IL-6 may exert part of its anti-
arthritic effect by inhibiting IL-17 production. In support of this, Veldhoen et al. 
(2006) and Bettelli et al. (2006) recently showed that IL-6 in the presence of TGF~ 
supports the differentiation of naIve CD4+ T cells into IL-17 producing T cells. Anti-
IL-6 may therefore inhibit the formation of IL-17 producing cells in vivo thereby 
blocking IL-17 and its immunological actions. The use of naIve CD4+ T cells in the 
papers by Veldhoen and Bettelli suggests this process may occur early on in the 
immune response to CII. This could again explain why blocking the I L-6R has little 
effect in CIA 7 days post-sensitisation as these IL-17 cells may have already 
differentiated. It would be interesting to see if IL-6 and TGF~ are capable of 
supporting further differentiation and activation of IL-17 producing cells in an 
already established immune response. The differentiation of IL-I 7 producing cells by 
IL-6 and TGF~ can be amplified with IL-I ~ and TNFa (Veldhoen et al., 2006) 
suggesting another possible mechanism of action of anti-IL-l ~ and anti-TNFa 
therapy. 
It has been shown in CIA, that regulatory T cells may have a protective role to play, 
as depletion of these cells results in exacerbation of disease (Morgan et al., 2003) and 
TGF~ has been implicated in the production of CD4" CD2S+ forkhead box protein 3 + 
(Foxp3 t-) regulatory T cells (Treg cells). Howe\'er, in the presence of IL-6 their 
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generation is completely inhibited (Bettelli et al., 2006). Blocking IL-6 may therefore 
increase the formation of a Treg cell population and inhibit CII immunity. 
In another model of arthritis, Wong et al. (2006) showed that CD4+ lymphocytes 
from IL-6 deficient mice had reduced antigen-induced proliferation and produced less 
IL-I7 than cells from wild type mice which is in support of the data in this thesis. It 
would have been interesting to see if the addition of anti-IL-6 in vitro in the CII 
stimulated CD4+ T cell proliferation assay was able to inhibit IL-17 production. This 
could indicate whether IL-6 can support IL-17 producing cells in an established 
immune response. It has been shown that blocking IL-I 7 therapeutically in the CIA 
model, in our hands (historical data) and in the literature (Lubberts et al., 2004), 
inhibits disease. However, the lack of effect seen with anti-IL-6R Ab when dosed 
later in disease suggests that anti-IL-6 may not inhibit IL-17 production. 
It would appear IL-6 plays a vital role in CII immunity and is capable of inducing B 
and T cell responses as well as supporting the generation of IL-I 7 producing cells and 
may synergise with IL-I ~ and TNFu. Blocking IL-6 therefore inhibits CII immunity 
and CIA, suggesting that this pleotropic cytokine is an attractive target for therapeutic 
intervention. These pre-arthritic readouts have been able to identify some of the 
mechanisms of action of anti-IL-6 and the analysis of IL-17 in cell culture 
supernatants has suggested a novel mechanism of action. Routine cytokine analysis of 
cell culture supernatants may be of value when trying to understand drug effects in an 
Immune response. 
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8.4.3 Mechanisms of action of anti-IL-17 
In recent years the pro-inflammatory cytokine, IL-17, has been shown to be produced 
by T cells resident in synovial tissue of RA patients and appears to mediate 
inflammation (Chabaud et al., 1999) and has therefore become a focus for possible 
therapeutic intervention. IL-17, like many of the other cytokines discussed. has a 
plethora of biological activities. Among these actions is its ability to synergise with 
IL-1 ~ to enhance IL-6 production (Chabaud et al., 1998) and with TNFa to enhance 
both IL-6 and IL-I ~ production from synoviocytes (Katz et al., 2001). This suggests 
another mechanism of action for both anti -IL-1 ~ and anti -TNF a as they can 
potentially inhibit this synergistic relationship with IL-17. 
IL-17 has also been implicated in the destruction of cartilage and bone in arthritis, 
where it has been shown to induce matrix metalloproteinases (Jovanovic et al .. 1998 
and Park et al., 2005), osteoclastogenesis (Sato et al., 2006), collagen destruction 
(Chabaud et al., 2001) and expression ofRANKL (Lubberts et al., 2004). 
Blockade of IL-17 with a mAb, in the current study, inhibited CIA. These data 
confirm research where IL-17 deficient mice (Nakae et al., 2003) and other blocking 
strategies have been shown to attenuate arthritis (Lubberts et al., 2001 and Lubberts 
et al., 2004). Additionally, systemic over-expression of IL-17 by adenoviral vector 
has been shown to increase the severity of CIA (Lubberts et al., 2001). These data 
indicate a key pathogenic role for IL-17 in CIA. 
Assessment of anti -IL-l 7 in the pre-arthritic readouts showed a profound effect on 
CII immunity, as it inhibited CII stimulated CD4+ T cell proliferation and CII-
induced hypersensitivity in the ear at 24 hours. However. no effect was seen on anti-
CII Ab levels or 6 hour hypersensitivity, suggesting anti-IL-17 exerts its effect 
preferentially on cellular immunity. In support of this, the work conducted by Nakae 
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et al. (2003) demonstrated that IL-17 deficient mice had a reduced T cell response to 
CII. In this study they also saw a reduced IgG2a response, which is in contrast to the 
current study. However, Nakae et al. took blood samples at termination of their study 
on Day 60, as compared to Day 15 in the present study. We too show an inhibition in 
anti-CII Abs at the end of a CIA study (historical data). Anti-IL-17 therefore appears 
to have an effect on the humoral response later on in disease, maybe through a 
delayed effect of inhibiting CD4+ T cells. 
Lubberts et al. (2001) showed that, although blocking IL-17 inhibited CIA, it had no 
effect on the level of anti-CII Abs or CII stimulated T cell proliferation and concluded 
that IL-17 had no effect on CII immunity. However, in this paper, the authors dosed 
an IL-17R:Fc fusion protein at boost or onset of disease symptoms. Data presented 
here indicates that IL-17 may play an important role initially in CII immunity but its 
immunomodulatory activity may be lost once the immune process has become 
established. The effects of anti-IL-17 dosed therapeutically in CIA suggest that, at 
this stage of disease, the effects of anti -IL-l 7 may be anti-inflammatory rather than 
immunomodulatory. 
IL-17 has also been shown to be involved in the induction of IL-l~, TNFa and IL-6 
(J ovanovic et aI., 1998) therefore blocking IL-17 may inhibit the production of these 
cytokines as well as their associated synergies and related immunomodulatory 
activity. It has been shown that anti-IL-l~ and anti-IL-6 inhibit CD4+ T cell 
proliferation when dosed in vivo. This suggests the effects of anti-IL-17 on CII 
stimulated CD4+ T cell proliferation when dosed in vivo may be due to suppression of 
IL-I ~ and IL-6 production. The in vitro addition of anti-IL-17 had no effect on CII 
stimulated CD4+ T cell proliferation suggesting, like IL-6, that I L-l 7 does not 
intluence CII specific cells. However, the addition of anti-IL-I ~ in \'itro was sho\\n 
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to inhibit CD4+ T cell proliferation. This indicates that the blockade of IL-17 in these 
conditions is not enough to inhibit IL-I P production, suggesting IL-I p can work 
independently of IL-17. Although the data reported here suggests anti-IL-17 cannot 
inhibit cell proliferation in an established immune response this cannot be completely 
ruled out in vivo. 
Blocking IL-I7 in CIA may also inhibit the destruction of cartilage and bone in the 
joint, which in tum may reduce the release of endogenous antigens such as CII that 
would normally drive the disease process. This may also apply to anti-TNFa and 
anti-IL-I p as their target cytokines have also been shown to playa role in bone 
erosion and cartilage degradation respectively (Bertolini et at., 1986 and Shingu et 
at., 1993). 
In addition to all these biological actions, Ryu et al. (2006) showed that IL-17 was 
able to induce the expression of vascular endothelial growth factor (VEGF) from 
fibroblast-like synoviocytes, which is essential for angiogenesis in rheumatoid 
synovium and supports pannus formation. Another potential mode of action of anti-
IL-I7 may be the inhibition of angiogenesis, resulting in decreased pannus formation 
and indirectly reducing the number of cells being able to enter the joint. However, 
these potential late stage effects of anti-IL-17 would have no impact on CII immunity 
in the predictive models of CIA as joint damage and pannus formation has not 
occurred. The fact that disease is inhibited more profoundly by prophylactic anti-IL-
17 treatment suggests that suppression of CII immunity and inflammation pre\'ents 
joint destruction from ever occurring. 
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8.4.4 Value of the short-term models in identifying drug mechanisms of action 
The use of these short-tenn readouts of CII immunity has identified the mechanisms 
of action of leflunomide and anti-CD40L and is consistent with data in the literature. 
These readouts also identified the mechanisms of action of anti -LF A -I in C I I 
immunity. However, it would appear that other factors can compensate for the 
blockade of LF A-I in CIA. The assessment of the anti-cytokine drugs in these short-
tenn models has identified both known and novel mechanisms of action. These data 
suggest that the short-tenn models and assays developed in this thesis have the 
potential to detennine how a drug is exerting its anti-arthritic effect, something that 
cannot be achieved using CIA alone. Moreover, the differential effect of some of 
these drugs on CII induced hypersensitivity, anti-CII Ab production and CII 
stimulated CD4+ T cell proliferation, suggests these readouts are capable of 
discriminating between drugs based on their mechanisms of action. 
8.5 The role of Thl, Th2 and Th17 cells in ell immunity 
To try to assess the role that IL-I7 plays in CII immunity further, Chapter 7 looked at 
its relationship with other cytokines. This research arose because IL-I7 was originally 
considered a Thl cytokine detected in activated CD4+ T cells (Yao et at .. 1995) but 
recent research has shown that IL-17 producing CD4+ T cells represent a population 
of cells distinct from Thl and Th2 subsets (Park et at., 2005 and Harrington et at., 
2005). This has thrown into question the traditional Th I/Th2 paradigm that has been 
used to explain immune responses for a number of years. IL-17 does not just 
represent another novel cytokine but is also derived from a distinct ne\\' cell type, 
tem1ed "Th 17 cells", that may be pathogenic in a number of diseases. This is 
therefore an exciting time in immunology with the relationship bet\\cen I L-J 7 
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secreting Th 17 cells, IFNy secreting Th 1 and IL-4 secreting Th2 cells being 
unravelled. However, very little is known about IL-17 secreting Th 1 7 cells in CIA 
and their relationship with Th 1 and Th2 cells. 
IL-17 is a key cytokine in CIA and in addition to the data in IL-1 7 deficient mice and 
blocking studies it was shown by Murphy et al. (2003) that mice deficient in IL-23, a 
cytokine involved in IL-17 production, are also protected against CIA. This was 
associated with an absence of IL-17 producing CD4+ T cells. However, the role of 
IFNy secreting Th1 cells in CIA is contradictory, with some researchers suggesting 
IFNy exacerbates disease (Cooper et al., 1988 and Boissier et al., 1995) and others 
suggesting it protects against disease (Nakajima et al., 1990 and Vermeire et al., 
1997). 
In more recent years, a series of studies has put more weight on the fact that IFNy is 
protective in CIA, as it has been shown that mice deficient in IFNyR develop a more 
severe form of disease than controls (Vermeire et al., 1997, Manoury-Schwartz et al" 
1997 and Kelchtermans et al., 2007). Furthermore, it has been demonstrated that 
mice, such as the C57B/6 strain, which are not normally susceptible to CIA, get 
disease when rendered deficient in IFNy (Guedez et al., 2001 and Chu et al., 2007). 
In addition, mice deficient in IL-12 (IL-12p35 deficient mice), a macrophage deri ved 
cytokine responsible for inducing IFNy production, develop severe CIA (Murphy f.!1 
al., 2003). This has lead to the general opinion that IFNy is protective in CIA. 
Studies conducted in IFNy or IFNyR deficient mice have suggested that IFNy may 
exert its protective effect by decreasing activated CD4+ T cells (Chu et at.. 2000), IL-
6 (Chu (!t al., 2007), IL-1 ~ (Guedez et al., 200 I) and IL-2 production (Vermeire el 
al., 1997) as well as inhibiting the granulocyte chemotactic protein-::~, a neutrophil 
attractant (Kelchtermans et al., 2007). It has also been shown that I FNy decreases I L-
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23 and increases IL-12 production from infected DCs (Cruz et al.. 2006) therefore 
producing a cytokine milieu supportive of further IFNy secretion. Furthermore. IF\:y 
has been shown to up-regulate IL-4 production (Vermeire et ai., 1997), IL-I Ra 
production (Tilg et ai., 1993) and support Treg cell activity (Kelchtermans et al .. 
2005). Thus IFNy has the potential to convey a strong inhibitory effect on immunity 
and inflammation. 
Recently there have been a number of studies suggesting that the suppressive effect of 
IFNy on the immune response is due to its influence on the production and 
development of IL-17 secreting Thl7 cells. IFNy has been shown to inhibit the 
differentiation of Thl7 cells from naIve T cells and the production of IL-17 in vitro 
(Harrington et ai., 2005 and Park et ai., 2005) therefore suggesting IFNy acts by 
reducing the activity of the pathogenic Th 17 cell. In support of this, it has been shown 
that IFNy and IL-l2 deficient mice, which get severe arthritis, have an associated 
increase in IL-l7 production (Chu et ai., 2007 and Murphy et al., 2003). In addition. 
Nakae et ai. (2007) has shown that IL-12 promotes Th1 cell differentiation but 
suppresses Th 1 7 cell differentiation. 
The role of IL-4 in CIA is more straightforward and has been shown to protect 
against CIA and joint damage when dosed systemically (Joosten et ai., 1999) with its 
blockade increasing disease activity (Yoshino. 1998). However. in the current work 
it would appear IL-4 secreting Th2 cells have little role to play in CII immunity as 
there was no detectable IL-4 produced in ex l'in) cell cultures from CI I sensitised 
mice in response to CII stimulation (Chapter 6). This difference may relate to the time 
of assessment. It may be that IL-4 is involved early on in the initial di fferentiation of 
Th subsets therefore blocking it could dive11 the immune response to a Th 1, Th 17 
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phenotype. This theory is supported by Yoshino (1998) who only administered anti-
IL-4 for 10 days over the sensitisation period, suggesting an early action of this Ab. 
Further support of this theory comes from Harrington et al. (2005) who showed that 
IL-4 and therefore by inference Th2 cells are capable of inhibiting the formation of 
Th17 cells from naIve T cells in culture, which would have to occur early in the 
immune response. This suggests that if the suppressive effect of IL-4 were blocked an 
increase in IL-17 secreting Th 17 cells may be expected. In addition, Park et al. (2005) 
has shown that anti -IL-4 increases the production of IL-1 7. The study by Yoshino 
(1998) also showed that the augmentation of CIA through IL-4 blockade was 
associated with an increase in IFNy secretion and suggested that Th 1 cells were 
responsible. However, the magnitude of the Th 17 response was not assessed. 
Blocking IL-4 may therefore allow the development of both Thl and Th17 cells with 
the latter being pathogenic and outnumbering the former, which is protective, 
resulting in arthritis. Without assessing IL-17 production it is easy to see why 
researchers conclude that IFNy secreting Th1 cells are pathogenic. This is true for a 
number of studies that have identified Th1 cells as the dominant arthritogenic Th 
subset in CIA such as Mauri et al. (1996) and Doncarli et al. (1997). The blockade of 
both IFNy and IL-4 in vitro has been shown to result in a synergistic increase in IL-I7 
production (Park et al., 2005 and Chu et al., 2007), again suggesting Thl and Th2 
cells can suppress Th 17 cells. 
In Chapter 7, it was shown that the addition of rmIL-4 in \'itro caused an increase in 
the nUlnber of IFNy secreting CD4+ T cells in culture. As IL-4 appears to he 
protective in CIA this suggests that an increase in IFNy may be a no\el mechanism of 
action of IL-4 therapy. Although this goes against the general understanding that Th2 
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cells inhibit Th1 cell activity and vice versa (Fiorentino et at., 1989 and Fitch £![ at.. 
1993) there is evidence that in the right situation IFNy can stimulate IL-4 production 
from Th2 cells (Bocek et al., 2004). However, the current finding is in contrast to 
other CIA studies. 
Kim et al. (2001) and Saidenberg-Kerrnanac'h et al. (2004) demonstrated that 
overexpression of IL-4 in vivo by transfected DCs or fibroblasts resulted in a decrease 
in IFNy production and arthritis, and Yoshino (1998) showed that blockade of IL-..J. 
enhanced IFNy secretion. The discrepancy between the effects of IL-4 in \'itro, as 
shown in this thesis, and data generated in vivo in the literature, suggests IL-4 may 
have additional effects in vivo. However, in all the in vivo studies, cells were taken for 
culture at a much later time point than Day 14 post-ClI sensitisation and in the papers 
by Kim et al. (2001) and Saidenberg-Kerrnanac'h et al. (2004) spleen cell cultures 
were used. It may be that later on in the disease process IL-4 is capable of inhibiting 
the production of both IFNy and IL-1 7 and is the key cytokine in the remission phase 
of disease. The difference between the actions of IL-4 in vivo as compared to in vitro 
could represent a difference in the time and site at which sampling was conducted. 
IL-4 is a difficult cytokine to detect in ex vivo cell cultures from CIA mice but IL-l 0, 
another Th2 cytokine, appears to be increased late in disease, suggesting Th2 cells are 
up regulated and responsible for disease remission (Mauri et al., 1996), which 
supports the theory that Th2 cells dominate at this stage. However, in these studies 
levels of IL-17 were not assessed and it would be interesting to see if IL-4 was able to 
suppress production of IL-17 in the later phase of disease. 
It is possible that IL-4 has a biphasic effect in CIA, increasing IFNy early in the 
disease process and then decreasing it in the later stages. The presence of hoth IF\'-( 
and IL-4 may act synergistically to suppress IL-l 7 production as suggested hy Park l'l 
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al. (2005), in the early stages of disease. This may be enough to inhibit development 
of CII immunity and hence CIA. Once the immune response is under control IL-4 
may then suppress IFNy and it is this reduction in IFNy that is detected in the studies 
which overexpressed IL-4. 
The data in this thesis has shown that CIA in DBAl1 mice is a Th17 driven response 
with IL-17 secreting CD4+ T cells being detected prior to IFNy secreting CD4+ T 
cells. Although the relative amounts of cytokine cannot be used to determine their 
hierarchy, it is also interesting that higher levels of IL-1 7 were produced in response 
to ClI than IFNy. In Chapter 7, it was shown that these Th 17 cells represent a \'ery 
small population of CD4+ T cells in CII immunity, which suggests they are potent 
pathogenic cells. 
IFNy secreting Th 1 cells and IL-4 secreting Th2 cells can suppress the differentiation 
of naIve T cells into IL-17 producing Th17 cells. However, the work in Chapter 7 
focused on the effect of these cytokines on committed CII specific CD4+ T cells. 
Harrington et al., (2005) had already reported that in vitro mature Th 17 cells are 
resistant to Th 1 and Th2 polarising conditions. The current work confirms and 
extends these findings, showing for the first time that in vivo derived CII specific IL-
17 secreting CD4+ T cells are not suppressed by IFNy or IL-4. These findings are 
similar to those reported by Murphy et al., (1996) for mature Th 1 and Th2 cells. 
which are not reversed by the presence of IL-4 or IFNy respectively. 
In contrast to the current study and Harrington et af. (2005), Chu <!l af. (2007) 
delllonstrated that IFNy was capable of inhibiting IL-17 production in cultures of cells 
from CII sensitised mice, suggesting IFNy can influence committed Th 17 cells. The 
endpoints in these studies was however slightly different with the (urrent stud\' 
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assessmg the frequency of IL-17 secreting CD4+ T cells by ELISpot. Harrington 
'-' 
assessing the development of Th I 7 cells by F ACS and Chu assessing the production 
of IL-17 in supernatants. The inhibitory effect of IFNy on committed Th 17 cells in 
terms of IL-17 production in the current study and in the Harrington paper can 
therefore not be ruled out. 
The discrepancy that exists between the Chu study and this thesis may be because 
Chu used cells from C57B/6 mice deficient in IFNy which have an altered immune 
system as compared to DBAIl mice. It would appear that adding IFNy to cell cultures 
where it is not naturally present is capable of inhibiting IL-17 production, as reported 
by Chu. Whereas, adding IFNy to cell cultures where it is already present has no 
effect, as reported here. Chu also showed that blocking IFNy in cell cultures from 
wild type C57B/6 mice, which were shown to have a dominant Th 1 response, 
increased IL-17 production suggesting endogenous IFNy is suppressing IL-I 7. 
CII stimulated CD4+ T cell cultures in this thesis had approximately 10 fold less IFNy 
production as detected by ELISA than cell cultures from wild type mice in the Chu 
paper and appears not to be the dominant cytokine. In addition, blocking IFNy in the 
ELISpot assay had no effect on the number of CII stimulated IL-17 secreting CD4 + T 
cells in culture. There appears to be a fundamental difference between cells from the 
two mouse strains, where cells from C57B/6 mice genetically favour a Th 1 response 
and those from DBA/I mice favour a Thl7 response. This may explain the 
differences between the studies. 
Researchers have been focusing on the role that IFNy secreting Th 1 and I L-4 
sccreting Th2 cells have on the development and regulation of I L-17 producing Th 17 
cells, but havc not addressed the effect IL-l 7 may ha\"e on Th 1 or Th2 cells. In the 
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current study, results in Chapter 7 demonstrated that endogenous IL-17 in CD4 - T 
cell cultures can suppress the formation of IFNy secreting Th I cells, but not IL-4 
secreting Th2 cells. This is a novel finding and demonstrates that anti-IL-17 ma\· 
exert part of its anti-arthritic effect by increasing the number of cells capable of 
secreting IFNy. This infers that Thl7 cells can suppress Thl cells, so that in IL-17 
dominant immune responses, such as CIA, Th I cells and their associated protecti \·e 
actions are inhibited, giving rise to arthritis. 
Nakae et al. (2007) showed in CD4+ T cell cultures from ovalbumin (OY A) specific 
TCR transgenic mice deficient in IL-I 7 that the formation of Th 1 cells was increased. 
However, in this study exogenous IL-12 was added to their cell cultures to force the 
differentiation of Th I cells. In the absence of IL-12 it was shown in the same paper 
that cells from IL-17 deficient mice have a decreased number of Th 1 cells as 
compared to wild type mice which suggests IL-17 does not suppress Th 1 
differentiation. In addition, these cultures used naIve T cells which have previously 
been shown to be susceptible to cytokine manipulation. The work carried out in this 
thesis has therefore shown for the first time in a disease model that endogenous I L-l 7 
is capable of suppressing committed CII specific Thl cells without any exogenous 
cytokine manipulation. 
An increase in IFNy secreting CD4+ T cells appears to represent a novel mechanism 
of action for anti-IL-17. It is possible that this mechanism of action may also apply to 
anti-IL-6, anti-IL-I ~ and anti-TNFa as their target cytokines have been implicated in 
the development of Th 17 cells. These drugs may therefore suppress Th 17 cdls and 
hence IL-17 production with an associated increase in IFNy secreting Th 1 cells. This 
may represent a common mechanism of action for these anti-cy10kine therapies. To 
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test this theory the cytokine profiles from cell culture supernatants of in \'i"o drug 
treated mice could be assessed along with ELISpot assays. Data in this thesis has 
already shown that in vivo anti-IL-6 administration inhibits ex vivo CII stimulated IL-
17 production, suggesting a role for IL-6 in the generation of Th 17 cells. It would 
therefore be of interest to see ifanti-IL-l~ and anti-TNFa have a similar effect on IL-
17 production and if these therapies increase the number of IFNy secreting Th 1 cells, 
The in vitro addition of anti-IL-17 in the CII stimulated CD4+ T cell proliferation 
assay had no effect. Although anti-IL-17 does not have an effect on CII specific CO·t 
T cell proliferation it may, in light of the current data, increase the number of IFNy 
secreting Thl cells. This may, in tum, alter the balance between Thl and Th17 cells 
in culture, with no change in proliferation being detected. If this is the case it is 
unlikely that IFNy is responsible for inhibiting the number ofTh17 cells, as anti-IFNy 
and rmIFNy had no effect on the number of IL-l 7 secreting cells, although this cannot 
be completely ruled out as the cell concentrations varied between studies. 
Furthermore, it would be interesting to assess the cytokine profile in the supernatants 
of in vitro drug treated cultures to see if there is a change in the balance between 
IFNy, IL-4 and IL-17. 
The data presented in this thesis suggests that IL-17 secreting Th 17 cells are the 
pathogenic subset of CD4+ T cells in CIA. However, it still remains to be seen if I L-
17 secreting Thl7 cells have an important role to play in RA, but if they do, bl()ckin~ 
IL-17 or depleting Th 17 cells may represent an effective therapy. 
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8.6 Conclusion 
The aim of this thesis, as outlined in the introduction, was to detennine the anti-
arthritic activity of a number of drugs in the CIA model and to development short-
term models of CII immunity that can predict anti-arthritic drug activity. This has 
now been addressed. 
It has been shown that short-term models of CII immunity are predictive of anti-
arthritic drug effects in CIA. These short-term readouts may provide the basis of a 
novel screening cascade (Figure 8.1) for anti-arthritic drugs. Such a screening 
strategy has not been reported previously and has the potential to decrease the 
timeframe involved in the assessment of novel therapeutics. It may also lead to a 
decrease in the number of mice used as well as the number rendered arthritic, which 
has obvious welfare advantages. 
In addition, these pre-arthritic readouts have been shown to be capable of 
discriminating between the mechanisms of action of anti-arthritic drugs, which may 
go some way to inform on where best to place novel therapies in the clinic. It has also 
been highlighted that the routine analysis of cytokine profiles in supernatants of CI I 
stimulated CD4 + T cell cultures may aid in this discrimination process. 
The work has confirmed that CIA and CII immunity are CD4+ driven responses. In 
addition, IL-17 has been shown to be a key cytokine in CII immunity and it appears 
that it is the Th17 subset of CD4+ T cells that are the dominant and pathogenic cell 
type. Studies also demonstrated that IL-6 plays a pivotal role in IL-17 production in 
CII immunity, thus confirming its importance in Th 17 cell development. 
It has been shown for the first time that ell specific IL-17 secreting Th17 cells are 
capable of suppressing IFNy secreting Th 1 cells. In addition, it appears that these ell 
specific Th 17 cells are resistant to IFNy secreting Th 1 and IL-4 secreting Th2 (l'lls. 
Chapter 8 
This supports the opinion that Th17 cells are disease promoting while Thl cells are 
disease suppressing. However, the importance of IL-17 in the pathogenesis of human 
disease is as yet unknown, but with therapies fast approaching the clinic it is only a 
matter of time before this question is answered. 
It will be of great interest to see if the novel therapies studied in this project ha\'e a 
beneficial impact in the clinical treatment of RA. The outcomes from the clinic will 
hopefully further support these short-term models as valuable tools in pre-clinical 
drug discovery. 
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